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I Structure of the thesis 
This thesis is composed of three main parts, introduction (1), results (2) and 
summarizing discussion (3). The first part introduces the reader to the biological 
functions of copper (1.1), to the molecular mechanisms of cellular copper 
transport (1.2), to the functions and metabolism of copper in the brain (1.3) and 
to the role of astrocytes in the copper metabolism of the brain (1.4). The second 
part (results) consists of five published articles that deal with copper transport 
(2.1 and 2.2), copper toxicity (2.3) and with copper-mediated alterations in the 
metabolism of cultured astrocytes (2.4 and 2.5). These publications are included 
as portable document format. For each article, the contributions of the first 
author are listed on the first page of the respective chapter. In the third part 
(summarizing discussion) the key-findings of this thesis are discussed and 
possible future directions for further research on the topics addressed by this 
thesis are proposed. 
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II Summary 
Copper is an essential element that is required for a variety of important 
cellular functions. Since not only copper deficiency, but also excess of copper 
can seriously affect cellular functions, cellular copper metabolism is tightly 
regulated. Disturbances of copper homeostasis are the underlying defect of the 
inherited diseases Menkes and Wilson’s disease and have also been linked to 
several neurodegenerative diseases including Alzheimer’s disease and 
Parkinson’s disease. Known astrocyte features strongly suggest a pivotal role of 
theses cells in the metal metabolism of the brain. Using astrocyte-rich primary 
cultures as model system, this thesis investigated the copper metabolism as well 
as copper-mediated alterations in the metabolism of astrocytes. Cultured 
astrocytes efficiently accumulated copper with saturable kinetics. The 
characteristics of the observed copper accumulation suggest that both copper 
transporter receptor 1 (Ctr1) and a Ctr1-independent mechanism are involved 
in astrocytic copper accumulation. Cultured astrocytes were also found to 
release copper in a time-, concentration- and temperature-dependent manner. 
Copper export from these cells most likely involves the copper-ATPase ATP7A. 
Thus, with being capable of both taking up and exporting copper, astrocytes 
possess the cellular machinery required to transport copper from the blood-
brain barrier to the brain parenchyma. Cultured astrocytes were remarkably 
resistant against copper-induced toxicity. Nevertheless, prolonged copper 
treatment led to profound alterations in their metabolism. For example, copper 
accumulation by cultured astrocytes was accompanied by a stimulation of 
glycolytic flux, an increase in the cellular glutathione content and an 
acceleration of glutathione export. Such copper-mediated alterations in the 
metabolism of astrocytes may also occur in vivo, for example in copper overload 
conditions such in Wilson’s disease and could either contribute to disease 
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progression or serve as compensatory response to protect the brain against the 
toxic effects of an excess of copper. 
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III Zusammenfassung 
Kupfer ist ein essentielles Spurenelement, welches für zahlreiche wichtige 
zelluläre Funktionen benötigt wird. Da sowohl ein Mangel an Kupfer als auch 
dessen übermäßige Anreicherung zu schwerwiegenden Beeinträchtigungen 
zellulärer Funktionen führen kann, wird der Kupferstoffwechsel strengstens 
reguliert. Eine Störung des Kupferstoffwechels liegt den Erbkrankheiten 
Morbus Menkes und Morbus Wilson zugrunde und auch neurodegenerative 
Krankheiten wie Morbus Alzheimer und Morbus Parkinson werden mit einer 
beinträchtigten Kupferhomeostase in Verbindung gebracht. Astrozyten weisen 
eine Vielzahl an Eigenschaften auf, die auf eine bedeutende Rolle dieser Zellen 
im Metall-Stoffwechsel des Gehirns hindeuten. In der vorliegenden Arbeit 
wurden Astrozyten-reiche Primärkulturen als Modellsystem verwendet, um 
den Kupferstoffwechsel von Astrozyten sowie die Auswirkungen von Kupfer 
auf den Metabolismus dieser Zellen zu untersuchen. Astrozytenkulturen 
akkumulierten Kupfer mit sättigbarer Kinetik. Die Charakteristika der 
beobachteten Kupferakkumulation lassen sowohl auf eine Beteiligung vom 
Kupfer-Transporter-Rezeptor 1 (Ctr1) als auch auf eine Beteiligung eines Ctr1-
unabhängigen Mechanismus’ schließen. Es konnte zudem gezeigt werden, daß 
Astrozyten Kupfer in Zeit-, Konzentrations- und Temperatur-abhängiger Weise 
freisetzen, höchstwahrscheinlich unter Beteiligung der Kupfer-ATPase ATP7A. 
Mit den Fähigkeiten Kupfer aufzunehmen und zu exportieren, weisen 
Astrozyten die notwendigen Voraussetzungen auf, um Kupfer von der Blut-
Hirn-Schranke in das Hirnparenchym zu transportieren. Astrozyten zeigten 
sich bemerkenswert resistent gegenüber Kupfer-bedingter Schädigung. 
Nichtsdestotrotz, führte eine längere Inkubation mit Kupfer zu ausgeprägten 
Änderungen ihres Stoffwechsels. So wurde die Kupferakkumulation von 
Astrozyten von einer Steigerung des glykolytischen Flusses, von einem Anstieg 
des zellulären Glutathiongehalts sowie von einem beschleunigten Glutathion-
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Export begleitet. Solche durch Kupfer bewirkten Veränderungen im 
Stoffwechsel von Astrozyten treten möglicherweise auch in vivo auf, z.B. bei 
einer übermäßige Anreicherung von Kupfer wie beim Morbus Wilson, und 
tragen so möglicherweise zur Krankheitsprogression oder kompensatorisch 
zum Schutz des Gehirn gegen die toxischen Effekte eines Kupfer-Überschusses 
bei. 
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Copper is the lightest element of group 11 of the periodic table of the chemical 
elements. Although some compounds exist with copper in the oxidation states 
Cu3+ and Cu4+, the copper chemistry is largely dominated by Cu+ and Cu2+ 
compounds (Holleman and Wiberg, 2007). Cu+ and Cu2+ form numerous 
complexes with both organic and inorganic ligands. The soft Cu+ ion prefers 
ligands that have large polarizable electron clouds, such as sulfur ligands or 
unsaturated nitrogen donor ligands usually exerting coordination numbers 
from two to four with linear, trigonal or tetrahedral coordination (Kaim and 
Rall, 1996; Crichton and Pierre, 2001; Wadas et al., 2007; Tisato et al., 2010). In 
contrast, the hard Cu2+ ion prefers hard sp3 hybridized nitrogen and oxygen 
ligands (Kaim and Rall, 1996; Crichton and Pierre, 2001; Wadas et al., 2007; 
Tisato et al., 2010). Coordination numbers in Cu2+ complexes range from four to 
eight, allowing a large variety of coordination geometries (Kaim and Rall, 1996; 
Crichton and Pierre, 2001; Wadas et al., 2007; Tisato et al., 2010). The redox 
potential of the Cu2+/Cu+ redox pair varies dramatically depending on the 
ligand environment and pH. Thus, the one electron oxidation of various Cu+-
complexes towards dioxygen has been reported to vary from -1.5 to + 1.3 V 
against the standard hydrogen electrode (Tisato et al., 2010). 
Copper is a relatively modern bioelement that became bioavailable about 2-3 
billion years ago with the advent of an oxygen atmosphere that allowed for the 
conversion of Cu+ to the more soluble Cu2+ ion (Kaim and Rall, 1996; Crichton 
and Pierre, 2001; MacPherson and Murphy, 2007). Since then copper has 
become an indispensable element for all organisms that have an oxidative 
metabolism. In humans, it represents the third most abundant essential 
transition metal (Lewinska-Preis et al., 2011). As a cofactor of several enzymes 
and/or as structural component, copper is involved in many physiological 
pathways. Furthermore, copper is associated with important biological 
processes including angiogenesis, response to hypoxia and neuromodulation. 
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1.1.1 Copper-dependent enzymes 
Copper is an essential cofactor and/or a structural component in a number of 
important enzymes of plants and animals (Table 1). In general, these enzymes 
are involved in redox reactions (Kaim and Rall, 1996). The relatively high redox 
potential for the Cu2+/Cu+ system found in copper enzymes is utilized by many 
of them for a direct oxidation of certain substrates that are easy to oxidize, such 
as superoxide by superoxide dismutase and catechols by tyrosinase (Tisato et 
al., 2010). Among others, copper-dependent enzymes participate in biological 
processes such as energy metabolism (e.g. cytochrome c oxidase), antioxidative 
defense (e.g. Zn,Cu-superoxide dismutase) and iron metabolism (e.g. 
ceruloplasmin). 
 Table 1: Mammalian copper-dependent enzymes 
Enzyme Function 
Cytochrome c oxidase Oxidative phosphorylation 
Cu,Zn superoxide dismutase (SOD1) Superoxide detoxification, signaling 
Ceruloplasmin (Cp) Ferroxidase 
Lysyl oxidase (LOX) Crosslinking of collagen and elastin 
Tyrosinase Melanin synthesis 
Dopamin-β-monoxygenase (DβM) Norepinephrine synthesis 
Peptidylglycine α-amidating enzyme 
(PAM) 
Activation of peptide hormones 
Copper amine oxidase Deamination of amines 
Hephaestin Ferroxidase 
Coagulation factors V and VIII Blood clotting 
On the basis of their optical and electron paramagnetic resonance (EPR) 
features, copper-dependent enzymes are classified as type 1, 2 or 3 copper 
enzymes (Kaim and Rall, 1996; Rosenzweig and Sazinsky, 2006; MacPherson 
and Murphy, 2007). The distinct copper centers vary in their coordination 
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geometries, ligand environments surrounding the metal center and functions 
(Holm et al., 1996; Kaim and Rall, 1996; MacPherson and Murphy, 2007). Most 
copper enzymes contain only one type of copper center, but in some (e.g. 
ceruloplasmin, cytochrome c oxidase) more than one type can be found.  
Type 1 copper sites, also known as blue copper sites, posses a very intense 
ligand-to-metal  charge  transfer  (LMCT)  absorption  in  the  600  nm  region 
(ε600 nm  5000 M-1 cm-1), due to an electron transfer from a cysteine thiolate 
ligand to Cu2+. These centers exhibit an unusual ground-state EPR spectrum 
(Kaim and Rall, 1996; Gerdemann et al., 2002; Solomon, 2006; MacPherson and 
Murphy, 2007; Kosman, 2010a). Type 1 copper centers are mononuclear copper 
sites that contain copper typically coordinated by one cysteine and two 
histidines in an approximately trigonal-planar arrangement (Holm et al., 1996; 
Kaim and Rall, 1996; MacPherson and Murphy, 2007; Kosman, 2010a). Often an 
additional methionine coordinates axially, resulting in a strongly distorted 
tetrahedral geometry (Kaim and Rall, 1996; MacPherson and Murphy, 2007). 
This “transition state” between the favored coordination geometries of Cu+ 
(tetrahedral) and Cu2+ (square-planar) contributes to the unanimously high 
reduction-potential of type 1 copper sites compared to that of inorganic copper 
complexes in aqueous solution (Gray et al., 2000; Gerdemann et al., 2002). The 
binuclear CuA copper center in cytochrome c oxidase is an extension of the type 
1 site (Holm et al., 1996; Kaim and Rall, 1996; Malmstrom and Leckner, 1998; 
MacPherson and Murphy, 2007). It is constituted of two copper ions that are 
connected via two bridging cysteine thiolates and a weak direct Cu-Cu bond 
(Blackburn et al., 1997; Solomon, 2006). Type 1 copper sites exclusively function 
in single electron transfer (Kaim and Rall, 1996; Solomon, 2006; MacPherson 
and Murphy, 2007; Kosman, 2010a).  
Type 2 copper sites lack unique features in their UV/Vis and EPR spectra; 
accordingly the spectroscopic and magnetic characteristics of type 2 copper 
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centers resemble that of aqueous copper complexes (Kaim and Rall, 1996; 
Gerdemann et al., 2002; MacPherson and Murphy, 2007). Type 2 copper is 
typically square-planar or square-pyramidal coordinated with histidine 
representing one or more of the ligands (Kaim and Rall, 1996; MacPherson and 
Murphy, 2007). Type 2 sites often have a low reduction potential (Lancaster et 
al., 2009) and vacant coordination positions that allow binding of exogenous 
ligands such as dioxygen (Kaim and Rall, 1996; MacPherson and Murphy, 
2007). Consequently, type 2 copper sites catalytically activate enzyme substrates 
by direct interaction rather than being involved in electron transfer (Kaim and 
Rall, 1996; MacPherson and Murphy, 2007).  
In contrast to type 1 and 2 sites, type 3 copper sites are binuclear (Kaim and 
Rall, 1996; Rosenzweig and Sazinsky, 2006; MacPherson and Murphy, 2007). 
These copper sites are constituted of two closely spaced antiferromagnetically 
coupled copper ions, each of them coordinated by three histidines, which can be 
reversibly bridged by dioxygen (Kaim and Rall, 1996; Gerdemann et al., 2002; 
Rosenzweig and Sazinsky, 2006; MacPherson and Murphy, 2007; Solomon et al., 
2011).  Type  3  copper  sites  exhibit  an  intense  LMCT  absorption  at  350  nm 
(ε350 nm  20000 mM-1 cm-1) when molecular oxygen is bound (Kaim and Rall, 
1996; Solomon et al., 2011) and are EPR silent due to the anti-parallel spin-spin 
coupling of the copper ions (Kaim and Rall, 1996; Gerdemann et al., 2002). The 
function of type 3 copper sites is the activation and transport of oxygen (Kaim 
and Rall, 1996; MacPherson and Murphy, 2007; Solomon et al., 2011). 
1.1.1.1 Cytochrome c oxidase 
Cytochrome c oxidase is a member of the super-family of heme-copper 
containing oxidases (Ferguson-Miller and Babcock, 1996; Stiburek et al., 2009; 
Popovic et al., 2010). It is embedded in the mitochondrial inner membrane 
where it catalyzes the electron transfer from reduced cytochrome c to dioxygen 
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in the final step of mitochondrial oxidative phosphorylation (Hatefi, 1985; 
Ferguson-Miller and Babcock, 1996; Tsukihara et al., 1996; Diaz, 2010). Since this 
four-electron reduction of molecular oxygen to water is coupled to a proton 
pumping process across the mitochondrial inner membrane, functional 
cytochrome c oxidase contributes to the maintenance of the mitochondrial 
membrane electrochemical gradient that provides the driving force for ATP 
synthase-dependent generation of ATP (Hatefi, 1985; Ferguson-Miller and 
Babcock, 1996; Hamza and Gitlin, 2002; Diaz, 2010).  
Mammalian cytochrome c oxidase is a multimeric protein complex consisting of 
13 subunits, encoded by both the mitochondrial and nuclear genome (Hatefi, 
1985; Tsukihara et al., 1995, 1996; Leary et al., 2009b; Stiburek and Zeman, 2010). 
Biogenesis of the functional holoprotein is a complicated process that requires 
several specific proteins, so-called assembly factors, including Cox17, Sco1 and 
Sco2, and even a greater number of proteins with broader substrate specificities, 
such as mitochondrial ATP-dependent proteases (Shoubridge, 2001; Hamza and 
Gitlin, 2002; Leary et al., 2004; Diaz, 2010; Stiburek and Zeman, 2010). The 
mitochondria encoded subunits of cytochrome c oxidase, Cox1, Cox2 and Cox3, 
constitute the catalytic core at which the dioxygen reduction and proton 
translocation are carried out (Hatefi, 1985; Ferguson-Miller and Babcock, 1996; 
Hamza and Gitlin, 2002; Diaz, 2010). Cox1 contains two heme moieties, 
designated heme a and heme a3, and one copper ion that is denoted CuB (Hatefi, 
1985; Tsukihara et al., 1995, 1996). Cox2 contains a binuclear copper center, 
designated CuA, which serves as the initial electron acceptor from cytochrome c 
(Tsukihara et al., 1995, 1996). During dioxygen reduction electrons derived from 
cytochrome c are transferred from the CuA center first to heme a and then to the 
site of dioxygen binding and reduction, a binuclear center consisting of heme a3 
and CuB (Tsukihara et al., 1995; Ferguson-Miller and Babcock, 1996; Tsukihara 
et al., 1996). In contrast to Cox 1 and Cox 2, Cox3 does not contain any 
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prosthetic groups (Hatefi, 1985; Michel et al., 1998). The function of this subunit 
is not fully understood, but it appears to be essential for the assembly of the 
functional holoprotein (Michel et al., 1998; Hoffbuhr et al., 2000).  
Cytochrome c oxidase deficiency is one of the most common causes of 
respiratory chain defects in humans (Borisov, 2002; Hamza and Gitlin, 2002; 
Diaz, 2010). Human cytochrome c oxidase deficiency comprehends a wide 
variety of disorders with distinct clinical phenotypes resulting from a number 
of unique genetic abnormalities (Borisov, 2002; Hamza and Gitlin, 2002; Diaz, 
2010). Pathological features range from metabolic acidosis, weakness, 
cardiomyopathy to neurodegeneration (Borisov, 2002; Hamza and Gitlin, 2002; 
Diaz, 2010). Cytochrome c oxidase deficiency rarely arise from mutations 
located in mitochondrial or nuclear genes encoding the cytochrome c oxidases 
subunits, but is rather secondary to loss-of-function mutations in genes 
encoding for proteins required for the assembly of the functional holoprotein 
(Shoubridge, 2001; Diaz, 2010). Thus, mutations in genes encoding Sco1 and 
Sco2, both critical for the metallation of the CuA site, result in impaired 
cytochrome c oxidase function (Leary et al., 2004). Reduced insertion of copper 
might also be the reason for cytochrome c oxidase impairment in copper 
deficiency (Kodama et al., 1989; Milne and Nielsen, 1996). 
1.1.1.2 Copper/zinc superoxide dismutase 
The members of the ubiquitous family of superoxide dismutases (SODs) 
convert superoxide to dioxygen and hydrogen peroxide for further disposal by 
catalase and glutathione peroxidase (Dringen and Hirrlinger, 2010). Superoxide 
is produced during the reduction of dioxygen that occurs in respiration and 
during autoxidation of catecholamines as well as its metabolites (Halliwell and 
Gutteridge, 2007; Dringen and Hirrlinger, 2010). Superoxide is also generated 
by some enzymes, for example by the enzymatic activity of NADPH oxidases in 
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macrophages and microglial cells during the immune response (Morel et al., 
1991; Dringen, 2005; Halliwell and Gutteridge, 2007). Since excess amounts of 
superoxide can lead to the formation of highly reactive oxygen species (ROS) 
that would damage cellular constituents and/or initiate lipid peroxidation 
(Halliwell and Gutteridge, 2007), SODs represent a first line of defense against 
the toxicity of the superoxide anion.  
In eukaryotic cells three distinct isoforms of SOD that are encoded by three 
different genes have been identified: copper/zinc superoxide dismutase (Cu/Zn-
SOD; SOD1), manganese superoxide dismutase (Mn-SOD; SOD2) and 
extracellular superoxide dismutase (EC-SOD; SOD3; Miao and St Clair, 2009; 
Perry et al., 2010). SOD1 is a homodimeric protein located largely in the cytosol 
with minor fractions being present in intracellular compartments including the 
nucleus, the intermembrane space of mitochondria, lysosomes and peroxisomes 
(Weisiger and Fridovich, 1973a; Thomas et al., 1974; Crapo et al., 1992; Okado-
Matsumoto and Fridovich, 2001). However, some cell types also secrete SOD1 
(Mondola et al., 1996; Mondola et al., 1998; Cimini et al., 2002). The 
homotetrameric SOD2 is a mitochondrial enzyme that resides within the matrix 
and is associated with the inner membrane of mitochondria (Weisiger and 
Fridovich, 1973a; Okado-Matsumoto and Fridovich, 2001; Miao and St Clair, 
2009; Perry et al., 2010). The homotetrameric glycoprotein SOD3 is secreted by 
fibroblasts and glial cells and has been found in the extracellular matrix of 
tissues as well as in plasma, lymph and cerebrospinal fluid, where it protects 
cell membranes against oxidative stress (Petersen and Enghild, 2005; Antonyuk 
et al., 2009). While SOD2 contains manganese as metal cofactor (Weisiger and 
Fridovich, 1973b, a; Miao and St Clair, 2009), both SOD1 and SOD3 contain 
catalytic copper and structural zinc ions in their active sites (Carrico and 
Deutsch, 1970; Weisiger and Fridovich, 1973b; Tibell et al., 1987; Antonyuk et 
al., 2009; Miao and St Clair, 2009).  
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Crystallographic studies have revealed the detailed enzymatic mechanism for 
the catalysis of superoxide disproportionation by SOD1, during which the 
catalytic copper ion is cyclically reduced and oxidized (Hart et al., 1999; Perry et 
al., 2010). SOD1 activity can be regulated at the post-translational level by 
copper insertion and disulfide formation, which is facilitated by the copper 
chaperon for SOD1 (CCS; Leitch et al., 2009b; Miao and St Clair, 2009). 
Consequently, a decrease in the activity of SOD1 is observed in copper deficient 
subjects (Milne and Nielsen, 1996), which is often accompanied by an increase 
in SOD2, a well-characterized response to oxidative stress (Uriu-Adams and 
Keen, 2005). 
Besides its function in the detoxification of superoxide, SOD1 has been 
connected with intracellular signaling (Mondola et al., 2004; Juarez et al., 2008). 
The activity of several growth factors, e.g. epidermal growth factor, platelet-
derived growth factor and vascular endothelial growth factor, is redox 
regulated (Valko et al., 2007) and SOD1 has been demonstrated to play an 
essential role in mitogen-activated protein kinase (MAPK) signaling by 
mediating a hydrogen peroxide-dependent oxidation and inactivation of 
phosphatases in several tumor cell lines (Juarez et al., 2006; Juarez et al., 2008). 
Furthermore, secreted SOD1 has been shown to bind to SK-N-BE 
neuroblastoma cells, leading to an increase in intracellular calcium 
concentrations through a phospholipase C-protein kinase C (PLC-PKC)-
dependent pathway and subsequently to an activation of the MAPK 
extracellular signal-regulated kinases 1 and 2 (Mondola et al., 2004). 
Interestingly the activation of the PLC-PKC pathway by SOD1 was independent 
of the enzymes superoxide dismutase activity (Mondola et al., 2004). Since 
SOD1 is also present in the neuronal microenvironment, a neuromodulatory 
role of SOD1 has been suggested (Mondola et al., 2004). 
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Mutations in SOD1 have been linked to amyotrophic lateral sclerosis (ALS) 
(Rosen, 1993). ALS is a progressive neurodegenerative disease preferentially 
but not exclusively affecting motor neurons in the spinal cord, brainstem and 
brain (Pasinelli and Brown, 2006; Bento-Abreu et al., 2010; Ticozzi et al., 2011). 
The gradual loss of motor-neurons results in weakness, muscle atrophy as well 
as spasticity and finally leads to death due to respiratory failure (Pasinelli and 
Brown, 2006; Zatta and Frank, 2007; Bento-Abreu et al., 2010; Ticozzi et al., 
2011). The majority of cases of ALS are sporadic without family history. Only 
about 10% of all cases are familial ALS (Rosen, 1993; Pasinelli and Brown, 2006; 
Bento-Abreu et al., 2010; Ticozzi et al., 2011). Mutations in SOD1 are the most 
common cause (around 20%) of the familial form, but have also been found in 
roughly 3% of sporadic ALS patients (Rosen, 1993; Pasinelli and Brown, 2006; 
Bento-Abreu et al., 2010; Ticozzi et al., 2011). Currently there is no definite 
explanation how a mutant SOD1 provokes ALS, but it appears to be due to a 
yet unknown gain of toxic functions rather than to a loss of function (Hough et 
al., 2004; Pasinelli and Brown, 2006; Bento-Abreu et al., 2010; Ticozzi et al., 
2011). The pathogenic capacity of mutant SOD1 has been ascribed to its 
potential to form harmful aggregates that result in endoplasmatic reticulum 
stress and malfunction of the proteasomal system, to its proapoptotic properties 
as well as to its abilities to damage mitochondria (Pasinelli and Brown, 2006; 
Kanekura et al., 2009; Bento-Abreu et al., 2010; Nassif et al., 2010; Shi et al., 
2010). In addition to the toxic intracellular effects of mutant SOD1, extracellular 
mutant SOD1 induces motor neuron death by triggering microgliosis 
(Urushitani et al., 2006; Zhao et al., 2010). 
1.1.1.3 Ceruloplasmin  
Ceruloplasmin (Cp) belongs to the family of multicopper oxidases (Hellman 
and Gitlin, 2002; Kosman, 2010a). Members of this group of enzymes, which is 
present in all kinds of phyla, are characterized by the concomitant presence of 
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type 1, type 2 and type 3 copper sites (Hellman and Gitlin, 2002; Healy and 
Tipton, 2007; Quintanar et al., 2007; Dittmer and Kanost, 2010; Kosman, 2010a). 
Multicopper oxidases couple the one-electron oxidation of four substrate 
molecules with the four-electron reduction of dioxygen to water (Hellman and 
Gitlin, 2002; Healy and Tipton, 2007; Quintanar et al., 2007; Kosman, 2010a). 
The reducing substrates utilized in this reaction vary among the enzyme family 
members (Hellman and Gitlin, 2002). Known substrates include such diverse 
compounds as low valent transition metal ions (Fe2+, Mn2+, Cu+), bilirubin, 
ascorbate, phenols and nitrate (Hellman and Gitlin, 2002; Quintanar et al., 2007; 
Kosman, 2010a). 
Cp exhibits ferroxidase activity and has a critical role in iron homeostasis 
(Hellman and Gitlin, 2002; Healy and Tipton, 2007; Kosman, 2010b). It has been 
suggested to be an important contributor to the plasma antioxidative capacity, 
since it displays ferroxidase, cuprous oxidase and glutathione-peroxidase 
activities as well as the ability to scavenge ROS (Atanasiu et al., 1998; Stoj and 
Kosman, 2003; Healy and Tipton, 2007). Cp also possesses amine oxidase, 
catechol oxidase and ascorbate oxidase activities, although the physical 
importance of these enzymatic activities remains to be elucidated (Bielli and 
Calabrese, 2002; Healy and Tipton, 2007). Even though copper bound to Cp 
accounts for up to 95% of plasma copper, there is no evidence for a direct role of 
this plasma protein in copper transport to tissues (Meyer et al., 2001; Bielli and 
Calabrese, 2002; Healy and Tipton, 2007; Choi and Zheng, 2009). 
Cp contains 6 copper atoms per molecule: three type 1 copper sites, a single 
type 2 copper ion and a binuclear type 3 copper site (Zaitseva et al., 1996; Bento 
et al., 2007). The LMCT absorption at 610 nm between the cysteine ligand sulfur 
and the type 1 copper ions confers the typical intense blue color to Cp (Bielli 
and Calabrese, 2002; Hellman and Gitlin, 2002; Healy and Tipton, 2007). The 
type 2 copper is located in close proximity to the type 3 copper center with 
1. Introduction 
1.1 Biology of copper 
15 
 
which it forms a trinuclear cluster that is the site of oxygen binding and 
reduction (Farver et al., 1999; Bielli and Calabrese, 2002; Bento et al., 2007; Healy 
and Tipton, 2007). During the catalytic cycle, electrons pass from the type 1 
copper ions to this trinuclear copper cluster and subsequently to the oxygen 
molecule bound at this site (Farver et al., 1999; Bielli and Calabrese, 2002; Bento 
et al., 2007; Healy and Tipton, 2007).  
The majority of Cp is synthesized by hepatocytes and secreted into circulation 
(Hellman and Gitlin, 2002; Healy and Tipton, 2007). Within the human central 
nervous system (CNS) and testes a glycosylphosphatidylinositol (GPI)-
anchored form of Cp that is generated by alternative splicing has been 
identified for astrocytes and Sertoli cells respectively (Klomp et al., 1996; Patel 
and David, 1997; Fortna et al., 1999; Jeong and David, 2003; Mittal et al., 2003). 
During biosynthesis copper insertion into apo-Cp takes place late in the 
secretory pathway (Sato and Gitlin, 1991; Hellman and Gitlin, 2002; Hellman et 
al., 2002). In hepatocytes the copper transporting ATPase ATP7B and the 
Niemann-Pieck C1 protein are required for proper metallation of Cp (Terada et 
al., 1998; Meng et al., 2004; Yanagimoto et al., 2009; Yanagimoto et al., 2011).  
Cp is an acute phase response protein whose synthesis and secretion can be 
strongly increased during pregnancy, inflammation, infection, and in diseases 
such as diabetes, cancer as well as cardiovascular diseases (Hughes, 1972; Louro 
et al., 2001; Bielli and Calabrese, 2002; Chiarla et al., 2008; Nowak et al., 2010). 
The elevated serum Cp levels in such conditions are mainly the result of 
increased Cp-biosynthesis in hepatocytes that can be induced in these cells by 
estrogen, proinflammatory cytokines and hypoxia-inducible factor (HIF)-1 
(Limpongsanurak et al., 1981; Mukhopadhyay et al., 2000; Persichini et al., 2010; 
Sidhu et al., 2011). Copper deficiency does not affect the rates of biosynthesis 
and release of Cp by hepatocytes (Holtzman and Gaumnitz, 1970; Gitlin et al., 
1992). However, impaired metallation causes an augmented release of apo-Cp 
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that lacks oxidase activity and possesses a shorter half-life than holo-Cp, thus 
leading to a lowering in Cp protein levels and oxidase activity in the serum of 
copper deficient rodents compared to control animals (Holtzman and 
Gaumnitz, 1970; Gitlin et al., 1992; Broderius et al., 2010). 
Aceruloplasminemia is an autosomal recessive disorder resulting from a loss of 
function mutation in the Cp gene (Harris et al., 1995; Yoshida et al., 1995; 
Takahashi et al., 1996). Due to the importance of Cp in iron homeostasis, the 
lack of functional Cp in affected individuals is accompanied by excessive iron 
accumulation in most tissues (Harris et al., 1995; Yoshida et al., 1995; Miyajima 
et al., 1996; Gonzalez-Cuyar et al., 2008). Patients with aceruloplasminemia 
suffer from neurological symptoms such as retinal degeneration, mild 
dementia, dysarthria, dystonia as well as from diabetes mellitus (Harris et al., 
1995; Yoshida et al., 1995; Miyajima et al., 1996; Takahashi et al., 1996; Gonzalez-
Cuyar et al., 2008; McNeill et al., 2008). The neurological symptoms mirror the 
site of iron deposition in the brain (Miyajima, 2003) and iron-mediated 
oxidative stress is likely to contribute to the pathogenesis of 
aceruloplasminemia (Kaneko et al., 2002a; Kaneko et al., 2002b; Miyajima et al., 
2002; Kono and Miyajima, 2006; Gonzalez-Cuyar et al., 2008). 
1.1.1.4 Lysyl oxidase 
Lysyl oxidase (LOX) is the eponym of the LOX-family of amine oxidases that 
currently consists of five members: LOX itself and the Lox-like proteins LOXL1-
4 (Kagan and Li, 2003; Payne et al., 2007). LOX catalyzes the posttranslational 
oxidative deamination of certain peptidyl lysines in their target proteins to the 
peptidyl aldehyde α-aminoadipic-δ-semialdehyde and can be found in the 
extracellular matrix (ECM) where it is well-known for its crucial role in the 
formation, maturation and stabilization of connective tissue by catalyzing the 
cross-linking of tropoelastin and tropocollagen to insoluble fibers (Rucker et al., 
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1998; Kagan and Li, 2003; Lucero and Kagan, 2006; Payne et al., 2007). LOX has 
also been demonstrated to be localized in the cytosol and/or nuclei in some cell 
types (Li et al., 1997; Nellaiappan et al., 2000; Li et al., 2004; Jansen and Csiszar, 
2007; Saad et al., 2010) and to exhibit physiological functions that extend far 
beyond the oxidation of structural proteins of the ECM (Lucero and Kagan, 
2006; Payne et al., 2007). Thus, LOX is likely to function in gene transcription 
and cell signaling, amongst others by deaminating specific lysyl residues in 
histone H1 and H2 as well as in basic fibroblast growth factor and transforming 
growth factor-1β (Kagan et al., 1983; Li et al., 1997; Giampuzzi et al., 2003; Li et 
al., 2003; Mello et al., 2011). Consequently, LOX has been demonstrated to 
influence tissue development, cell proliferation, intracellular signal responses 
and cell migration and to act as an antagonist or protagonist of malignant 
processes (Li et al., 2003; Maki et al., 2005; Erler and Giaccia, 2006; Payne et al., 
2007; Polgar et al., 2007; Atsawasuwan et al., 2008; Saad et al., 2010).  
LOX contains two cofactors essential for its catalytic function: a tightly bound 
copper ion and a lysyl tyrosine quinone (LTQ), a unique covalently integrated 
organic cofactor that is auto-catalytically derived from a specific tyrosine and a 
specific lysine residue within the nascent polypeptide chain (Gacheru et al., 
1990; Wang et al., 1996; Rucker et al., 1998; Bollinger et al., 2005; Lucero and 
Kagan, 2006). Copper in LOX has long been considered to be involved in the 
transfer of electrons to and from oxygen in order to facilitate the oxidative 
deamination of targeted peptidyl lysyl groups. However, experimental 
evidence suggests that the copper is required for LTQ formation and enzyme 
integrity rather than being directly involved in the catalytic process of oxidative 
deamination (Tang and Klinman, 2001). According to the proposed mechanism 
for the formation of LTQ the enzyme-bound copper atom catalyzes in the first 
step the oxidation of the tyrosine residue to peptidyl dihydroxyphenylalanine 
quinone which is then followed by covalent addition of the ε-amino group of 
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the attacking lysine residue to the quinone ring (Wang et al., 1996; Rucker et al., 
1998; Bollinger et al., 2005). 
LOX is synthesized as a catalytically inactive propeptide that is processed 
further by glycosylation, addition of copper and autocatalytical formation of the 
LTQ cofactor (Kosonen et al., 1997; Rucker et al., 1998). The propeptide is 
activated by proteolytic cleavage by procollagen C-proteinase following 
secretion (Rucker et al., 1998; Kagan and Li, 2003; Lucero and Kagan, 2006). 
Copper incorporation takes place in the trans-Golgi network (TGN) where it is 
delivered to the propeptide by the copper transporting ATPase ATP7A 
(Kosonen et al., 1997; Tchaparian et al., 2000; Hardman et al., 2007). 
Accordingly, LOX activity is low in patients suffering from Menkes disease, 
which is caused by mutations in the ATP7A gene and is characterized by 
marked connective tissue dysfunctions (Royce et al., 1980; Royce and 
Steinmann, 1990; Tumer and Moller, 2010; Kodama et al., 2011). Dietary copper 
status also affects LOX activity, but does not alter tissue levels of the LOX 
protein (Rucker et al., 1996; Rucker et al., 1998). Interestingly, LOX activity is 
not only diminished when copper levels are low, but does also increase with 
rising copper levels which is hypothesized to be due to improved LTQ cofactor 
formation (Rucker et al., 1996; Rucker et al., 1998). 
1.1.1.5 Tyrosinase 
Tyrosinase is the key enzyme in the biogenesis of melanin pigments in all 
organisms. In mammals, tyrosinase is mainly expressed in melanocytes and 
retinal pigment epithelium cells where it is localized to specialized organelles 
known as melanosomes (Petris et al., 2000; Wang and Hebert, 2006; Ray et al., 
2007; Simon et al., 2009). Mammalian melanins are assumed to function as 
photoprotectives that absorb UV radiation, as antioxidants that scavenge ROS 
and as sinks for heavy metals (Meredith and Sarna, 2006; Brenner and Hearing, 
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2008; Simon et al., 2008). Mutations in tyrosinase lead to the absence or reduced 
synthesis of melanins and thus are responsible for oculocutaneous albinism 
(Gronskov et al., 2007; Ray et al., 2007; Fistarol and Itin, 2010). Affected 
individuals are characterized by reduced or absent pigmentation of the skin, 
hair and eyes, defects of the visual system and enhanced sensitivity to skin and 
ocular cancers (Gronskov et al., 2007; Ray et al., 2007; Fistarol and Itin, 2010). 
While in lower organisms and plants tyrosinase is the only enzyme controlling 
melanin synthesis, in mammals, two additional enzymes that have originated 
by duplication of the ancestral tyrosinase gene, the tyrosinase-related proteins 
Tyrp1 and Tyrp2, participate in this biosynthetic pathway (Garcia-Borron and 
Solano, 2002; Wang and Hebert, 2006; Olivares and Solano, 2009). 
Tyrosinase possesses cresolase activity, the ability to catalyze the oxidation of o-
diphenols to o-quinones, as well as catecholase acticity, the capability to 
catalyze the hydroxylation of monophenols to o-diphenols (Solomon et al., 1996; 
Garcia-Borron and Solano, 2002; Gerdemann et al., 2002; Wang and Hebert, 
2006; Olivares and Solano, 2009). Amongst others, tyrosinase catalyzes the 
hydroxylation of L-tyrosin to L-3,4-dihydroxyphenylalanin (L-DOPA), the rate-
limiting step in the biosynthesis of melanins and dopamine, and its subsequent 
oxidation to DOPA quinone (Garcia-Borron and Solano, 2002; Wang and 
Hebert, 2006; Olivares and Solano, 2009). It contains two antiferromagnetically-
coupled copper ions in their active centers, which serve as the site of substrate 
and oxygen binding (Solomon et al., 1996; Garcia-Borron and Solano, 2002; 
Gerdemann et al., 2002; Rosenzweig and Sazinsky, 2006; Decker et al., 2007). 
The active site of tyrosinase shares strong sequential, structural and mechanistic 
homology with that of catechol oxidases found in plants, insects and 
crustaceans, and that of hemocyanins found in the hemolymph of many 
mollusks and arthropods (Solomon et al., 1996; Jaenicke and Decker, 2004; 
Decker et al., 2007; Olivares and Solano, 2009; Solomon et al., 2011). Catechol 
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oxidases are capable of oxidizing catechols but lack cresolase activity, whereas 
hemocyanins are oxygen carrier proteins analogous to hemoglobins 
(Gerdemann et al., 2002; Jaenicke and Decker, 2004; Decker et al., 2007; Olivares 
and Solano, 2009). Together with these proteins, tyrosinases constitute the 
family of type 3 copper proteins (Gerdemann et al., 2002; Jaenicke and Decker, 
2004; Decker et al., 2007; Olivares and Solano, 2009). The highest degree of 
conservation in members of this group of proteins is found in the copper 
binding regions, termed CuA and CuB for tyrosinases (Gerdemann et al., 2002; 
Jaenicke and Decker, 2004). Each CuA and CuB, as well as the respective 
regions in catechol oxidases and hemocyanins, contain three histidine residues 
that coordinate to the pair of copper ions and are almost perfectly conserved 
throughout the type 3 copper proteins (Gerdemann et al., 2002; Jaenicke and 
Decker, 2004; Decker et al., 2007). The functional differences between 
tyrosinases, catechol oxidases and hemocyanins are based on the different 
accessibilities of the dinuclear copper centers to potential substrates (Solomon 
et al., 1996; Gerdemann et al., 2002; Rosenzweig and Sazinsky, 2006; Solomon et 
al., 2011). 
In mammalian cells the first DOPA oxidase-positive compartment is the TGN, 
so that presumably tyrosinase acquires copper in this organelle (Wang and 
Hebert, 2006; Ray et al., 2007; Setty et al., 2008). During trafficking from TGN to 
melanosomes tyrosinase looses its copper and must be reloaded within 
melanosomes to sustain its activity (Setty et al., 2008). For both compartments, 
copper loading depends on the copper transporting ATPase ATP7A (Petris et 
al., 2000; Wang and Hebert, 2006; Ray et al., 2007; Setty et al., 2008). 
Consequently, mutations in ATP7A are associated with diminished tyrosinase 
activity which manifests clinically in diffuse subcutaneous hypopigmentation 
(Fistarol and Itin, 2010). The presence of the typical copper-chaperone CxxC 
motif in both tyrosinase and ATP7A has led to the hypothesis that copper is 
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transferred from ATP7A first to the CxxC motif of tyrosinase and then to the 
final histidine-rich active sites (Garcia-Borron and Solano, 2002). However, the 
precise mechanism how ATP7A transfers copper to tyrosinase remains to be 
elucidated. 
1.1.1.6 Dopamine-β-monoxygenase and peptidylglycine α-amidating monoxygenase 
Dopamine-β-mooxygenase (DβM) and peptidylglycine α-amidating 
monoxygenase (PAM) belong to a small class of copper proteins found 
exclusively in animals (Klinman, 2006). Both enzymes, also referred to as 
noncoupled binuclear copper proteins, catalyze the dioxygen- and ascorbate-
dependent hydroxylation of specific C-H-bonds in their target substrates 
(Klinman, 1996; Chen and Solomon, 2004; Klinman, 2006; Solomon et al., 2011). 
Among others, DβM catalyzes the oxidative hydroxylation of dopamine to 
norepinephrine and thus plays an important role in the metabolism of these 
catecholamines (Stewart and Klinman, 1988; Klinman, 1996; Kim et al., 2002; 
Timmers et al., 2004; Klinman, 2006). DβM is a homotetrameric glycoprotein 
that localizes primarily within the chromaffin granules of the adrenal medulla 
and the large dense-core synaptic vesicles of noradrenergic neurons where it 
exists as both a soluble and a membrane-bound protein (Geffen et al., 1969; 
Stewart and Klinman, 1988; Kim et al., 2002). The stimulus-dependent secretion 
of the soluble enzyme accounts for the presence of DβM in blood and CSF 
(Stewart and Klinman, 1988; Kim et al., 2002).  
Expression of PAM in adults is highest in the secretory vesicles of atrial 
myocytes, endocrine cells of the pituitary gland and in many neurons, but not 
limited to theses cell types (Rhodes et al., 1990; Prigge et al., 2000). PAM 
exclusively catalyzes the C-terminal α-amidation of various glycine-extended 
propeptides, a post-translational modification essential for the bioactivity of 
diverse physiological regulators including peptide hormones, 
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neurotransmitters and growth factors (Klinman, 1996; Prigge et al., 1997; Prigge 
et al., 2000; Bousquet-Moore et al., 2010a). Due to the physiological importance 
of PAM, lack of functional PAM in mice is embryonic lethal (Bousquet-Moore et 
al., 2010a). PAM is composed of two enzymatic domains that act sequentially 
on the target substrate (Klinman, 1996; Prigge et al., 1997; Prigge et al., 2000; 
Bousquet-Moore et al., 2010a). The amino-terminal domain, peptidylglycine α-
hydroxylating monoxygenase (PHM) catalyzes the stereospecific hydroxylation 
of the glycine α-carbon of the peptidylglycine substrates whereas the second 
domain, peptidyl- α-hydroxyglycine α-amidating lyase (PAL), generates the α-
amidated peptide product and glyoxylate (Prigge et al., 1997; Prigge et al., 2000; 
Bousquet-Moore et al., 2010a). The isolated domains that can be separated 
either through endoprotease cleavage or through independent expression retain 
their enzymatic activity (Prigge et al., 1997; Prigge et al., 2000). Tissue-specific 
and developmentally regulated alternative splicing gives rise to multiple 
isoforms of PAM, the most important being PAM-1, -2 and -3 (Klinman, 1996; 
Prigge et al., 2000; Bousquet-Moore et al., 2010a). While PAM-3 is a soluble 
protein, both PAM-1 and -2 are membranous proteins (Klinman, 1996; 
Bousquet-Moore et al., 2010a). However, PAM-1 can be post-translationally 
modified generating separated, soluble PHM and PAL, which are stored in 
large dense-core vesicles and secreted along with the neuropeptides or peptide 
hormones (Klinman, 1996; Prigge et al., 2000; Bousquet-Moore et al., 2010a). 
Comparison of the primary sequence of the catalytic core of PHM with DβM 
indicates a central core of around 300 amino acids that is 27% identical and 40% 
homologues to the catalytic domain of PHM (Southan and Kruse, 1989; Prigge 
et al., 2000; Klinman, 2006; Kapoor et al., 2011). In particular, the copper binding 
sites of PHM and DβM show strong sequence similarity (Klinman, 1996, 2006). 
Both enzymes contain two type 2 coppers sites per subunit termed CuM and 
CuH, the former being coordinated by two histidine and one methionine, the 
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latter by three histidine residues (Solomon et al., 1996; Prigge et al., 1997; Prigge 
et al., 2004; Klinman, 2006; Hess et al., 2008; Chufan et al., 2010; Solomon et al., 
2011). The nonequivalent copper centers are largely separated in space with no 
bridging ligand and no observable magnetic interaction (Klinman, 1996; Prigge 
et al., 1997; Gherman et al., 2006; Solomon et al., 2011). CuH solely functions as 
an electron transfer site, whereas CuM is the site at which dioxygen binding, 
activation and subsequent substrate hydroxylation take place (Prigge et al., 
1997; Evans et al., 2003; Prigge et al., 2004; Gherman et al., 2006; Hess et al., 
2008). In addition to its established catalytic function, the CuM site also plays a 
significant structural role (Siebert et al., 2005). During catalytic cycling one 
electron is transferred by each copper to molecular oxygen by a yet unclear 
mechanism (Prigge et al., 1997, 1999; Prigge et al., 2000; Evans et al., 2003; Chen 
and Solomon, 2004; Prigge et al., 2004; Klinman, 2006; Solomon et al., 2011). Due 
to the separation of the two copper ions by about 11 Å a direct electron transfer 
from CuH to the CuM-dioxygen complex is prohibited (Prigge et al., 1997, 1999; 
Prigge et al., 2000; Prigge et al., 2004). Several pathways for the electron transfer 
between the two copper sites have been proposed, but the exact mechanism 
remains an open question (Prigge et al., 1999; Prigge et al., 2000; Evans et al., 
2003; Prigge et al., 2004; Klinman, 2006; Solomon et al., 2011).  
Proper metallation of DβM and PHM is essential for their activity. In Menkes 
disease patients plasma catechol levels are altered and levels of amidated 
peptides are low, reflecting DβM and PHM deficiency, respectively (El Meskini 
et al., 2003; Steveson et al., 2003; Niciu et al., 2007; Kaler et al., 2008; Goldstein et 
al., 2009). Menkes disease is an inherited disorder caused by defects in the 
copper transporting ATPase ATP7A, which transports copper out of the cell as 
well as into the secretory pathway (Tumer and Moller, 2010). Thus, copper 
loading of both, DβM and PHM, is likely to depend on ATP7A. In support of 
this view, PAM activity is compromised in cells lacking functional ATP7A, 
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although expression levels of PAM are normal (El Meskini et al., 2003; Steveson 
et al., 2003; Niciu et al., 2007). 
1.1.1.7 Copper amine oxidases 
Amine oxidases catalyze the oxidative deamination of various amines and the 
subsequent reduction of oxygen to hydrogen peroxide (Klinman, 1996; Lyles, 
1996; Toninello et al., 2006; Sebela et al., 2007; Boobis et al., 2009). Ubiquitously 
expressed in all forms of life, amine oxidases allow bacteria, yeast and fungi the 
use of amines as nitrogen source via the oxidative release of ammonium and 
play an important role in regulating the levels of various biogenic amines in 
higher eukaryotes (Klinman, 1996; Mure, 2004; O'Sullivan et al., 2004; Toninello 
et al., 2006; Boobis et al., 2009). Amine oxidases are a heterogeneous group of 
enzymes that can be divided according to their cofactor into copper amine 
oxidases and flavin-containing amine oxidases (Toninello et al., 2006; Sebela et 
al., 2007; Boobis et al., 2009).  
Copper amine oxidases are almost always observed to be homodimers with the 
two subunit containing each a type 2 copper center (Klinman, 1996; Brazeau et 
al., 2004; MacPherson and Murphy, 2007). In addition to copper, 
trihydroxyphenylalanine quinone (TPQ) is utilized as cofactor (Klinman, 1996; 
Brazeau et al., 2004; Mure, 2004; MacPherson and Murphy, 2007; Sebela et al., 
2007; Boobis et al., 2009). TPQ is auto-catalytically derived from a tyrosine 
residue within the nascent protein (Klinman, 1996; Brazeau et al., 2004; 
MacPherson and Murphy, 2007). The bound copper participates in this process, 
most likely by coordinating to the pre-TPQ residue and reaction intermediates 
(DuBois and Klinman, 2005; MacPherson and Murphy, 2007). Amine oxidation 
by copper amine oxidases follows a ping-pong mechanism during which TPQ is 
first reduced by the amine substrate and subsequently reoxidized by molecular 
oxygen (Klinman, 1996; Kishishita et al., 2003; Shepard et al., 2008). While the 
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reduction of TPQ is believed to proceed independent of copper (Kishishita et 
al., 2003), its role in the reoxidation step is still under debate. Copper may either 
be directly involved in the transfer of electrons from the reduced organic 
cofactor to dioxygen by activating molecular oxygen or may solely provide 
electrostatic stabilization of the superoxide anion intermediate (Mills et al., 
2002; Kishishita et al., 2003; Brazeau et al., 2004; DuBois and Klinman, 2005; 
Mukherjee et al., 2008; Shepard et al., 2008). 
In mammals two principal classes of copper amine oxidases exist: primary 
amine oxidases (also often referred to as semicarbazide-sensitive amine 
oxidase) and diamine oxidases (Schwelberger, 2007; Sebela et al., 2007; Boobis et 
al., 2009). Primary amine oxidases prefer primary monoamines as substrates 
and have no or little activity towards diamines (O'Sullivan et al., 2004; Boobis et 
al., 2009; Kaitaniemi et al., 2009). The physiological substrates are unspecified, 
but are believed to include methylamine, aminoacetone, dopamine and/or 
tyramine (Lizcano et al., 1991; O'Sullivan et al., 2004; Kaitaniemi et al., 2009). 
Mammalian primary amine oxidases comprise vascular adhesion protein-1 
(VAP-1) and the homologous retinal-specific amine oxidase (Bono et al., 1998; 
Smith et al., 1998; Zhang et al., 2003; Schwelberger, 2007). Both enzymes are 
membrane proteins mainly located in the plasma membrane with large 
extracellular domains that harbor the catalytic site (Salmi and Jalkanen, 1992; 
Morris et al., 1997; Zhang et al., 2003). Proteolytic cleavage of VAP-1 from 
adipocytes and endothelial cells results in a soluble enzyme which accounts for 
the majority of primary amine oxidases activity in human and mouse plasma 
(Kurkijarvi et al., 1998; Kurkijarvi et al., 2000; O'Sullivan et al., 2004; 
Schwelberger, 2007). VAP-1 has been demonstrated to mediate leukocyte 
adhesion, to stimulate glucose uptake and to induce cell differentiation of 
adipocytes in a hydrogen peroxide-dependent manner (Salmi and Jalkanen, 
2001; Salmi et al., 2001; Yu et al., 2003; O'Sullivan et al., 2004). Furthermore, the 
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products of the amine oxidase reaction have been postulated to have an 
important role in signaling, but may also contribute to the pathogenesis of 
various inflammation-associated diseases (Salmi and Jalkanen, 2001; O'Sullivan 
et al., 2004). Thus, plasma as well as membrane-bound primary amine oxidase 
activities are observed to be elevated in Alzheimer’s disease, cancer and 
diabetes type 1 and 2 (Yu et al., 2003; O'Sullivan et al., 2004; Toninello et al., 
2006). However, the physiological functions of primary amine oxidases are still 
not well understood (Salmi and Jalkanen, 2001; O'Sullivan et al., 2004; 
MacPherson and Murphy, 2007; Kaitaniemi et al., 2009). 
Diamine oxidase preferentially oxidizes diamines (Sessa and Perin, 1994; 
Elmore et al., 2002; Boobis et al., 2009). Its physiological substrates include 
histamine, putrescine, cadaverine and the polyamine spermidine (Sessa and 
Perin, 1994; Elmore et al., 2002). Diamine oxidase is a soluble enzyme localized 
to intracellular vesicles with the highest expression levels found in kidney, 
placenta and intestine (Schwelberger et al., 1998; Elmore et al., 2002; 
Schwelberger, 2007). Plasma levels are usually very low, but increase in 
response to heparin and during pregnancy (Sessa and Perin, 1994; Elmore et al., 
2002; Schwelberger, 2007; Boobis et al., 2009). Diamine oxidase is the main 
enzyme for metabolism of exogenous histamine and is postulated to play a role 
in the regulation of cell proliferation, inflammation and ischemia (Sessa and 
Perin, 1994; Elmore et al., 2002; Maintz and Novak, 2007; McGrath et al., 2009; 
Jones and Kearns, 2011).  
1.1.2 Angiogenesis 
Angiogenesis, the formation of new blood vessels from existing vasculature, is 
involved in many physiological and pathological conditions (Costa et al., 2004; 
Gupta and Zhang, 2005; D'Andrea et al., 2010; Carmeliet and Jain, 2011). 
Angiogenesis is a strictly regulated process that plays an essential role in 
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embryonic development, wound healing and ovulation (Costa et al., 2004; 
Gupta and Zhang, 2005; D'Andrea et al., 2010; Carmeliet and Jain, 2011). 
Insufficient angiogenesis is associated with cardiovascular diseases, stroke as 
well as a reduced capacity for tissue repair, while excessive angiogenesis is 
observed in cancer, retinopathies, arthritis and psoriasis (Gupta and Zhang, 
2005; D'Andrea et al., 2010; Carmeliet and Jain, 2011). The crucial role of 
angiogenesis in the progression of tumor growth and metastasis has prompted 
extensive research into anti-angiogenic strategies as cancer-therapeutics (Gupta 
and Zhang, 2005; Finney et al., 2009; Tisato et al., 2010; Carmeliet and Jain, 
2011). Several studies point to a pivotal role of copper in normal and 
pathological angiogenesis. However, in addition to the requirement of copper 
in the angiogenic process, copper itself has been identified to be angiogenic 
(Parke et al., 1988; Hu, 1998; Gerard et al., 2010). 
The copper content of rabbit corneas has been shown to increase in response to 
an angiogenic stimulus (Gullino et al., 1990) and nutrition-induced copper 
depletion or treatment with copper chelators have been shown to inhibit 
neovascularization as well as endothelial cell proliferation and migration 
(Matsubara et al., 1989; Brem et al., 1990; Gullino et al., 1990; Juarez et al., 2006; 
Mamou et al., 2006; Finney et al., 2007; Hassouneh et al., 2007; Lowndes et al., 
2009). In addition, the observed elevated tissue and serum levels of copper and 
Cp in patients suffering from various cancers with extensive angiogenesis 
further hint to an important role of copper in tumor angiogenesis (Coates et al., 
1989; Gullino et al., 1990; Senra Varela et al., 1997; Nayak et al., 2004; Uriu-
Adams and Keen, 2005; Doustjalali et al., 2006). The precise mechanisms by 
which bioavailable copper exerts its multiple effects on angiogenesis are not 
fully understood. However, numerous processes important for the regulation of 
angiogenesis have been found to be influenced by copper, either directly or 
indirectly (Finney et al., 2009; D'Andrea et al., 2010). Specifically copper, but not 
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other transition metals, has been shown to be required for the expression and/or 
secretion of several angiogenic mediators, including vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF)-1 , interleukin (IL)-1α and 
IL-8 (Prudovsky et al., 2003; Martin et al., 2005; Soldi et al., 2007; Di Serio et al., 
2008; D'Andrea et al., 2010). X-ray fluorescence microprobe (XFM) approaches 
have shown copper to be highly spatially regulated during the angiogenic 
processes, as it is translocated from the cells perinuclear areas towards the tips 
of extending filopodia, followed by subsequent release into the extracellular 
space (Finney et al., 2007; Finney et al., 2009). Based on these result it has been 
postulated that copper activates an extracellular target essential for the 
angiogenic process (Finney et al., 2007; Finney et al., 2009). Consistent with this 
hypothesis copper influences the biological activity of proteins and protein-
derived fragments that modulate several biological processes involved in 
angiogenesis, endothelial cell migration and proliferation. Copper has been 
shown to enhance the effects of VEGF and FGF-2 on angiogenesis (Gerard et al., 
2010) and to increase specific binding of the potent angiogenic protein 
angiogenin to endothelial cells (Badet et al., 1989; Soncin et al., 1997; Hu, 1998). 
Furthermore, biomolecules such as heparin and the peptide glycyl-L-hystidyl-
L-lysine have been found to induce the formation of new capillaries when 
bound to copper (Gullino et al., 1990). 
Recognition of copper as critical factor in angiogenesis has encouraged research 
into the use of copper chelators in anti-angiogenic cancer therapy. Depletion of 
copper has been shown to inhibit angiogenesis in a wide variety of cancer cell 
and xenograft systems (Brem et al., 1990; Juarez et al., 2006; Hassouneh et al., 
2007; Khan and Merajver, 2009; Kumar et al., 2010). Phase I and II clinical trials 
utilizing copper chelation as either an adjuvant or as primary therapy have 
shown promising results (Henry et al., 2006; Lowndes et al., 2008; Pass et al., 
2008; Khan and Merajver, 2009; Lin et al., 2011). 
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1.1.3 Non-classical secretion  
The transport of polypeptides across or into biological membranes is an 
important process in all living organisms. Proteins destined for translocation 
frequently possess specific signal sequences that target them to their particular 
destinations (van Vliet et al., 2003; Derby and Gleeson, 2007; Neupert and 
Herrmann, 2007; Wente and Rout, 2010). Most secretory proteins contain a 
hydrophobic N-terminal sequence for targeting into the endoplasmic reticulum 
(ER) from where they are exported from the cell through the classical ER-Golgi 
pathway (Prudovsky et al., 2003; van Vliet et al., 2003; Prudovsky et al., 2008). 
However, some proteins found in the extracellular milieu lack such sequences 
and are released via non-classical ER-Golgi-independent routes (Prudovsky et 
al., 2003; Prudovsky et al., 2008; Nickel, 2011). FGF-1 and IL-1α that belong to 
this group of proteins are secreted by a copper-dependent mechanism 
(Landriscina et al., 2001; Mandinova et al., 2003; Prudovsky et al., 2003; Sivaraja 
et al., 2006; Soldi et al., 2007; Di Serio et al., 2008). Both are exported as 
components of multiprotein complexes and a crucial role in the assembly of 
these complexes has been ascribed to copper (Landriscina et al., 2001; 
Mandinova et al., 2003; Sivaraja et al., 2006). In addition, copper might be 
required for the formation of FGF-1 homodimers that is critical for FGF-1 
release (Landriscina et al., 2001; Prudovsky et al., 2008). 
1.1.4 Hypoxia-inducible factor 1 
The hypoxia-inducible factor (HIF)-1 is a key regulator of the transcriptional 
response to hypoxia in mammals (Martin et al., 2005; Ke and Costa, 2006; 
Majmundar et al., 2010). Among others, the corresponding gene products are 
involved in erythropoiesis, iron metabolism, angiogenesis, glucose uptake and 
glycolysis (Martin et al., 2005; Ke and Costa, 2006; Majmundar et al., 2010). HIF-
1 is a α1β1 heterodimer specifically recognizing HIF-1-binding sites within cis-
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regulatory hypoxia response elements (Martin et al., 2005; Ke and Costa, 2006; 
Majmundar et al., 2010). Although constitutively synthesized, protein levels of 
the α-subunit (HIF-1α) are almost not detectable under normoxic conditions, 
since HIF-1α is subject of rapid ubiquitination by the van Hippel-Landau tumor 
suppressor protein and subsequent proteasomal degradation (Martin et al., 
2005; Ke and Costa, 2006; Majmundar et al., 2010). Ubiquination by the van 
Hippel-Landau tumor suppressor protein requires the modification of HIF-1α 
by prolyl-4-hydroxylation, which is accomplished by a family of oxygen- and 
iron-dependent prolyl-4-hydroxylases (Martin et al., 2005; Ke and Costa, 2006; 
Majmundar et al., 2010). Hypoxic conditions diminish prolyl-4-hydroxylases 
activity and thus facilitate HIF-1α accumulation and translocation into the 
nucleus, where it dimerizes with HIF-1β and interacts with transcriptional 
cofactors to assemble the HIF-1 transcriptional complex (Martin et al., 2005; Ke 
and Costa, 2006; Majmundar et al., 2010). HIF-1 activity is further controlled by 
another iron-dependent dioxygenase, the factor inhibiting HIF-1, which can 
hydroxylate HIF-1α at a C-terminal asparagine residue, thereby preventing the 
recruitment of transcriptional cofactors (Martin et al., 2005; Ke and Costa, 2006; 
Majmundar et al., 2010).  
Being required for HIF-1 binding to the hypoxia response elements of target 
genes as well as for the formation of the HIF-1 transcriptional complex, copper 
is essential for HIF-1 transcriptional activity (Feng et al., 2009). Consequently, 
copper deprivation suppresses the transcriptional activity of HIF-1 under 
conditions otherwise known to activate it (Jiang et al., 2007; Feng et al., 2009). 
Besides the need of copper for HIF-1 transcriptional activity, excess of copper 
stabilizes the HIF-1α protein, most likely by inhibition of prolyl-4-hydroxylases 
(Martin et al., 2005). 
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1.1.5 Essentiality and toxicity of copper 
Copper is an essential element for all forms of life. According to the World 
Health Organization (WHO), a metal is categorized as essential when “absence 
or deficiency of the element from the diet produces either functional or 
structural abnormalities and that the abnormalities are related to, or a 
consequence of specific biochemical changes that can be reversed by the 
presence of the essential metal” (WHO, 1996). However, also excessive intake of 
copper can cause adverse health effects (Chambers et al., 2010). Beside 
inappropriate dietary copper supply a number of human disorders result in 
copper deficiency or copper toxicity (Huster, 2010; Tumer and Moller, 2010). 
Health effects in connection with states of low or elevated copper may range 
from sub-clinical effects via clinical effects to lethal effects (WHO, 2002; Zatta 
and Frank, 2007).  
In the US the estimated mean copper intake from food is 1.2 – 1.6 mg/d for men 
and 1.0 – 1.1 mg/d for women (Food and Nutrition Board, 2001). Higher copper 
intakes have been reported for the European Union, where mean dietary copper 
intakes have been reported to range from 2.4 mg/d (United Kingdom) to 4.2 
mg/d (Germany) in men and from 1.7 mg/d (United Kingdom) to 3.3 mg/d 
(Germany) in women (Flynn et al., 2009). The main dietary sources of copper 
are shellfish, organ meat, seeds, grains, nuts and beans (Hunt and Meacham, 
2001; Tapiero et al., 2003; de Romana et al., 2011). Besides food, drinking water 
can significantly contribute to daily intake, although this strongly varies from 
country to country (de Romana et al., 2011). Dietary supplements containing 
copper are consumed by approximately 15% of adults in the US (Food and 
Nutrition Board, 2001; Flynn et al., 2009). For men and women the 
recommended dietary copper intake is 0.9 mg Cu/d in the US (Food and 
Nutrition Board, 2001; Trumbo et al., 2001) and 1.1 mg Cu/d in the European 
Union (Scientific Committee on Food, 2003). The upper safe limit of daily 
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copper intake was prescribed to 10 mg Cu/d and 5 mg Cu/d in the US (Food 
and Nutrition Board, 2001; Trumbo et al., 2001) and in the European Union 
(Scientific Committee on Food, 2003; Flynn et al., 2009), respectively. However, 
the upper safe limit was largely based on liver toxicity endpoints and does not 
take less severe but clinically important responses into consideration 
(Chambers et al., 2010). 
1.1.5.1 Copper deficiency 
Copper deficiency in humans can occur through multiple mechanisms (Uriu-
Adams and Keen, 2005; Zatta and Frank, 2007; de Romana et al., 2011). It can be 
observed in premature and low-birth weight infants who can be born with low 
hepatic copper stores (Walravens, 1980; Nassi et al., 2009), in individuals 
receiving total parenteral nutrition without adequate copper supplementation 
(Angotti et al., 2008; Imataki et al., 2008; Shike, 2009), in malnourished infants 
(Cordano, 1998) and in persons with malabsorption syndromes (Jameson et al., 
1985; Jaiser and Winston, 2010). Low copper intakes in the diet can result in 
marginal copper deficiency. Although the mean dietary copper intake in the US 
and European Union is higher then the recommended one, the diets of 
approximately 25% of individuals do not meet this recommendation (Stern, 
2010; Klevay, 2011). Marginal copper deficiency is therefore assumed to be 
widespread among populations (Stern et al., 2007; Stern, 2010; Klevay, 2011). 
Secondary copper deficiency can occur as consequence of high dietary intake of 
zinc (Horvath et al., 2010), of pharmacological treatments with copper chelating 
agents such as D-penicillamine or tetrathiomolybdate and after gastrointestinal 
surgery (O'Donnell and Simmons, 2011). Furthermore, severe copper deficiency 
is a hallmark of the hereditary diseases Menkes disease and occipital horn 
syndrome, both originating from genetic defects in the copper transporting 
ATPase ATP7A (Tumer and Moller, 2010; Kaler, 2011; Kodama et al., 2011). 
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The clinical symptoms of copper deficiency in humans are numerous (Danks, 
1988; Uauy et al., 1998). Early and common signs of acquired copper deficiency 
are hematological manifestations such as anemia, leucopenia, neutropenia and 
pancytopenia (Angotti et al., 2008; Halfdanarson et al., 2008; Imataki et al., 
2008). Bone abnormalities including osteoporosis, bone fractures and bone 
malformation have often been observed in copper deficient low-birth-weight 
infants and young children (Sutton et al., 1985; Stern et al., 2007). Acquired 
copper deficiency may manifest with neurological symptoms, the clinical 
presentation resembling that of myeloneuropathy observed in vitamin B12 
deficiency (Schleper and Stuerenburg, 2001; Jaiser and Winston, 2010). 
Moreover, acquired copper deficiency has been identified as a dietary factor 
that may increase the risk of colon cancer (Chambers et al., 2010). The clinical 
features of Menkes disease include severe progressive neurological 
degeneration, connective tissue abnormalities, muscular hypotonia and 
hypopigmentation of skin and hair (Tumer and Moller, 2010; Kaler, 2011; 
Kodama et al., 2011).  
Many of the clinical symptoms of acquired copper deficiency and Menkes 
disease can be attributed to a decrease in the activities of copper-dependent 
enzymes. Thus, hypopigmentation of skin and hair results from reduced 
tyrosinase activity and abnormalities of bone and connective tissue are 
principally due to lowered LOX activity (Petris et al., 2000; Kaler, 2011; Kodama 
et al., 2011). While the exact mechanism of copper deficiency myelopathy is not 
known (Jaiser and Winston, 2010), neurological degeneration in Menkes disease 
is believed to be primarily caused by a decrease in the activity of neuronal 
cytochrome c oxidase (Rossi et al., 2004; Kodama et al., 2011). Oxidative stress 
as a consequence of  a low copper status may contribute to some of the clinical 
effects observed in human copper deficiencies (Uriu-Adams and Keen, 2005). 
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1.1.5.2 Copper toxicity 
Excess of copper compared to cellular needs is harmful. Acute copper toxicity 
has been described for individuals that accidentally or with suicidal intention 
ingested high doses of copper (Gunay et al., 2006; Franchitto et al., 2008; Sood 
and Verma, 2011). For copper doses up to 1 gram, gastrointestinal symptoms 
predominate (Gunay et al., 2006; Franchitto et al., 2008). Following ingestion of 
higher doses, nausea, vomiting, headache, diarrhea, hemolytic anemia, 
gastrointestinal hemorrhage, liver and kidney failure as well as death may 
occur (Gunay et al., 2006; Franchitto et al., 2008; Sood and Verma, 2011).   
Chronic copper toxicity is a feature of Wilson’s disease, Indian Childhood 
Cirrhosis and Idiopathic Chronic Toxicosis (Scheinberg and Sternlieb, 1996; 
Tanner, 1998; Huster, 2010). Wilson’s disease originates from a genetic defect in 
the copper transporting ATPase ATP7B that results in excessive copper 
accumulation particular in liver and brain (Scheinberg and Sternlieb, 1996; 
Pfeiffer, 2007; Huster, 2010). Wilson’s disease is connected with hepatic 
ophthalmologic, neurological and/or psychiatric symptoms (Scheinberg and 
Sternlieb, 1996; Pfeiffer, 2007; Huster, 2010). Indian Childhood Cirrhosis and 
Idiopathic Chronic Toxicosis are severe chronic liver diseases that are 
characterized by excessive hepatic copper accumulation (Scheinberg and 
Sternlieb, 1996; Tanner, 1998). The etiology of these rare diseases has been 
hypothesized to be a combination of an unknown genetic defect affecting the 
copper metabolism and high dietary copper intake (Scheinberg and Sternlieb, 
1996; Tanner, 1998). However, the causative role of copper in Indian Childhood 
Cirrhosis has recently been doubted (Sriramachari and Nayak, 2008). Chronic 
copper toxicity in individuals with no genetic susceptibility is rare and not 
considered as a major human health concern (Uriu-Adams and Keen, 2005; de 
Romana et al., 2011). 
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Both acute and chronic copper toxicity are in part a consequence of the redox 
activity of copper. Similar to low-molecular weight iron, unbound or loosely 
bound copper can catalyze the production of hydroxyl radicals in a Fenton-like 
reaction, which may induce oxidative stress and subsequent damage of cellular 
components (Gunther et al., 1995; Britton, 1996; Burkitt, 2001; Uriu-Adams and 
Keen, 2005; Halliwell and Gutteridge, 2007). In addition, excess of copper has 
been discussed to manifests its toxicity by direct inhibition of protein functions 
(Boulard et al., 1972; Letelier et al., 2005; Pamp et al., 2005; Letelier et al., 2006; 
Schwerdtle et al., 2007). 
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Homeostasis denotes “the process through which a tightly controlled set of 
physiological mechanisms monitors and regulates the absorption, transport, 
distribution, tissue storage and excretion of essential nutritions in order to 
ensure a constant and sufficient supply under varying conditions of intake 
while simultaneously avoiding excessive body levels that may lead to toxicity” 
(Stern, 2010). Given the requirement for copper on one hand and the potential 
toxicity of copper on the other, cells have evolved mechanisms to regulate 
cellular copper concentrations. Many of the components involved in cellular 
copper homeostasis are well known at the molecular level. These include 
transporters that mediate the uptake and efflux of copper, biomolecules that 
sequester and store copper and specialized proteins called copper chaperones 
that guide copper to copper-dependent enzymes and to organelles (Table 2). 
 Table 2: Proteins involved in mammalian copper homeostasis 
Protein Function 
Copper transporter receptor 1 (Ctr1) Copper uptake 
Copper transporter receptor 2 (Ctr2) Copper uptake 
Divalent metal transporter 1 (DMT1) Copper uptake 
Copper chaperone for superoxide dismutase 
(CCS) 
Intracellular copper trafficking 
ATOX1 Intracellular copper trafficking 
Cox17 Intracellular copper trafficking 
Glutathione (GSH) Intracellular copper trafficking, 
storage and detoxification 
Metallothionein (MT) Storage and detoxification 
ATP7A Copper export 
ATP7B Copper export 
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1.2.1 Copper uptake 
Members of the copper transporter receptor (Ctr) family that were first 
described for Saccharomyces cerevisiae (Dancis et al., 1994; Knight et al., 1996), 
play a key role in the uptake of copper in eukaryotic cells. In man, the two Ctr-
members hCtr1 and hCtr2 have been identified (Zhou and Gitschier, 1997). Ctr1 
is considered as the major contributor to high-affinity copper uptake in 
mammalian cells (Lee et al., 2001; Eisses et al., 2005; Maryon et al., 2007b; Kim et 
al., 2008). The human and mouse homologues, hCtr1 and mCtr1, were 
identified by functional complementation of a growth defect of a yeast copper 
uptake mutant (Zhou and Gitschier, 1997; Lee et al., 2000). Ctr1 mediates 
copper uptake with an apparent KM-value of 1-8 µM (Eisses and Kaplan, 2002; 
Lee et al., 2002a; Lee et al., 2002b; Eisses and Kaplan, 2005). The transport of 
copper by hCtr1 does not depend on ATP hydrolysis or an ion gradient (Lee et 
al., 2002a), suggesting that hCtr1 is neither an ion pump nor a secondary active 
transporter. Since Ctr1-mediated copper uptake is effectively inhibited by Ag+, 
which is isoelectric to Cu+, and strongly stimulated by ascorbate, monovalent 
copper is thought to be the copper species transported by Ctr1 (Lee et al., 2002a; 
Lee et al., 2002b; Bertinato et al., 2010). In addition to hCtr1, hCtr2 has been 
shown to mediate the uptake of Cu+ (van den Berghe et al., 2007; Bertinato et al., 
2008). However, since hCtr2 transports copper with lower affinity compared to 
hCtr1 (Bertinato et al., 2008), does not complement the yeast copper uptake 
deficiency (Zhou and Gitschier, 1997) and is predominately located in 
intracellular compartments (van den Berghe et al., 2007; Bertinato et al., 2008), 
its exact role in copper transport in mammalian cells remains unclear (Gupta 
and Lutsenko, 2009). 
hCtr1 is composed of 190 amino acids and is predicted to have a molecular 
mass of 23 kDa (Zhou and Gitschier, 1997). However, due to N- and O-
glycosylation hCtr1 resolves as 30-35 kDa band in polyacrylamide gels (Eisses 
1. Introduction 
1.2 Cellular copper homeostasis 
41 
 
and Kaplan, 2002; Klomp et al., 2002; Lee et al., 2002a). Human Ctr1 is 
substantially smaller than the yeast analogue (406 amino acids) and shares only 
23% sequence homology with this protein (Dancis et al., 1994; Zhou and 
Gitschier, 1997). In contrast, the mouse and rat Ctr1-homologues share more 
than 90% sequence identity with hCtr1 (Zhou and Gitschier, 1997; Lee et al., 
2000). Despite the poor sequence identity, mammalian Ctr1 and yeast Ctr1 have 
a similar overall architecture consisting of (1) an extracellular N-terminus, (2) an 
intracellular loop connecting the first and second transmembrane domain, (3) 
three membrane spanning α-helices and (4) an intracellular C-terminus. 
The extracellular N-terminus of hCtr1 (Eisses and Kaplan, 2002; Puig et al., 
2002; Klomp et al., 2003) contains two histidine-rich regions and two 
methionine motifs (Zhou and Gitschier, 1997; Eisses and Kaplan, 2002) and is N- 
and O-linked glycosylated at residues Asp15 and Thr27, respectively (Eisses and 
Kaplan, 2002; Klomp et al., 2002; Maryon et al., 2007a). Mutation analysis 
revealed that deletion of the first methionine motif and/or of the His-rich 
regions has almost no effect on copper transport activity of hCtr1 (Puig et al., 
2002; Eisses and Kaplan, 2005). However, these regions may be of importance 
under physiological conditions in accepting copper ions from copper binding 
proteins or copper complexes (Eisses and Kaplan, 2005; Maryon et al., 2007a). In 
contrast, mutation or deletion of methionine residues in the second methionine 
motif had a strong inhibitory effect on hCtr1-mediated copper uptake (Puig et 
al., 2002; Eisses and Kaplan, 2005; Larson et al., 2010). Glycosylation is not 
required for protein stability (Eisses and Kaplan, 2005) or plasma membrane 
delivery (Klomp et al., 2003) of hCtr1, but is essential for its copper transport 
activity and for endocytotic response to copper (Guo et al., 2004; Eisses and 
Kaplan, 2005). N-glycosylation has been suggested to stabilize or modify the 
structure of hCtr1 in a way that facilitates copper transport (Maryon et al., 
2007a). O-glycosylation is required to protect the N-terminus of hCtr1 against 
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proteolytic cleavage (Maryon et al., 2007a; Maryon et al., 2009). In addition, the 
N-terminal domain has been shown to interact with itself and thus, may be 
involved in the constitution and/or stabilization of hCtr1-trimers (Klomp et al., 
2003). 
The function of the intracellular loop of Ctr proteins has not been reported so 
far. In hCtr1 a conserved dileucine motif (van den Berghe and Klomp, 2010), 
that is known to play a role in the internalization of membrane proteins in 
mammalian cells (Sandoval and Bakke, 1994), and a Yxx-(hydrophobic amino 
acid) internalization sequence (YNSM), suggests a possible function in the 
endocytosis of hCtr1 (van den Berghe and Klomp, 2010). 
In contrast to most other transporters that are predicted to have 6-12 
membrane-spanning domains, Ctr1 contains only three membrane spanning α-
helices (Eisses and Kaplan, 2002; Klomp et al., 2003). Since three α-helices are 
insufficient to form a translocation pore, Ctr1 has to oligomerize to provide a 
pore that allows copper to pass through the plasma membrane (Eisses and 
Kaplan, 2005; De Feo et al., 2007). Indeed, biochemical, genetic and electron 
microscopy studies have demonstrated that Ctr1 forms homotrimers (Eisses 
and Kaplan, 2002; Lee et al., 2002a; Aller and Unger, 2006) and that 
oligomerization is essential for Ctr1 functionality (Aller et al., 2004). The 
primary sequences of the transmembrane regions are poorly conserved among 
Ctr proteins (De Feo et al., 2007). An exception is a MxxxM-X12-GxxxG-motif, 
which links a MxxxM motif (MM4-motif) at the end of the second 
transmembrane domain (TM2) with an GxxxG-motif (GG4-motif) in the center 
of the third membrane spanning domain (TM3), and consequently was 
considered to represent a Ctr signature motif (De Feo et al., 2007). The strict 
conservation of the MM4- and GG4-motifs suggests that these two motifs and 
hence TM2 and TM3 contribute to the copper-permeable pore and/or to the 
mechanism of copper translocation (De Feo et al., 2007). Indeed, mutation 
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analysis have revealed the importance of the metal binding properties of the 
methionine residues in the MM4-motif for the copper transport activity of hCtr1 
as well as of yeast Ctr1 (Puig et al., 2002; Eisses and Kaplan, 2005; De Feo et al., 
2009) and the necessity of the GG4-motif for the oligorimerization of Ctr1 to 
functional homotrimers (Aller et al., 2004). 
Truncation of the intracellular C-terminus of hCtr1 lowers the efficiency of 
hCtr1 mediated copper transport (Eisses and Kaplan, 2005). Since the 
carboxyterminus of yeast Ctr1 has been shown to be involved in protein-protein 
interactions with the copper chaperon Atox1 (Xiao and Wedd, 2002), it was 
speculated that truncation of the C-terminus impairs copper uptake at the 
copper release step (Eisses and Kaplan, 2005). Recently, a mechanistic model for 
Cu+ transport by hCtr1 has been proposed in which an important role is 
attributed to the HCH-sequence located at the C-terminus (De Feo et al., 2009). 
In addition, the C-terminus of yeast Ctr1 has been demonstrated to be required 
for the down-regulation of copper transport activity in the presence of excess 
copper (Wu et al., 2009). 
Mammalian Ctr1 is ubiquitously expressed; however, expression levels are 
tissue specific, being highest in the liver, kidney and intestine (Zhou and 
Gitschier, 1997; Lee et al., 2002b; Kuo et al., 2006). In some tissues the expression 
level of Ctr1 depends on the copper status and is influenced by the 
physiological state, such as pregnancy and lactation (Kuo et al., 2006). Ctr1 
plays an essential role in embryonic development as deletion of Ctr1 is 
embryonic lethal, most likely due to an insufficient supply of the developing 
embryo with copper (Kuo et al., 2001b; Lee et al., 2001). In brain and spleen of 
Ctr1-heterozygous knock-out mice copper levels are lowered to about 50% of 
that of wild type animals, but were normal in other organs, suggesting that 
alternative Ctr1-independent copper transport systems play an important role 
in the supply of these organs with copper (Lee et al., 2001). In addition, Ctr1-
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homozygous knock-out cells, isolated from embryos obtained from the inter-
cross of Ctr1-heterozygous mice, possess a residual copper transport activity 
(Lee et al., 2002b), further supporting the presence of alternative copper uptake 
pathways. Nevertheless, the importance of Ctr1 for a proper copper 
homeostasis is demonstrated by lower basal copper levels and lower activities 
of copper dependent enzymes in Ctr1-deficient cells compared to wild type 
cells (Lee et al., 2002b). Tissue-specific deletion of Ctr1 in mice intestine 
revealed an important role of this protein in dietary copper absorption (Nose et 
al., 2006). Intestinal epithelial cells generated from these mice 
hyperaccumulated copper, whereas all organs tested suffered from a severe 
copper deficit (Nose et al., 2006). Despite the up to 10 times higher copper levels 
in these cells compared to that of intestinal epithelial cells from control animals, 
activities of copper dependent enzymes were strongly reduced and levels of the 
copper chaperone for superoxide dismutase dramatically increased. These 
results and the absence of Ctr1 from the apical membrane (Zimnicka et al., 
2007) indicate that Ctr1 is not responsible for transport of copper across the 
apical membrane, but is required to make copper absorbed from the lumen 
bioavailable (Nose et al., 2006).   
In cultured cells, Ctr1 is typically observed at the plasma membrane and in 
cytoplasmic vesicles (Klomp et al., 2002; Gupta and Lutsenko, 2009), but the 
ratio of theses localizations depends on the cell type (Klomp et al., 2002). In 
polarized cells of the intestine, kidney and placenta Ctr1 was found both 
intracellularly and at the basolateral membrane (Hardman et al., 2006; Kuo et 
al., 2006; Nose et al., 2006; Zimnicka et al., 2007). The subcellular localization of 
hCtr1 in HEK293 and HeLa cells has been demonstrated to represent a steady-
state localization which is the result of a dynamic process involving constitutive 
endocytosis and recycling of hCtr1 from and to the plasma membrane (Klomp 
et al., 2002; Petris et al., 2003). In some cell types the presence of copper in 
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concentrations close to the KM-value for copper transport stimulates endocytosis 
of hCtr1 from the plasma membrane, thereby establishing a new steady-state 
(Petris et al., 2003; Guo et al., 2004; Molloy and Kaplan, 2009). Interestingly, Ag+, 
which is isoelectric to Cu+, is also capable to trigger endocytosis of hCtr1 with 
comparable efficiency as copper (Petris et al., 2003). Mutation analysis identified 
the second methionine motif in the amino-terminal region and the MM4-motif 
in TM2, which both are of great importance for the copper transport activity, to 
be also essential for the endocytotic response of hCtr1 to low micromolar 
copper concentrations (Guo et al., 2004). The fate of internalized hCtr1 remains 
uncertain, since two studies showed hCtr1 to be degraded (Petris et al., 2003; 
Guo et al., 2004), whereas another study found it to recycle back to the plasma 
membrane after removal of the copper stimulus (Molloy and Kaplan, 2009).  
The stimulated endocytosis of hCtr1 in response to copper could represent a 
homeostatic control mechanism to prevent excessive copper uptake and 
potential copper toxicity (Petris et al., 2003). On the other hand, the observation 
that already copper concentrations close to the KM-value for copper uptake by 
hCtr1 enhance endocytosis of hCtr1 has led to the proposal that copper uptake 
by Ctr1 is reminiscent to the uptake of transferrin-bound iron by the transferrin-
receptor (Petris et al., 2003). In this model, binding of copper to Ctr1 is thought 
to trigger endocytosis of the copper-Ctr1 complex into an intracellular 
compartment from which copper is transported into the cytosol by hCtr1 (Petris 
et al., 2003).  
A function of Ctr1 in the transport of copper from intracellular vesicles into the 
cytosol has also been assumed to explain the role of Ctr1 in dietary copper 
acquisition (Zimnicka et al., 2007). However, the apical copper entry into 
intestinal cells has clearly been demonstrated to be mediated by a copper 
transport system other than Ctr1 (Nose et al., 2006; Zimnicka et al., 2007). Also 
in other cell types alternative copper transport pathways are likely to contribute 
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to cellular copper uptake (Lee et al., 2002b). The identity of that system remains 
to be elucidated. One study provided evidence that the divalent metal 
transporter (DMT) 1 is involved in apical copper uptake by intestinal cells 
(Arredondo et al., 2003). DMT1 is constituted of 561 amino acids, contains 12 
membrane spanning domains and is widely expressed in several tissues such as 
intestine, kidney and brain (Gunshin et al., 1997). It mediates ferrous iron 
transport across the plasma membrane and from intracellular compartments 
into the cytosol by a process that is coupled to the co-transport of H+, hence, the 
transport of iron by DMT1 generates a positive inward current (Gunshin et al., 
1997). In addition to iron, other transition metal ions including manganese, 
cadmium and copper provoked large inward currents in DMT1 expressing 
oocytes, suggesting that these metals might also be transported by DMT1 
(Gunshin et al., 1997). Indeed, a decreased apical uptake of copper by CaCo2 
cells was observed following partial knock-down of DMT1 and competition 
experiments revealed that copper inhibits apical iron uptake and vice versa 
(Arredondo et al., 2003). On the other hand it should also be pointed out that 
another study found no evidence for a role of DMT1 in apical copper transport 
by CaCo2 cells (Zimnicka et al., 2007). 
Embryonic Ctr1-homozygous knock-out cells have been demonstrated to 
possess a residual copper transport activity of approximately 30% of that of 
wild type cells (Lee et al., 2002b). In contrast to Ctr1-mediated copper uptake, 
Ctr1-independent copper transport activity is of low affinity (KM-value: 10 µM) 
and most likely represents the transport of divalent copper (Lee et al., 2002b). 
Even though the KM-value of this transport pathway is close to that reported for 
hCtr2 (Bertinato et al., 2008) the lack of inhibition by Ag+ makes Ctr2 unlikely to 
contribute to the copper uptake observed in Ctr1-deficient cells. Also, iron, 
manganese and cadmium, high-affinity substrates for DMT1 (Garrick et al., 
2003), only slightly inhibited the residual copper uptake (Lee et al., 2002b). In 
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contrast, zinc strongly competed for Ctr1-independent copper transport, 
leading to the assumption that the alternative copper transport activity could be 
mediated by members of the ZIP (ZRT-/IRT-like protein) family of metal 
transporters (Lee et al., 2002b). In mammals, 14 ZIP transporters have been 
described (Kambe et al., 2004; Lichten and Cousins, 2009). These proteins have 
broad substrate specificity and were shown to transport zinc, manganese, 
cadmium and iron ions (Kambe et al., 2004; Eide, 2006). A contribution of ZIP 
members in copper transport has not been reported, but copper has been shown 
to compete for zinc and cadmium uptake by Zip1, Zip2 and Zip14 (Gaither and 
Eide, 2000, 2001; Girijashanker et al., 2008). However, no direct evidence for a 
contribution of Zip1 and Zip2 to Ctr1-independent copper uptake activity has 
been found (Lee et al., 2002b). Whether other members of this protein family 
may contribute to Ctr1-independent copper accumulation, remains to be 
elucidated.    
Finally, Ctr1-independent copper uptake may not require a specific transporter, 
but may occur by endocytosis (Ferruzza et al., 2000; Zimnicka et al., 2007). In 
support of such a mechanism, apical copper uptake in CaCo2 cells has been 
shown to be not saturable (Ferruzza et al., 2000; Zimnicka et al., 2007). 
However, this lack of saturation might also simply result from the action of an 
unidentified transporter with a very high KM-value for copper ions (Zimnicka et 
al., 2007). 
1.2.2 Copper sequestration and storage  
The accumulation of copper in the cytosol induces a risk for copper-mediated 
oxidative damage and binding of copper to essential biomolecules. However, 
under physiological conditions the concentration of free copper within the cell 
has been calculated to be around 10-18 M which amounts to less than one free 
copper ion per cell (Rae et al., 1999). Such low concentrations of free copper are 
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maintained by binding of copper to metallothioneins (MTs) and ligands of low 
molecular mass such as glutathione (GSH). MTs and GSH also represent the 
major molecules involved in the intracellular sequestering and storing of excess 
copper. In addition, mitochondria have been suggested to contribute to the 
cellular copper buffering capacity (Cobine et al., 2004; Maxfield et al., 2004; 
Leary et al., 2009b). 
1.2.2.1 Glutathione 
The tripeptide GSH is the most abundant low-molecular weight thiol in living 
cells, being present in millimolar concentrations (Hirrlinger and Dringen, 2010; 
Schmidt and Dringen, 2012). GSH is essential for the detoxification of reactive 
oxygen species, maintains the cellular thiol reduction potential in a strongly 
reduced state and is involved in redox regulation and signaling (Hirrlinger and 
Dringen, 2010; Schmidt and Dringen, 2012). In addition, GSH has been linked to 
the transport and the detoxification of metal ions including copper (Ballatori et 
al., 2009; Jomova et al., 2010). 
GSH forms stable complexes with Cu+ in cell-free systems even in the presence 
of oxygen (Ciriolo et al., 1990; Ascone et al., 1993; Kachur et al., 1998; Banci et 
al., 2010). Consistent with GSH functioning as an intracellular copper chelator, 
an elevation of the cellular GSH content has been shown to lower the 
bioavailable intracellular pool of copper (Chen et al., 2008a). Indeed, the 
majority of cytosolic copper is bound to GSH (Freedman et al., 1989) and copper 
in the form of a Cu(I)-GSH complex is believed to be a major contributor to the 
copper exchangeable pool in the cytosol (Miras et al., 2008; Banci et al., 2010). In 
accordance with this function, Cu(I)-GSH is capable of transferring copper to 
MTs (Ferreira et al., 1993) and SOD1 (Ciriolo et al., 1990; Ascone et al., 1993; 
Carroll et al., 2004) in vitro. In vivo, Cu(I)-GSH has been demonstrated to be 
required for the incorporation of copper into MTs and for the CCS-independent 
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activation of SOD1 (Freedman et al., 1989; Carroll et al., 2004; Jensen and 
Culotta, 2005; Leitch et al., 2009a; Huang et al., 2011). Cu(I)-GSH has further 
been suggested to represent the major source of copper for antioxidant protein 1 
(Miras et al., 2008; Poger et al., 2008).  
The susceptibility of cells to copper toxicity strongly correlates with their 
cellular GSH content (Freedman et al., 1989; Steinebach and Wolterbeek, 1994; 
White et al., 1999; Chen et al., 2008a; Du et al., 2008; Vidyashankar and Patki, 
2010). Sequestering of copper by GSH protects cells from the toxic effects of free 
copper that arise from its ability to bind indiscriminately to essential proteins 
and/or to catalyze ROS generation (Hanna and Mason, 1992; Milne et al., 1993; 
Jimenez and Speisky, 2000; Burkitt, 2001). However, Cu(I)-GSH is redox-active 
and continuously reacts with molecular oxygen to produce superoxide (Speisky 
et al., 2008; Speisky et al., 2009; Aliaga et al., 2010; Aliaga et al., 2011). This 
feature accounts for the ability of Cu(I)-GSH to stimulate the release of Fe2+ 
from ferritin and to reduce Fe3+ (Aliaga et al., 2011), thus fostering iron-
catalyzed production of hydroxyl radicals by the Fenton reaction in the 
presence of hydrogen peroxide. This pro-oxidative behavior of the Cu(I)–GSH 
complex has been postulated to underlie the oxidative stress and toxicity 
associated with the over-exposure of cells to copper (Aliaga et al., 2011)  
GSH depletion has been found to lower the rates of copper uptake into liver 
cells and trophoblasts (Freedman et al., 1989; Tong and McArdle, 1995). Hence, 
the formation of the Cu(I)-GSH complex has been assumed to be involved in 
copper uptake (Freedman et al., 1989; Tong and McArdle, 1995). Alternatively, 
this lowered copper uptake might reflect the adaption of the cells to their 
intracellular bioavailable pool of copper. In accord with this view, down-
regulation of hCtr1 was shown to account for lower rates of copper uptake in 
GSH depleted liver cells compared to control cells, whereas hCtr1 abundance 
and copper uptake rates were increased in cells with elevated GSH levels (Chen 
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et al., 2008a). Despite being slower in copper uptake, GSH depleted cells 
accumulate more copper than control cells, since copper export in these cells is 
impaired (Singleton et al., 2010). 
In addition to its copper chelating and copper trafficking properties, GSH can 
participate in cellular copper homeostasis by regulating the activities of copper 
transport proteins via glutathionylation/deglutathionylation (Lim et al., 2006; 
Voronova et al., 2007a; Voronova et al., 2007b; Singleton et al., 2010). At least the 
activities of the copper transporting ATPases ATP7A and ATP7B have recently 
been demonstrated to be regulated by this post-translational mechanism 
(Singleton et al., 2010). Glutathionylation might also be involved in the 
regulation of the copper chaperone function of Cox17 as it has been shown to 
form mixed disulfides with GSH in vitro (Voronova et al., 2007a; Voronova et 
al., 2007b). 
1.2.2.2 Metallothioneins 
Metallothioneins (MTs) constitute a heterogeneous family of low-molecular 
weight, cysteine-rich proteins (Pulido et al., 1966; Buhler and Kagi, 1974; Kagi et 
al., 1974; Bremner and Davies, 1975; Palacios et al., 2011; Vasak and Meloni, 
2011). Phylogenetically conserved members of this protein family are found in 
all eukaryotes, most fungi and certain prokaryotes (Capdevila and Atrian, 2011; 
Palacios et al., 2011). Several biological functions have been ascribed to MTs. In 
addition to a presumed role in zinc and copper homeostasis, MTs have been 
implicated in the detoxification of non-essential metals, protection against ROS, 
maintenance of the intracellular redox balance, regulation of cell proliferation 
and apoptosis, as well as in neuroprotection (Hidalgo et al., 2001; Cherian and 
Kang, 2006; Colvin et al., 2010; Maret, 2011; Thirumoorthy et al., 2011; Vasak 
and Meloni, 2011). 
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In mammals, four distinct MT isoforms exist that are denoted MT-1 to MT-4 
(Kagi and Valee, 1960; Palmiter et al., 1992; Quaife et al., 1994; Thirumoorthy et 
al., 2011; Vasak and Meloni, 2011). The predominant isoforms MT-1 and MT-2 
are ubiquitously expressed in almost all organs and tissues, being most 
abundant in liver and kidney (Thirumoorthy et al., 2011; Vasak and Meloni, 
2011). The expression of MT-3 and MT-4 is confined mainly to the brain and 
stratified epithelium, respectively (Palmiter et al., 1992; Tsuji et al., 1992; Quaife 
et al., 1994; Garrett et al., 1999a; Garrett et al., 1999b; Hozumi et al., 2008; 
Thirumoorthy et al., 2011; Vasak and Meloni, 2011). MT-3 and MT-4 are 
constitutively expressed, while MT-1 and MT-2 are both basally expressed and 
inducible by various stressors, including heavy metals, oxidative stress and pro-
inflammatory cytokines (Leone et al., 1985; Andrews, 2000; Kawai et al., 2000; 
Haq et al., 2003; Santon et al., 2008; Vasak and Meloni, 2011). Principally located 
in the cytosol, MTs have been observed to translocate into the nucleus under 
several physiological and pathological conditions (Nishimura et al., 1989; 
Kiningham et al., 1995; Nagano et al., 2000). In addition, despite the absence of a 
classical secretion sequence, MT-1, MT-2 and MT-3 have been demonstrated to 
be secreted by certain cell types (Moltedo et al., 2000; Trayhurn et al., 2000; 
Uchida et al., 2002; Chung et al., 2008; Miyazaki et al., 2011). 
Mammalian MTs consist of a single polypeptide chain of 61-68 amino acids, 20 
of which are strictly conserved cysteines that are arranged in a distinct pattern 
of CxC, CC and CxxC sequences (Kojima et al., 1976; Kissling and Kagi, 1977; 
Palmiter et al., 1992; Vasak and Meloni, 2011). They contain two metal binding 
domains, the N-terminal β-domain and the C-terminal α-domain, with different 
abilities for metal ion binding, the folding of each of these independent 
domains being induced by metal coordination to the apo-protein (Boulanger et 
al., 1982; Winge and Miklossy, 1982; Hunt et al., 1984; Salgado and Stillman, 
2004; Duncan et al., 2006; Vasak and Meloni, 2011). Within cells MTs are present 
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in their apo-forms as well as in their metal bound forms (Yang et al., 2001; 
Petering et al., 2006). One MT can reversibly bind up to seven divalent metal 
ions in a three-metal-thiolate cluster (β-domain) and a four-metal-thiolate 
cluster (α-domain) or up to 12 monovalent ions in two six-metal-thiolate 
clusters (Boulanger et al., 1982; Hunt et al., 1984; Roschitzki and Vasak, 2002; 
Duncan et al., 2006). Although all mammalian MT isoforms can bind a variety 
of heavy metals, the physiological metals to bind to MTs are copper and zinc 
(Uchida et al., 1991; Quaife et al., 1994; Stillman, 1995; Bogumil et al., 1996; 
Orlowski and Piotrowski, 1998; Vasak and Meloni, 2011) 
Multiple evidences suggest that MTs are involved in the maintenance of cellular 
copper homeostasis. MTs have been postulated to function as cytosolic copper 
storage in normal copper metabolism and to serve as metal reservoir in the 
event of copper deficit (Suzuki et al., 2002; Tapia et al., 2004; Ogra et al., 2006). 
Consistent with such functions, cells lacking MT-1 and MT-2 contain lower 
basal copper contents and are more sensitive to copper depletion than wild-
type cells (Ogra et al., 2006; Miyayama et al., 2009). However, MT-1 and MT-2 
appear not to play an obligatory role in normal copper homeostasis, since MT-
1/2 knock-out mice do not show a copper-related phenotype (Michalska and 
Choo, 1993; Camakaris et al., 1999).  
The expression of MTs is induced by an excess of copper (Wake and Mercer, 
1985; Hidalgo et al., 1994; Kawai et al., 2000; Kuo et al., 2001a; Jiang et al., 2002). 
Elevated MT contents have been demonstrated in Wilson’s disease patients and 
in some animal models (Klein et al., 1990; Mercer et al., 1992; Mulder et al., 
1992; Sakurai et al., 1992; Suzuki-Kurasaki et al., 1997). Since MTs are capable of 
binding excess cellular copper an increase in the cellular MT content confers 
resistance against copper-induced toxicity (Freedman et al., 1986; Kawai et al., 
2000; Jiang et al., 2002). Hence, the rise in MT levels reflects an adaption of cells 
to copper overload conditions. Despite the function of MTs in the cellular 
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detoxification of copper, cells lacking MT-1 and MT-2 are only slightly more 
sensitive to excess copper than wild type cells (Kelly and Palmiter, 1996; Park et 
al., 2001; Jiang et al., 2002; Tapia et al., 2004). This counterintuitive finding can 
be attributed to a lesser copper uptake by these cells (Tapia et al., 2004; 
Armendariz et al., 2006). Thus, in addition to their role in cytosolic copper 
storage and copper detoxification, MTs appear to be involved in the regulation 
of copper uptake by controlling the intracellular concentration of free copper. 
1.2.3 Copper trafficking 
The intracellular trafficking of copper is mediated by a group of proteins 
termed copper chaperones. These specialized proteins shuttle copper to specific 
cellular targets, thereby protecting it from being scavenged by MTs or GSH. 
1.2.3.1 Antioxidant protein 1 
Antioxidant protein 1 (Atx1) is a small copper-binding protein originally 
identified as a copper-dependent suppressor of oxygen toxicity in yeast strains 
lacking both SOD1 and SOD2 (Lin and Culotta, 1995). In yeast, Atx1 shuttles 
copper to the copper transporting P-type ATPase Ccc2 for subsequent transport 
into the secretory pathway and incorporation into copper-dependent enzymes 
(Klomp et al., 1997; Lin et al., 1997). For example Atx1-deficient yeast mutants 
are also deficient in iron uptake due to impaired copper incorporation into the 
multicopper oxidase Fet3, that is required to generate ferric iron as substrate for 
the high affinity iron importer Ftr1 (Lin et al., 1997; Robinson and Winge, 2010). 
Atx1 is phylogenetically conserved and homologous proteins have been found 
in many prokaryotic and eukaryotic species (Klomp et al., 1997; Boal and 
Rosenzweig, 2009).  
The human homologue of Atx1, termed Hah1 or Atox1, is a 68 amino acid 
protein that shares 47% amino acid identity and 58% similarity with Atx1 
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(Klomp et al., 1997). Hah1 is abundant in all human tissues and distributed 
throughout the cytosol and nucleus of cells (Klomp et al., 1997; Hamza et al., 
1999). Both expression level and intracellular localization of Hah1 do not 
depend on the intracellular copper content (Klomp et al., 1997; Hamza et al., 
1999). Hah1 functionally complements mutant yeast strains deficient in Atx1 
(Klomp et al., 1997; Hung et al., 1998) and has been demonstrated to bind and 
transfer Cu+ to the N-terminal metal-binding domains (MBDs) of the copper 
transporting P-type ATPases ATP7A and ATP7B (Hung et al., 1998; Hamza et 
al., 1999; Ralle et al., 2003; Tanchou et al., 2004; Wernimont et al., 2004; Banci et 
al., 2007a; Banci et al., 2008a; Banci et al., 2009b; Hussain et al., 2009; Rodriguez-
Granillo et al., 2010; Benitez et al., 2011). In addition, Hah1 is involved in the 
regulation of the copper mediated intracellular trafficking and catalytic activity 
of both ATP7A and ATP7B (Tanchou et al., 2004; Banci et al., 2007a).  
Hah1 adopts a βαββαβ ferredoxin fold regardless of the presence of copper ions 
(Hung et al., 1998; Wernimont et al., 2000; Anastassopoulou et al., 2004; Boal 
and Rosenzweig, 2009). The loop connecting the first β-strand with the first α-
helix contains a copper-binding motif, MxCxxC, that is also present six times in 
the N-terminal MBDs of ATP7A and ATP7B (Klomp et al., 1997; Hung et al., 
1998; Ralle et al., 2003; Tanchou et al., 2004). The cysteine residues within this 
motif are necessary and sufficient for copper binding by Hah1 (Klomp et al., 
1997; Hung et al., 1998; Wernimont et al., 2000; Ralle et al., 2003; 
Anastassopoulou et al., 2004; Tanchou et al., 2004). Both monomeric (Ralle et al., 
2003; Anastassopoulou et al., 2004; Wernimont et al., 2004) and dimeric 
(Wernimont et al., 2000; Tanchou et al., 2004) forms of copper-loaded Hah1 (Cu-
Hah1) have been described. The copper induced homo-dimerization has been 
proposed to contribute to the sensing and/or regulation of the intracellular 
copper pool (Tanchou et al., 2004). 
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The transfer of copper from Cu-Hah1 to the N-terminal MBDs of ATP7A and 
ATP7B occurs most likely via specific protein-protein interactions (Hamza et al., 
1999; Wernimont et al., 2000; Wernimont et al., 2004; Banci et al., 2007a; Banci et 
al., 2008a; Banci et al., 2009b). Accordingly, Hah1 has been demonstrated to 
form heterocomplexes with both copper transporting P-type ATPases (Hamza 
et al., 1999; Tanchou et al., 2004; Banci et al., 2007a; Banci et al., 2009b; Benitez et 
al., 2011). The interactions between Cu-Hah1 and its target proteins depend on 
the metal-binding cysteines in the MxCxxC motifs of the target domains, 
providing evidence for the presence of a bridging copper ion in the 
intermolecular adduct (Banci et al., 2007a; Banci et al., 2009a; Banci et al., 2009b; 
Benitez et al., 2011). In addition, electrostatic interactions between lysine 
residues on the surface of Hah1 with negatively charged residues on the 
surfaces of the target domains of ATP7A and ATP7B have been suggested to 
contribute to the stabilization of the heterocomplexes (Hamza et al., 1999; 
Wernimont et al., 2000; Ralle et al., 2003). Indeed lysine in position 60 of Hah1, 
has recently been demonstrated to facilitate adduct stability and copper transfer 
(Hussain et al., 2009). The copper transfer reaction from Cu-Hah1 to the MBDs 
of ATP7A and ATP7B has been proposed to proceed via intermediates in which 
the copper ion is coordinated by two cysteines of the MxCxxC motif of one 
protein and one cysteine of the MxCxxC motif of the other (Ralle et al., 2003; 
Wernimont et al., 2004; Banci et al., 2009b; Rodriguez-Granillo et al., 2010). Since 
the copper transfer reaction from Cu-Hah1 to the target domain is 
thermodynamically disadvantageous, it has been suggested to be coupled to 
subsequent Cu+ translocation into the Golgi lumen and to ATP hydrolysis 
(Wernimont et al., 2004; Rodriguez-Granillo et al., 2010). 
Mutations in ATP7B that lead to an impairment of protein-protein interaction 
with Hah1 have been identified in patients suffering from Wilson’s disease 
(Hamza et al., 1999). This highlights the importance of specific protein-protein 
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interactions in the transfer of copper from Hah1 to the copper transporting P-
type ATPases as well as the significance of Hah1 in cellular copper homeostasis.  
1.2.3.2 Copper chaperone for superoxide dismutase 
The copper chaperone for superoxide dismutase (CCS) is found widely 
distributed throughout eukaryotes (Casareno et al., 1998; Rae et al., 2001; Leitch 
et al., 2009b). CCS is involved in the maturation of SOD1 by inserting copper 
into SOD1 and facilitating the formation of the intramolecular disulfide 
between Cys57 and Cys146 that is critical for SOD1 function (Culotta et al., 1997; 
Rae et al., 2001; Furukawa et al., 2004; Leitch et al., 2009b). Although SOD1 from 
most species can be activated independently of CCS, maximal SOD1 activity in 
the majority of organisms relies on the presence of CCS (Rae et al., 2001; Leitch 
et al., 2009a; Leitch et al., 2009b). Primarily localized to the cytosol and nucleus 
of cells, CCS possesses a similar cellular distribution as its target protein 
(Culotta et al., 1997; Casareno et al., 1998). The expression level of CCS depends 
on the cellular copper content (Bertinato and L'Abbe, 2003; Prohaska et al., 2003; 
Caruano-Yzermans et al., 2006). Thus, copper deficiency has been demonstrated 
to result in an increase in CCS protein abundance due to a lowered rate of 
proteosomal degradation of CCS (Bertinato and L'Abbe, 2003; Caruano-
Yzermans et al., 2006). 
CCS consists of three structural domains (Casareno et al., 1998; Lamb et al., 
1999; Leitch et al., 2009b). The N-terminal domain 1 is an Atx1-like region 
capable of binding Cu+ via the two cysteines of the MxCxxC motif (Lamb et al., 
1999; Rae et al., 2001; Stasser et al., 2005; Stasser et al., 2007; Barry and 
Blackburn, 2008; Leitch et al., 2009b). The function of this domain in the CCS-
mediated activation of SOD1 remains puzzling. For yeast CCS domain 1 has 
been shown to be functionally important only when cellular copper is limited, 
whereas it is essential for the activation of SOD1 by human CCS (hCCS; 
1. Introduction 
1.2 Cellular copper homeostasis 
57 
 
Schmidt et al., 1999; Caruano-Yzermans et al., 2006; Stasser et al., 2007). A 
function of domain 1 in the acquisition of copper from an upstream source of 
copper (e.g. Ctr1) has been hypothesized (Rae et al., 2001; Leitch et al., 2009b; 
Wright et al., 2011). The central domain 2 of CCS strongly resembles its target 
protein, SOD1. Notably, the residues constituting the dimer interface of SOD1 
are well conserved in CCS (Casareno et al., 1998; Lamb et al., 1999; Lamb et al., 
2000; Lamb et al., 2001; Rae et al., 2001). Consequently, domain 2 is involved in 
the recognition and binding of SOD1 which is essential for the CCS-mediated 
activation of SOD1 (Lamb et al., 1999; Schmidt et al., 2000; Lamb et al., 2001; 
Caruano-Yzermans et al., 2006; Stasser et al., 2007; Barry and Blackburn, 2008; 
Leitch et al., 2009b; Robinson and Winge, 2010). The C-terminal domain 3 of 
CCS harbors a copper-binding CxC motif that is critical for its metal transfer 
and disulfide isomerase activity (Lamb et al., 2001; Rae et al., 2001; Stasser et al., 
2005; Caruano-Yzermans et al., 2006; Stasser et al., 2007; Robinson and Winge, 
2010). Further, the CxC motif has been shown to be required for the 
dimerization of CCS with SOD1 and the copper-dependent regulation of CCS 
expression (Schmidt et al., 2000; Caruano-Yzermans et al., 2006).  
Regardless of its copper content, hCCS predominantly exists as a dimer 
(Casareno et al., 1998; Rae et al., 2001; Stasser et al., 2007; Leitch et al., 2009b; 
Wright et al., 2011). Apo-hCCS has been proposed to dimerize via the domain 2 
SOD-like dimer interface (Stasser et al., 2007). Upon copper-loading, hCCS is 
believed to rearrange into a dimeric species in which the monomers are linked 
via a polynuclear copper cluster formed between the CxC motifs, thereby 
opening the domain 2 SOD-like dimer interface for association with SOD1 
(Stasser et al., 2005; Stasser et al., 2007; Barry and Blackburn, 2008; Barry et al., 
2008). 
The activation of SOD1 by CCS is not a simple copper transfer reaction, but a 
oxygen-dependent redox process in which copper incorporation is 
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accompanied by the generation of the critical intramolecular disulfide between 
Cys57 and Cys146 (Brown et al., 2004; Furukawa et al., 2004; Stasser et al., 2007). 
Following association of the heterodimeric CCS-SOD1 complex, a disulfide 
bond forms between Cys57 of SOD1 and a cysteine of the CxC motif in domain 3 
of CCS (Lamb et al., 2001; Stasser et al., 2007; Leitch et al., 2009b; Robinson and 
Winge, 2010). This intermolecular disulfide is believed to facilitate metal ion 
insertion by opening the SOD1 active site and to convert to the critical 
intramolecular disulfide in SOD1 (Lamb et al., 2001; Furukawa et al., 2004; 
Barry and Blackburn, 2008; Robinson and Winge, 2010).  
1.2.3.3 Copper chaperones for cytochrome c oxidase 
Biogenesis of cytochrome c oxidase requires the assembly of 13 subunits to a 
multimeric protein complex and the concomitant insertion of cofactors, 
including three copper ions, two heme a groups, one zinc ion and a magnesium 
ion (Hatefi, 1985; Diaz, 2010; Stiburek and Zeman, 2010). This complicated 
process is facilitated by several nuclear-encoded proteins, so-called assembly 
factors (Shoubridge, 2001; Hamza and Gitlin, 2002; Leary et al., 2004; Diaz, 2010; 
Stiburek and Zeman, 2010). Formation of the CuB and CuA site in the 
mitochondrial encoded subunits Cox1 and Cox2 takes place within the 
mitochondrial intermembrane space (IMS), and thus requires both the delivery 
of copper into this mitochondrial compartment as well as the insertion of 
copper into the two copper centers. Mitochondria have been shown to contain a 
significant matrix pool of non-proteinaceous copper which has been suggested 
to supply the IMS with copper (Cobine et al., 2004; Maxfield et al., 2004). 
However, the mechanism by which copper is shuttled into mitochondria is yet 
unknown (Kim et al., 2008; Leary et al., 2009b; Robinson and Winge, 2010). A 
number of proteins have been identified so far to be involved in the insertion of 
copper ions into mammalian cytochrome c oxidase (Heaton et al., 2000; 
Nobrega et al., 2002; Barros et al., 2004; Rigby et al., 2007; Banci et al., 2008c). 
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The initial event in the transfer of copper to Cox1 and Cox2 is the Cox17-
mediated transfer of copper to the Sco-proteins Sco1 and Sco2 and Cox11 (Beers 
et al., 1997; Horng et al., 2004; Banting and Glerum, 2006; Banci et al., 2008b; 
Leary et al., 2009b; Robinson and Winge, 2010). This is followed by the 
subsequent insertion of copper into the nascent CuA and CuB sites (Beers et al., 
1997; Banting and Glerum, 2006; Leary et al., 2009b; Robinson and Winge, 2010). 
Cox17, initially identified in a yeast mutant displaying a respiratory defect, is 
essential for the metallation of eukaryotic cytochrome c oxidases (Glerum et al., 
1996a; Heaton et al., 2000; Takahashi et al., 2002; Oswald et al., 2009). Cox17 is a 
small cysteine-rich, hydrophilic protein localized in the IMS and in the cytosol 
of cells (Glerum et al., 1996a; Beers et al., 1997; Maxfield et al., 2004; Oswald et 
al., 2009). Although this dual localization suggests a role of Cox17 in the 
shuttling of copper from the cytosol into the IMS, the primary function of Cox17 
is the transfer of copper to Sco1, Sco2 and Cox11 within the IMS (Horng et al., 
2004; Maxfield et al., 2004). Cox17 is composed of a coiled-coil-helix-coiled-coil-
helix (CHCH) domain  formed by a conserved twin Cx9C motif and an 
unstructured N-terminal tail of about 15 amino acid residues (Banci et al., 
2008c). A conserved KxCCxC motif, also present in MTs, is located between 
these two regions (Amaravadi et al., 1997; Banci et al., 2008c). The copper 
chaperone function of Cox17 depends essentially on the two adjacent cysteines 
in this motif (Heaton et al., 2000; Takahashi et al., 2002; Banci et al., 2008c), 
whereas the CHCH motif is important for the import of Cox17 into the IMS by 
the mitochondrial disulfide relay system (Mesecke et al., 2005; Banci et al., 
2008c; Sideris et al., 2009; Banci et al., 2011). Mammalian Cox17 can exist in 
three different redox states (Palumaa et al., 2004; Voronova et al., 2007b). The 
fully reduced state (Cox17SH) that contains no disulfide is thought to represent 
the prevalent oxidation state in the cytosol (Palumaa et al., 2004; Voronova et 
al., 2007b). Cox17SH binds four copper ions in a copper-thiolate cluster similar to 
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that observed in copper-substituted MTs, and a similar role of Cox17SH in 
storing and detoxification of potential toxic copper ions as known for MTs has 
been suggested (Palumaa et al., 2004; Voronova et al., 2007b). The partial 
reduced state (Cox172S-S) is considered to be the predominant redox species in 
the IMS (Voronova et al., 2007b; Banci et al., 2008c). The cysteines within the 
twin Cx9C motif are present as two disulfides that are introduced during the 
import of Cox17SH into the IMS by the mitochondrial disulfide relay system 
(Mesecke et al., 2005; Banci et al., 2008c). Cox172S-S binds one copper ion that is 
coordinated by the sulfurs of the two adjacent cysteines in the KxCCxC motif 
(Palumaa et al., 2004; Banci et al., 2008c). Metal-transfer experiments are 
consistent with Cu1Cox172S-S being the biologically active form, donating copper 
to its target proteins (Banci et al., 2008b). In the fully oxidized protein (Cox173S-S) 
also the two cysteines of the KxCCxC motif form a disulfide. Consequently, 
Cox173S-S is not able to bind copper (Palumaa et al., 2004; Voronova et al., 2007b; 
Banci et al., 2008c). Cox173S-S represents most likely only a transient intermediate 
in the course of copper transfer from Cox172S-S to Sco1 (Voronova et al., 2007b; 
Banci et al., 2008b). 
Sco proteins are required for the formation of the CuA site of cytochrome c 
oxidase (Mattatall et al., 2000; Leary et al., 2004; Horng et al., 2005; Stiburek et 
al., 2009). In humans, the two homologs hSco1 and hSco2 contribute to this 
process by transferring copper to the binuclear copper center and by acting as 
thiol-disulfide oxidoreductases (Leary et al., 2004; Horng et al., 2005; Leary et 
al., 2009a). Consistent with their critical role in the formation of the binuclear 
CuA center, mutations in Sco1 and Sco2 cause severe cytochrome c oxidase 
deficiencies (Horng et al., 2005; Leary et al., 2007; Stiburek et al., 2009; Diaz, 
2010). In addition, hSco1 and hSco2 have been implicated in the maintenance of 
cellular copper homeostasis (Leary et al., 2007; Leary et al., 2009b; Stiburek et 
al., 2009; Stiburek and Zeman, 2010), especially in the regulation of copper 
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efflux (Leary et al., 2007). Sco proteins are tethered to the mitochondrial 
membrane by a single transmembrane domain and contain a large soluble 
domain, which protrudes into the IMS and adopts a thioredoxin-like fold 
(Glerum et al., 1996b; Rentzsch et al., 1999; Balatri et al., 2003; Abajian and 
Rosenzweig, 2006; Banci et al., 2006; Banci et al., 2007b). Sco-proteins can bind 
one copper ion by the cysteine residues of a CxxxC motif and a conserved 
histidine residue both located on the soluble domain (Glerum et al., 1996b; 
Rentzsch et al., 1999; Balatri et al., 2003; Horng et al., 2005; Banci et al., 2006; 
Banci et al., 2007b). Besides functioning in copper binding, the two cysteines of 
the CxxxC motif have been proposed to be the active site residues in the thiol-
disulfide oxidoreductase function of Sco proteins (Banci et al., 2006; Leary et al., 
2009a).  
The CuB site of cytochrome c oxidase receives its copper ion from Cox11 (Hiser 
et al., 2000; Carr et al., 2002). Accordingly, cells lacking functional Cox11 have 
impaired cytochrome c oxidase activity (Hiser et al., 2000; Carr et al., 2002; 
Banting and Glerum, 2006; Thompson et al., 2010). Like the Sco proteins, Cox11 
is tethered to the mitochondrial membrane and has a C-terminal domain 
protruding into the IMS (Carr et al., 2002; Carr et al., 2005). Cox11 forms a stable 
dimer that can bind two copper ions in a binuclear copper-thiolate cluster with 
each monomer contributing two cysteine residues from a CFCF motif strictly 
conserved among species (Carr et al., 2002; Banci et al., 2004; Horng et al., 2004; 
Banting and Glerum, 2006; Thompson et al., 2010). A third conserved cysteine, 
also absolutely required for function of Cox11, has been proposed to act as a 
transient copper ligand during copper transfer to Cox1 (Carr et al., 2002; 
Banting and Glerum, 2006; Thompson et al., 2010). 
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1.2.4 Copper export 
Cellular copper export in mammals relies on the function of two proteins, 
ATP7A and ATP7B. These proteins belong to the protein family of P1B-type 
ATPases, which have key functions in metal homeostasis in organisms of all 
kind of phyla (Vulpe et al., 1993; Arguello et al., 2007; Lutsenko et al., 2007a). 
P1B-type ATPases are a subgroup of P-type ATPases that use the energy of ATP 
hydrolysis to transport heavy metals across cellular membranes (Arguello et al., 
2007). Both ATP7A and ATP7B mediate Cu+ translocation with apparent KM-
values in the low micromolar range (Voskoboinik et al., 1998; Voskoboinik et 
al., 1999; Voskoboinik et al., 2001a; Voskoboinik et al., 2001b). In addition to 
their critical function in the efflux of excess cellular copper, ATP7A and ATP7B 
shuttle copper to the secretory pathway for incorporation into copper-
dependent enzymes such as tyrosinase, PAM, DβM, LOX and Cp (Kosonen et 
al., 1997; Terada et al., 1998; Petris et al., 2000; Tchaparian et al., 2000; El Meskini 
et al., 2003; Steveson et al., 2003; Meng et al., 2004; Wang and Hebert, 2006; 
Hardman et al., 2007; Niciu et al., 2007; Ray et al., 2007; Setty et al., 2008). The 
importance of these proteins in the maintenance of copper homeostasis is 
dramatically illustrated by the human genetic disorders Menkes and Wilson’s 
disease that are caused by mutations in ATP7A and ATP7B, respectively 
(Scheinberg and Sternlieb, 1996; Pfeiffer, 2007; Huster, 2010; Tumer and Moller, 
2010; Kaler, 2011; Kodama et al., 2011). 
Human ATP7A and ATP7B are large multispanning membrane proteins that 
share 50-60% amino acid sequence homology (Bull et al., 1993; Tanzi et al., 1993; 
Yamaguchi et al., 1996; Hung et al., 1997; Payne and Gitlin, 1998). Their overall 
structure consists of (1) a cytosolic amino-terminus, (2) eight transmembrane 
helices, (3) an ATP-binding domain (4) an actuator domain, and (5) a cytosolic 
carboxyl-terminus (Lutsenko et al., 2007a; Boal and Rosenzweig, 2009; Barry et 
al., 2010). 
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The N-terminal tail of human ATP7A and ATP7B harbors six MBDs (Bull et al., 
1993; Chelly et al., 1993; Mercer et al., 1993; Tanzi et al., 1993; Vulpe et al., 1993; 
Petrukhin et al., 1994; Payne and Gitlin, 1998), each capable of binding one Cu+-
ion (Lutsenko et al., 1997; Jensen et al., 1999; DiDonato et al., 2000; Banci et al., 
2007a; Banci et al., 2009b). The MBDs are similar in amino acid sequence and 
structure to Hah1, adopting a βαββαβ ferredoxin-like fold and containing a 
copper-binding MxCxxC sequence motif within the loop connecting the first β-
strand with the first α-helix (Lutsenko et al., 2007a; Boal and Rosenzweig, 2009). 
Copper can be transferred by Cu-Hah1 to any of the six MBDs of ATP7A and 
ATP7B (Hung et al., 1998; Hamza et al., 1999; Ralle et al., 2003; Tanchou et al., 
2004; Wernimont et al., 2004; Banci et al., 2007a; Banci et al., 2008a; Banci et al., 
2009b; Hussain et al., 2009; Rodriguez-Granillo et al., 2010; Benitez et al., 2011). 
However, only the MBDs closest to the membrane, MBD5 and MBD6, are 
important for efficient copper transport (Forbes et al., 1999; Strausak et al., 1999; 
Mercer et al., 2003; Cater et al., 2004; Cater et al., 2007), while MBD1-4 primarily 
function in the regulation of the catalytic activity in response to copper 
(Lutsenko et al., 2007a; Barry et al., 2010). 
The eight transmembrane helices of ATP7A and ATP7B are involved in the 
formation of the copper translocation pathway (Lutsenko et al., 2007a; Barry et 
al., 2010). Specific residues within TM6-TM8 are thought to contribute to the 
intramembrane copper coordination sites required for copper transmembrane 
transport (Arguello et al., 2007; Lutsenko et al., 2007a; Barry et al., 2010). Indeed, 
mutation of the cysteines in a CPC motif located in TM6, common for all P1B-
type ATPases (Arguello et al., 2007), and mutation of Met1393 in TM8 have been 
shown to result in an impaired catalytic activity of human ATP7B and murine 
ATP7A (Voskoboinik et al., 2001a; Cater et al., 2007). 
The ATP-binding domain of both ATP7A and ATP7B, located between TM6 
and TM7, comprises a nucleotide-binding domain (N-domain) and a 
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phosphorylation domain (P-domain) containing the DKTG, TGDN and 
GDGxND signature motifs of P-type ATPases (Bull et al., 1993; Tanzi et al., 
1993; Vulpe et al., 1993; Petrukhin et al., 1994). The invariant Asp residue in the 
DKTG sequence motif of the P-domain is crucial for the catalytic cycle of P-
type-ATPases (Voskoboinik et al., 2001b; Petris et al., 2002; Palmgren and 
Nissen, 2011). In the case of ATP7A and ATP7B, it accepts the γ-phosphate from 
the ATP upon binding of ATP to the N-domain and copper to the 
intramembrane copper sites (Voskoboinik et al., 2001b; de Bie et al., 2007; 
Lutsenko et al., 2007b). The formation of this phosphorylated intermediate 
induces conformational changes that allow the copper ion to be released on the 
other side of the membrane (Voskoboinik et al., 2001b; de Bie et al., 2007; 
Lutsenko et al., 2007b). The catalytic cycle is closed by the hydrolysis of the 
aspartyl phosphate bond and the return of the enzyme to its initial state 
(Voskoboinik et al., 2001a; de Bie et al., 2007; Lutsenko et al., 2007b). The 
dephosphorylation step is facilitated by the actuator domain (A-domain) linked 
to TM4 and TM5 (Voskoboinik et al., 2001b; de Bie et al., 2007; Lutsenko et al., 
2007b). This domain harbors the TGE signature motif of the P-type ATPases 
that is strictly required for their phosphatase activity (Bull et al., 1993; Tanzi et 
al., 1993; Vulpe et al., 1993; Petrukhin et al., 1994; Palmgren and Nissen, 2011). 
Consequently, mutations of the TGE motif in ATP7A and ATP7B result in 
hyperphosphorylated and catalytic inactive proteins (Petris et al., 2002; Cater et 
al., 2007).  
ATP7A continuously recycles between the TGN and the plasma membrane, 
whereas ATP7B traffics between the TGN and a cytosolic vesicular 
compartment (Petris et al., 1996; Petris and Mercer, 1999). When copper levels 
are normal both ATP7A and ATP7B have steady state localization at the TGN, 
where they transport copper from the cytosol to the TGN lumen for 
incorporation into copper-dependent enzymes (Petris et al., 1996; Yamaguchi et 
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al., 1996; Hung et al., 1997; La Fontaine et al., 1998; Petris and Mercer, 1999). A 
rise in cytosolic copper levels induces a shift in the steady state distribution 
from the TGN to the plasma membrane and/or to a distinct cytosolic vesicular 
compartment in close proximity to the plasma membrane (Petris et al., 1996; 
Hung et al., 1997; La Fontaine et al., 1998; Voskoboinik et al., 1998; Petris and 
Mercer, 1999; Voskoboinik et al., 1999; Forbes and Cox, 2000; Pase et al., 2004; 
Nyasae et al., 2007). Redistribution of ATP7A and ATP7B back to the TGN 
occurs when cellular copper levels return to normal (Petris et al., 1996; Pase et 
al., 2004; Nyasae et al., 2007). The ability of ATP7A and ATP7B to efflux copper 
is linked to their ability to undergo copper-induced redistribution (La Fontaine 
and Mercer, 2007). Consistently, mutations that impair the copper-dependent 
trafficking of these proteins have been associated with Menkes and Wilson’s 
disease (Forbes and Cox, 2000; Kim et al., 2003).  
ATP7A is expressed in most tissues, including intestine, skeletal muscle, 
placenta, brain heart and kidney, but its expression in liver is very low (Chelly 
et al., 1993; Vulpe et al., 1993; Paynter et al., 1994). In contrast, ATP7B is 
abundantly expressed in the liver and at lower levels in kidney, placenta, brain, 
lung and heart (Bull et al., 1993; Tanzi et al., 1993; Yamaguchi et al., 1996). This 
difference in expression patterns correlates well with the observed alterations in 
body copper homeostasis seen in Menkes and Wilson’s disease. Inactivation of 
ATP7A in Menkes disease results in systemic copper deficiency due to 
diminished copper export from the intestine into the portal blood (Tumer and 
Moller, 2010; Kaler, 2011; Kodama et al., 2011), while failure of biliary copper 
excretion by ATP7B in Wilson's disease leads to copper overload in liver and 
other tissues (Scheinberg and Sternlieb, 1996; Pfeiffer, 2007; Huster, 2010). 
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The brain concentrates heavy metals including copper for metabolic use (Bush, 
2000). Copper is of great importance for the normal development and function 
of the brain. Since not only copper deficiency, but also excess of copper can 
seriously affect brain functions, also the brain possesses mechanisms to regulate 
copper homeostasis. Impairments of these homeostatic mechanisms are 
associated with neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson’s disease or Huntington’s disease.  
1.3.1 Copper content and spatial distribution 
The estimated copper content of the human brain ranges from 3.1 to 5.1 µg/g 
wet weight (Rahil-Khazen et al., 2002; Lech and Sadlik, 2007). Compared to 
human brains, mice appear to have a similar brain copper content (5.5 µg 
copper/g wet weight; Waggoner et al., 2000) whereas rat brains contain less 
copper (1 to 2.5 µg/g wet weight; Sugawara et al., 1992; Olusola et al., 2004). The 
cerebrospinal fluid contains copper in a concentration of 0.3 – 0.5 µM 
(Stuerenburg, 2000; Forte et al., 2004; Nischwitz et al., 2008; Strozyk et al., 2009). 
However, the extracellular copper concentration in brain tissue may be higher. 
At least for the synaptic cleft copper concentrations of up to 250 µM have been 
reported (Kardos et al., 1989; Hopt et al., 2003). 
Several studies have demonstrated that copper is unevenly distributed in the 
brain (Warren et al., 1960; Smeyers-Verbeke et al., 1974; Bonilla et al., 1984; Faa 
et al., 2001; Becker et al., 2005; Dobrowolska et al., 2008; Serpa et al., 2008; 
Popescu et al., 2009; Wang et al., 2010). In general, copper contents are higher in 
the grey matter (1.6 to 6.5 µg/g wet weight) than in the white matter (0.9 to 2.5 
µg/g wet weight; Warren et al., 1960; Smeyers-Verbeke et al., 1974; Bonilla et al., 
1984; Becker et al., 2005; Dobrowolska et al., 2008). Quantification of copper in 
human brain sections by atomic absorption spectroscopy demonstrated that 
copper is enriched in the locus coeruleus and the substantia nigra, which both 
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are pigmented tissues and contain catecholaminergic cells (Warren et al., 1960; 
Goldberg and Allen, 1981; Popescu et al., 2009). Two-dimensional copper maps 
of human brain slices, obtained by laser ablation inductively coupled plasma 
mass spectroscopy (LA-ICP-MS), revealed that areas strongly enriched in 
copper are also present within the hippocampus (Dobrowolska et al., 2008). 
Compared to other grey matter regions the thalamus of human brain contains 
lower copper levels (Warren et al., 1960; Smeyers-Verbeke et al., 1974), whereas 
the copper content of the thalamus of rats is higher (Jackson et al., 2006), 
indicating that not only the copper content but also the copper distribution 
within the brain varies between species. 
Histochemical and more recently LA-ICP-MS investigations showed that 
copper contents are higher in glial cells in brain than in neurons, under both 
pathological and normal conditions (Szerdahelyi and Kasa, 1986; Kodama et al., 
1991; Becker and Salber, 2010). This finding indicates that copper is stored in 
glial cells, suggesting that glial cells play an important role in the copper 
metabolism of the brain. Furthermore, the presence of glial cells containing very 
high copper levels in regions near the ventricles suggests that glial cells also 
play a role in the uptake of copper from the cerebrospinal fluid (Szerdahelyi 
and Kasa, 1986). It is notable that in the locus coeruleus and the substantia 
nigra, the regions with the highest copper content in human brain, copper was 
not detectable in neurons but was exclusively observed in glial cells 
(Szerdahelyi and Kasa, 1986). However, another study found that most of the 
copper in the locus coeruleus was located on presynaptic membranes of a part 
of the afferent terminals contacting dendrites or somatic spines of neurons (Sato 
et al., 1994). The presence of substantial amounts of copper in nerve terminals 
was confirmed by subcellular fractionation of the rat cerebral cortex 
demonstrating that 23% of the total copper of the brain is contained in 
synaptosomes (Matsuba and Takahashi, 1970). The copper concentration in 
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synaptosomes was estimated to be about 15 µM, whereas the copper 
concentration in the synaptic vesicles was estimated to be about 291 µM, 
indicating an active transport of copper into the vesicles (Hopt et al., 2003). 
Both brain copper content and distribution change during development, with 
age and in neurodegenerative diseases (Tarohda et al., 2004; Serpa et al., 2008; 
Wang et al., 2010). For example, the copper content in brains of Wilson’s disease 
patients has been reported to be up to 125 µg/g dry weight, a strong increase 
compared to the reference value of 13 to 60 µg/g dry weight (Faa et al., 2001). In 
contrast, the brain copper contents of Menkes disease patients are strongly 
reduced (Nooijen et al., 1981; Willemse et al., 1982). 
1.3.2 Importance of copper for the brain 
Copper is utilized in the brain for general metabolic as well as for more brain 
specific functions (Lutsenko et al., 2010). In humans, the brain requirement for 
copper is best illustrated by Menkes disease. This fatal disease is characterized 
by a general copper deficit and the failure of copper delivery to several copper-
dependent enzymes (Tumer and Moller, 2010; Kaler, 2011; Kodama et al., 2011). 
As a consequence of the reduced delivery of copper to the brain, Menkes 
disease patients exhibit severe mental and developmental impairment (Tumer 
and Moller, 2010; Kaler, 2011; Kodama et al., 2011). 
1.3.2.1 Energy metabolism  
The brain is one of the most energy-dependent tissues of the body (Rossi et al., 
2004). Most of this energy requirement relates to active ion transport (Vergun et 
al., 2007). Since 95% of total ATP in the brain is estimated to be generated in 
mitochondria (Vergun et al., 2007), mitochondrial efficiency is essential for 
brain function, and consequently its impairment is associated with 
neurodegeneration (Rossi et al., 2004). Impaired mitochondrial function is also 
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thought to be a major factor in the devastating brain damage associated with 
Menkes disease (Kaler, 1998). Deficient cytochrome c oxidase activity has been 
observed in the brain of Menkes disease patients (Maehara et al., 1983) and 
animal models (Yoshimura et al., 1993) as well as in copper deficient rodents 
(Rusinko and Prohaska, 1985; Prohaska, 1991; Prohaska et al., 1995; Kunz et al., 
1999; Gybina and Prohaska, 2006, 2008a, b). Elevated brain lactate levels and 
decreased levels of brain N-acetylaspartate, the synthesis of which is coupled to 
mitochondrial energy production in neurons (Moffett et al., 2007), are further 
indicators for a failure of oxidative phosphorylation under these conditions 
(Rusinko and Prohaska, 1985; Gybina and Prohaska, 2008a, 2009; Gybina et al., 
2009). The alteration in ATP levels under copper deficiency in the brindled 
mouse model for Menkes disease appears to depend on age. A 50% decrease 
has been found in older mice (Rossi et al., 2001), whereas in younger mice, 
despite an impaired mitochondrial energy production, the levels of ATP, ADP 
and AMP did not differ to control animals (Rusinko and Prohaska, 1985). Also 
in copper deficient rats ATP, ADP and AMP levels were not altered compared 
to control animals, suggesting a compensatory mechanism (Gybina and 
Prohaska, 2008a). Indeed, AMP kinase has been shown to be activated in rat 
brain under copper deficiency conditions (Gybina and Prohaska, 2008b, a). 
However, despite this higher content of phosphorylated AMP kinase, lower 
concentrations of fructose-2,6-bisphosphate, most likely due to higher 
concentrations of citrate that may inhibit phosphofructokinase 2 and glycolytic 
inhibition due to the accumulation of lactate (Sotelo-Hitschfeld et al., 2012), 
were observed in cerebellum of copper-deficient rats (Gybina and Prohaska, 
2008b). 
1.3.2.2 Antioxidative defense  
The brain is extremely prone to oxidative stress (Dringen, 2000; Rossi et al., 
2004; Halliwell, 2006). Amongst others it has a high rate of oxidative 
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metabolism, shows low activities of enzymes involved in the antioxidant 
defense and is rich in polyunsaturated fatty acids (Dringen, 2000; Rossi et al., 
2004; Halliwell, 2006). Copper deficit may render the brain even more 
susceptible to oxidative stress, since defective cytochrome c oxidase activity 
may result in increased superoxide production and/or impaired activity of 
SOD1 and SOD3 may weaken the antioxidant defense. Indeed, SOD1 
immunoreactivity in brain of Menkes disease patients is strongly reduced, 
whereas the expression level of SOD2 was observed to be elevated (Shibata et 
al., 1995), a well-characterized response to oxidative stress (Uriu-Adams and 
Keen, 2005). However, while SOD1 activity under copper deficient conditions in 
rodents is strongly reduced in liver (Prohaska, 1991; Lai et al., 1994), it is 
maintained at almost normal levels in brain (Prohaska, 1991; Lai et al., 1994; 
Prohaska et al., 2003; Gybina and Prohaska, 2006). Moreover, although 
superoxide levels are enhanced in brain slices from SOD1-deficient mice 
compared to wild type mice (Sasaki et al., 2011), these mice show normal 
neurodevelopment (Reaume et al., 1996; Ho et al., 1998). Thus, the relative 
contribution of partial SOD deficiency to the neurodegeneration in Menkes 
disease is difficult to assign. 
1.3.2.3 Iron metabolism 
Iron is a necessary cofactor in many metabolic processes and the brain has a 
substantial requirement for this essential metal (Dringen et al., 2007; Crichton et 
al., 2011). However, just as iron deficiency can seriously affect brain function, an 
excess of iron can too (Dringen et al., 2007; Crichton et al., 2011). Cp has a 
critical role in iron-homeostasis (Hellman and Gitlin, 2002; Healy and Tipton, 
2007; Kosman, 2010b) and thus represents a link between copper and iron 
metabolism. Aceruloplasminemia is an autosomal recessive disorder resulting 
from a loss of function mutation in the Cp gene (Harris et al., 1995; Yoshida et 
al., 1995; Takahashi et al., 1996) and is characterized by marked iron 
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accumulation in the brain and other tissues (Harris et al., 1995; Yoshida et al., 
1995; Miyajima et al., 1996; Gonzalez-Cuyar et al., 2008). Amongst others, 
patients suffer from neurological symptoms such as dysarthria, dystonia and 
mild dementia (Harris et al., 1995; Yoshida et al., 1995; Miyajima et al., 1996; 
Takahashi et al., 1996; Gonzalez-Cuyar et al., 2008; McNeill et al., 2008). In 
Wilson’s disease the transfer of copper to apo-Cp is impaired, at least in the 
liver (Terada et al., 1998; Meng et al., 2004), and the basal ganglia and the 
cortical grey matter of Wilson’s disease patients contained more iron than the 
normal control (Cumings, 1948). Also in the brains of older Long-Evans 
Cinnamon (LEC) rats, an animal model for Wilson’s disease, elevated iron 
contents have been reported (Sugawara et al., 1992; Kim et al., 2005). The lack of 
iron accumulation in the brains of younger LEC rats (Sugawara et al., 1992; Kim 
et al., 2005) is consistent with observations for Cp-deficient mice (Patel et al., 
2002; Jeong and David, 2006). Copper deficient rodents also display a reduction 
in holo-Cp levels compared to control animals (Holtzman and Gaumnitz, 1970; 
Gitlin et al., 1992; Broderius et al., 2010). However, the consequences of copper 
deficiency on brain iron metabolism have not been studied so far. 
1.3.2.4 Neurotransmitter and neuropeptide synthesis 
Norepinephrine is the principal sympathetic neurotransmitter and an important 
modulator of mood, attention, arousal and cardiovascular function (Kim et al., 
2002; Goldstein et al., 2003; Berridge, 2008; Goddard et al., 2010). The final step 
in norepinephrine synthesis, the oxidative hydroxylation of dopamine, is 
catalyzed by DβM located in granulated vesicles of sympathetic nerve 
terminals, adrenal medulla chromaffin cells, and noradrenergic and adrenergic 
neurons of the brain (Geffen et al., 1969; Stewart and Klinman, 1988; Klinman, 
1996; Kim et al., 2002; Timmers et al., 2004; Klinman, 2006). An elevated 
dopamine to norepinephrine ratio has been observed in the plasma of Menkes 
disease patients (Prohaska and Smith, 1982; Kaler et al., 2008; Goldstein et al., 
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2009) as well as in the brains of animal models for Menkes disease and copper 
deficient-rodents (Prohaska and Smith, 1982; Nelson and Prohaska, 2009), 
indicating a lack of DβM under severe copper deficiency conditions. 
Paradoxically, DβM activity measurements revealed an increased activity in the 
brain of copper deficient rodents (Prohaska and Smith, 1982; Prohaska et al., 
1995; Nelson and Prohaska, 2009). However, the depletion of norepinephrine is 
known to induce apo-DβM synthesis, which is likely to become activated in 
vitro by trace amounts of copper during assaying the DβM activity (Prohaska 
and Smith, 1982; Nelson and Prohaska, 2009). Despite the fundamental role of 
norepinephrine in central nervous system function, the fact that patients with 
congenital DβM deficiency exhibit only subtle signs of central nervous system 
dysfunction (Robertson et al., 1991; Kim et al., 2002) makes a contribution of 
DβM deficiency to the neurodegeneration in Menkes disease difficult to assign.  
Amidated neuropeptides are expressed in almost every neuron and are 
involved in a variety of function in the brain, including neuronal proliferation, 
energy metabolism and neuromodulation (Magistretti et al., 1998; Hansel et al., 
2001; Bousquet-Moore et al., 2010b). The only enzyme known to catalyze the α-
amidation of peptide precursors is PAM (Klinman, 1996; Prigge et al., 1997; 
Prigge et al., 2000; Bousquet-Moore et al., 2010a). Decreased PAM activity and 
low levels of several α-amidated peptides have been observed in the brains of 
animal models for Menkes disease and copper deficient rodents (Prohaska et 
al., 1995; Hansel et al., 2001; Steveson et al., 2003; Prohaska et al., 2005; 
Bousquet-Moore et al., 2010b). The lack of amidated peptides due to decreased 
PAM activity is though to contribute to neurodevelopmental delay and 
increased seizure frequency associated with Menkes disease (Steveson et al., 
2003; Bousquet-Moore et al., 2010b; Kaler, 2011). 
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1.3.2.5 Neuromodulatory function  
Synaptosomes and primary hippocampal neurons have been shown to release 
copper following depolarization, resulting in copper concentrations in the 
synaptic cleft that have been reported to range from 15 µM to 250 µM (Hartter 
and Barnea, 1988; Kardos et al., 1989; Hopt et al., 2003; Schlief et al., 2005). This 
suggests a potential neuromodulatory function of copper as has been 
demonstrated for zinc (Frederickson and Bush, 2001). Indeed, exogenous 
application of already low micromolar concentrations of copper produce an 
antagonistic effect on N-methyl-D-aspartate (NMDA)-, kainite-, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)- and γ-aminobutyric acid 
(GABA)-receptors as well as on the P2Y1, P2X4 and P2X7 purinoreceptors 
(Kardos et al., 1989; Li et al., 1996; Trombley and Shepherd, 1996; Vlachova et 
al., 1996; Weiser and Wienrich, 1996; Doreulee et al., 1997; Xiong et al., 1999; 
Sharonova et al., 2000; Horning and Trombley, 2001; Zhu et al., 2002; Coddou et 
al., 2003; Huidobro-Toro et al., 2008; Peters et al., 2011). Copper has further been 
shown to block glycine-mediated currents, when glycine receptors are activated 
by low, non-desensitizing concentrations of glycine (Trombley and Shepherd, 
1996; Wang et al., 2002) and to potentate P2X2 receptor activity (Xiong et al., 
1999; Huidobro-Toro et al., 2008). In contrast to its acute inhibitory effect on 
AMPA- and GABA-mediated currents, treatment of rat hippocampal neurons 
with copper for 3 h enhances synaptic activity (Peters et al., 2011). In addition to 
its effect on ligand-gated receptors, copper has been shown to inhibit voltage-
gated Ca2+- and K+-channels (Horning and Trombley, 2001; Niu et al., 2005; Niu 
et al., 2006). 
AMPA/kainite as well as NMDA receptors in cultured rat cortical neurons are 
noncompetitively blocked by copper (Vlachova et al., 1996; Weiser and 
Wienrich, 1996), whereas GABAA receptors and glycine receptors are blocked in 
a competitive manner (Sharonova et al., 2000; Wang et al., 2002; Zhu et al., 
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2002). The inhibitory effect of copper on GABA-, NMDA- and glycine receptor-
mediated currents is voltage-independent, in contrast to the effect of Mg2+, 
suggesting that copper acts at a specific neuromodulatory site rather than as 
channel blocker (Trombley and Shepherd, 1996; Vlachova et al., 1996; Weiser 
and Wienrich, 1996; Wang et al., 2002). Experimental evidence suggests that 
copper catalyzes an S-nitrosylation of the NMDA receptor, which is a known 
mechanism of regulation of NMDA receptors (Schlief et al., 2006). An oxidation 
process has also been proposed to be involved in the inhibition of 
AMPA/kainate receptors by copper (Weiser and Wienrich, 1996). The increase 
in AMPAergic neurotransmission in response to prolonged exposure to copper 
has been ascribed to a copper-induced enrichment of the AMPA receptor at the 
plasma membrane (Peters et al., 2011). 
The exact role of copper in synaptic physiology remains to be elucidated. 
However, synaptically released endogenous as well as exogenously applied 
copper protect primary hippocampal neurons against NMDA-mediated 
excitotoxic cell death, most likely by lowering the NMDA receptor-mediated 
intracellular Ca2+-elevation following depolarization/activation (Schlief et al., 
2006). Copper also appears to be involved in the modulation of synaptic 
plasticity. NMDA receptors participate in both the induction and the 
maintenance of long-term potentiation (LPT; Voglis and Tavernarakis, 2006). 
Consistent with its inhibitory function on NMDA receptor-mediated Ca2+-
currents hippocampus slices that had been exposed to exogenous copper 
(Doreulee et al., 1997; Salazar-Weber and Smith, 2011) as well as hippocampal 
slices of rats that had been fed a high-copper diet did not show any LTP 
(Goldschmith et al., 2005; Leiva et al., 2009). LTP has been associated with 
learning and memory in many organisms (Voglis and Tavernarakis, 2006). 
However, despite blocking LTP in the hippocampus, copper did not alter 
learning and memory in rats (Leiva et al., 2009). 
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1.3.3 Transport and storage  
Currently little is known about the mechanism of copper transport and 
homeostasis in the brain. To enter the brain, copper has to be transported across 
the blood-brain barrier (BBB) and/or the blood-cerebrospinal fluid barrier 
(BCB), which separates the blood from the brain interstitial space and CSF, 
respectively (Zheng and Monnot, 2012). At both brain barrier systems copper is 
transported into the brain primarily as free copper (Choi and Zheng, 2009). 
Although the copper uptake into cerebral capillaries is much slower than into 
the choroid plexus, the copper acquired by cerebral capillaries appears to be 
more readily transported into the brain parenchyma than copper from the 
choroid plexus to the CSF (Choi and Zheng, 2009; Monnot et al., 2011). In fact, 
recent evidence indicates that the role of the BCB in brain copper homeostasis is 
rather to efflux copper from the CSF to the blood (Monnot et al., 2011). Based on 
theses findings, the following model has been postulated for the copper 
transport between the blood and the brain (Monnot et al., 2011; Zheng and 
Monnot, 2012). The BBB represents the major route for the transport of copper 
from the blood circulation into the brain parenchyma, where copper is utilized 
and subsequently released into the CSF via the brain interstitial fluid. The 
copper in the CSF can be taken up by choroid epithelial cells where it may be 
stored or effluxed to the blood. Thus, while the BBB determines the influx of 
copper into the brain, the BCB functions in the maintenance of the copper 
homeostasis in the brain extracellular fluids. However, the situation might be 
different in the developing brain for which the BCB has been suggested to be 
the primary route of copper entry (Donsante et al., 2010). 
The knowledge of the copper handling machinery in different cell types of the 
central nervous system is rudimentary. Nevertheless, it is clear that all the key 
copper handling proteins mediating copper homeostasis in peripheral tissues 
are also present in the brain (Lutsenko et al., 2010; Tiffany-Castiglioni et al., 
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2011). As for peripheral cells, Ctr1 is likely to be the major pathway for copper 
entry into brain cells. Ctr1 appears to be essential for delivery of copper into the 
brain, since the copper levels in brains of Ctr1-heterozygous knock-out mice are 
reduced to about 50% of that of wild type animals (Lee et al., 2001). In 
mammalian brain Ctr1 is ubiquitously distributed with its expression being 
most abundant in the choroid plexus and high in the endothelial cells of the 
capillaries (Nishihara et al., 1998; Gybina and Prohaska, 2006; Kuo et al., 2006; 
Zheng and Monnot, 2012). Ctr1 is enriched on the apical membrane of the 
choroid plexus where it may extract copper from the CSF, consistent with the 
proposed function of the choroid plexus in the maintenance of the copper 
homeostasis in the brain extracellular fluids (Kuo et al., 2006; Zheng and 
Monnot, 2012). Uptake of copper by the BCB could also be mediated by DMT1, 
which is also located towards the apical membrane of the choroid plexus (Wang 
et al., 2008). In brain capillary endothelial cells, Ctr1 has been proposed to be 
located at the luminal side where it may regulate the uptake of copper from the 
blood (Zheng and Monnot, 2012). Since DMT1 seems not to be expressed in 
brain capillary endothelial cells (Moos et al., 2006), Ctr1 is likely to be the 
predominant transporter involved in copper uptake at the BBB. In neural 
parenchymal tissue, expression of Ctr1 has only been studied in rat dorsal root 
ganglion tissue (Liu et al., 2009; Ip et al., 2010). In this tissue intense Ctr1-
immunoreactivity has been observed in large-sized neurons, which are thought 
to have a strong need for Ctr1 to meet their high demands for copper delivery 
to cytochrome c oxidase (Liu et al., 2009; Ip et al., 2010).  
Copper entering brain cells is likely to be sequestered by GSH and either stored 
as MT-copper complex or shuttled by copper chaperons to their specific cellular 
target sites. MTs exist in three isoforms in the brain: MT1, MT2 and MT3 and 
has been shown to be expressed in the BBB and BCB as well as in astrocytes and 
neurons, whereas microglial cells and oligodendrocytes are essentially devoid 
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of MTs (Uchida et al., 1991; Hidalgo et al., 1994; Anezaki et al., 1995; Hidalgo et 
al., 2001). Elevated brain copper levels have been observed to be accompanied 
by an increase in MT levels, most likely reflecting a compensatory response 
against copper-induced toxicity (Ono et al., 1997; Haywood et al., 2008; Zatta et 
al., 2008). Detailed studies of copper chaperones in the brain are scare. 
However, the copper chaperons Atox1, CCS and the copper chaperons for 
cytochrome c oxidase Cox17, Sco1 and Sco2 have been shown to be expressed in 
brain (Klomp et al., 1997; Nishihara et al., 1998; Naeve et al., 1999; 
Papadopoulou et al., 1999; Rothstein et al., 1999; Hamza et al., 2000; Punter et 
al., 2000; Takahashi et al., 2002; Gybina and Prohaska, 2006). Atox1 is expressed 
ubiquitously in the brain with the expression level being highest in the choroid 
plexus (Nishihara et al., 1998). CCS is expressed at a similar level in various 
human brain regions, with the exception of white matter from where it is 
largely absent (Rothstein et al., 1999). On a cellular level CCS was found to be 
more abundant in neurons than in astrocytes (Rothstein et al., 1999). 
ATP7A is crucial for the supply of the brain with copper as demonstrated by 
the low brain copper levels observed in Menkes disease patients (Nooijen et al., 
1981; Willemse et al., 1982) and animal models (Hunt, 1974; Kumode et al., 
1993). ATP7A was shown to be expressed ubiquitously in brain with expression 
levels being most abundant in the choroid plexus (Chelly et al., 1993; Vulpe et 
al., 1993; Paynter et al., 1994; Nishihara et al., 1998; Niciu et al., 2006; Niciu et 
al., 2007). A dysfunction of ATP7A has been shown to result in copper 
accumulation in brain capillaries of macular and brindled mutant mice 
(Kodama, 1993; Yoshimura, 1994) indicating that ATP7A plays a role in copper 
transport across the BBB. The importance of ATP7A in copper export from 
brain capillary endothelial cells has also been demonstrated in a cell culture 
model for these cells (Qian et al., 1998b). In brain parenchyma, ATP7A has been 
shown to be expressed in both neurons and non-neuronal cells (Barnes et al., 
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2005; El Meskini et al., 2005; Schlief et al., 2005; Niciu et al., 2006; Niciu et al., 
2007). In cerebellum of adult mice, ATP7A is expressed in Bergmann glial cells 
but not in Purkinje cells (Barnes et al., 2005). In Bergmann cells ATP7A has been 
proposed to function in the regulation of the cytosolic copper concentration as 
well as in the export of copper for delivery to Purkinje neurons (Barnes et al., 
2005). ATP7A has further been shown to be strongly expressed in small-sized 
neurons of the rat dorsal root ganglion that are the primarily site of substance P 
synthesis in this tissue (Ip et al., 2010). Since the biosynthesis of substance P 
requires PAM the strong expression of ATP7A in these neurons is thought to 
meet their high demands for copper delivery to PAM (Ip et al., 2010). In 
addition to its well known role in the export and delivery of copper to 
cuproenzymes in peripheral tissues, ATP7A is also required in the brain to 
release copper from hippocampal neurons upon NMDA-activation (Schlief et 
al., 2005). NMDA-receptor mediated Ca2+-entry induces the identical trafficking 
of ATP7A to a cytoplasmic compartment adjacent to the plasma membrane as 
observed with copper (Schlief et al., 2005; Schlief et al., 2006) where ATP7A is 
thought to accumulate copper into a membrane bound compartment, forming 
and/or replenishing a pool of potentially releasable copper (Schlief et al., 2005; 
Schlief and Gitlin, 2006). Moreover, an ATP7A-mediated copper efflux has been 
suggested to play a role in neuronal process outgrowth and/or synaptogenesis 
of maturing olfactory receptor neurons (El Meskini et al., 2005). However, a 
secretion of copper into the extracellular space has not been observed during 
the formation of neuritic processes (Finney et al., 2007; Finney et al., 2009). 
Compared to ATP7A, the function of ATP7B in the brain is less clear. ATP7B is 
ubiquitously expressed in all brain regions (Bull et al., 1993; Tanzi et al., 1993; 
Yamaguchi et al., 1996; Niciu et al., 2007) and has been observed in brain 
capillary endothelial cells, in choroidal epithelial cells, in ependymal cells as 
well as in Purkinje neurons of adult mice (Qian et al., 1998b; Barnes et al., 2005; 
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Niciu et al., 2006; Zheng and Monnot, 2012). The expression of ATP7B in 
Purkinje neurons is consistent with the expression of Cp being localized to these 
cells (Barnes et al., 2005). The pineal gland and adult retina express an 
alternative-spliced form of ATP7B, the pineal gland night-specific ATPase 
(PINA), which lacks the N-terminal MBDs and the first four membrane 
segments (Borjigin et al., 1999). Although representing only the C-terminal half 
of ATP7B, PINA has been shown to possess some copper transport activity 
(Borjigin et al., 1999). The pineal gland is a functional compartment of the 
circadian timing system and the expression of PINA is 100-fold higher at night 
than at daytime (Borjigin et al., 1999), suggesting a function of rhythmic copper 
metabolism in circadian rhythm. Interestingly, mice subjected to total darkness 
for up to 60 days showed a marked elevation in their brain copper content 
(Beltramini et al., 2004). 
1.3.4 Neurodegenerative diseases 
Impairment of copper homeostasis can lead to neurodegeneration, as 
exemplified by Menkes and Wilson’s disease (Lorincz, 2010; Kodama et al., 
2011). Alterations of copper homeostasis have also been associated with 
neurodegenerative diseases such as prion diseases, Alzheimer’s disease, 
Parkinson’s disease or Huntington’s disease (Gaggelli et al., 2006; Rivera-
Mancia et al., 2010). However, in contrast to Menkes and Wilson’s disease the 
role of copper in these diseases is not fully understood. 
1.3.4.1 Prion diseases 
Refolding of the prion protein (PrP) into an abnormal conformation has been 
associated with transmissible neurodegenerative diseases, such as Creutzfeld-
Jacob disease, Kuru and fatal familial insomnia in humans, bovine spongiform 
encephalopathy (BSE) in cattle and scrapie in sheep, which are summarized as 
prion diseases or transmissible spongiform encephalopathies (Aguzzi et al., 
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2008; Cobb and Surewicz, 2009; Moore et al., 2009; Holman et al., 2010). Prion 
diseases are rare, but are generally fatal for anyone who gets infected (Moore et 
al., 2009; Holman et al., 2010). The most common prion disease in humans, with 
an annual incidence rate of about 1 case per 1.000.000, is the Creutzfeld-Jacob 
disease. It is characterized by a rapidly progressive dementia and neurological 
features including ataxia, tremor, bradykinesia and rigidity, with death 
occurring within 1 to 2 year of disease onset (Aguzzi et al., 2008; Cobb and 
Surewicz, 2009; Brown and Mastrianni, 2010). The PrP is ubiquitously 
expressed but most abundantly in neurons (Hu et al., 2007; Westergard et al., 
2007; Linden et al., 2008). Being subject to constitutive endocytosis it 
continuously recycles between the plasma membrane and endosomes (Brown 
and Sassoon, 2002; Westergard et al., 2007; Linden et al., 2008). The 
physiological roles of the PrP are still under discussion. Among others it has 
been implicated in the protection against apoptosis and oxidative stress, in 
transmembrane signaling as well as in the formation and function of synapses 
(Brown and Sassoon, 2002; Rachidi et al., 2003; Hu et al., 2007; Westergard et al., 
2007; Linden et al., 2008). 
Cells expressing PrP are much more resistant to copper-treatment than PrP-
deficient cells (Brown et al., 1998; Rachidi et al., 2003; Haigh and Brown, 2006). 
PrP is known to bind copper with low micromolar affinity (Brown et al., 1997; 
Westergard et al., 2007) and may protect against copper-induced toxicity by 
capturing extracellular copper and reducing copper-mediated ROS production 
(Brown et al., 1998; Rachidi et al., 2003; Haigh and Brown, 2006; Millhauser, 
2007). Moreover, copper has been shown to stimulate endocytosis of PrP (Pauly 
and Harris, 1998; Brown and Harris, 2003). Based on this observation the PrP 
has been suggested to serve as a receptor for cellular uptake or efflux of copper 
(Pauly and Harris, 1998; Brown and Harris, 2003). Indeed some studies reported 
that the rate of cellular copper uptake depended on the expression level of PrP 
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(Brown, 2004; Urso et al., 2012). Further supporting a role of PrP in copper 
homeostasis, the copper contents of brain fractions of mice were shown to 
increase with increasing abundance of PrP (Brown et al., 1997). Also the copper 
contents of synaptosomes of PrP-deficient mice were found to be lower 
compared to that of wild type mice, which has led to the proposal that the PrP 
may play a role in regulating copper release at the synapse (Brown et al., 1997). 
Furthermore, the prion protein has been shown to be capable of reducing Cu2+ 
to Cu+ with maximal activity at pH 6.5 (Miura et al., 2005). Thus, it has been 
concluded that the PrP does not only transports extracellular copper into 
endosomes, but also reduces Cu2+ prior to the release into the cytosol (Miura et 
al., 2005). However, the potential role of PrP in cellular copper homeostasis is 
still under controversial debate (Westergard et al., 2007), since other studies did 
not found any alteration in the copper content of brain fractions of mice 
expressing different levels of prion protein (Waggoner et al., 2000; Giese et al., 
2005) or failed to show a contribution of PrP to cellular copper uptake (Rachidi 
et al., 2003). 
An alteration of copper homeostasis may also play a role in the development 
and progression of prion diseases (Leach et al., 2006; Millhauser, 2007; Rana et 
al., 2009). Brain copper contents of scrapie infected mice were found to be 
decreased by around 60%, pointing to a severe copper deficit in prion diseases 
(Wong et al., 2001; Thackray et al., 2002; Mitteregger et al., 2009). Consistently, 
copper supplementation of these mice reduced the progression of scrapie 
(Mitteregger et al., 2009). In contrast to copper, the manganese contents were 
shown to be elevated in prion-infected brain tissue (Wong et al., 2001; Thackray 
et al., 2002; Mitteregger et al., 2009) and manganese supplementation 
accelerated disease progression in scrapie infected mice (Mitteregger et al., 
2009). Since PrP with manganese bound is able to induce nucleated-
polymerization of PrP (Brazier et al., 2008), copper deficiency was hypothesized 
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to foster the development of prion diseases by favoring the incorporation of 
manganese into PrP instead of copper (Brown et al., 2000). However, whether 
the observed perturbation of copper and manganese in the brain are a cause or 
a consequence of prion diseases remains to be evaluated (Rana et al., 2009).  
1.3.4.2 Alzheimer’s disease 
Alzheimer’s disease (AD) is an irreversible and progressive disease that causes 
memory loss and psychiatric disturbances (Castellani et al., 2010; Salawu et al., 
2011). It represents the most common neurodegenerative disease in humans, 
with currently an estimate of 18-25 million people worldwide suffering from 
this disease (Castellani et al., 2010; Ballard et al., 2011; Kenche and Barnham, 
2011). The major risk factor in AD is advanced age and as a direct consequence 
of increased life span expectancies the number of people suffering from AD is 
projected to increase dramatically within the next decades (Castellani et al., 
2010; Ballard et al., 2011; Kenche and Barnham, 2011; Salawu et al., 2011). Aside 
from age, other risk factors include genetic factors, gender and environmental 
factors (Castellani et al., 2010; Ballard et al., 2011). The pathological hallmarks of 
AD are the extracellular senile plaques and the intracellular neurofibrillary 
tangels in brain (Castellani et al., 2010; Ballard et al., 2011). The principal 
constituents of senile plaques are amyloid-β (Aβ) peptides of 40 and 42 
residues, which are generated form the integral membrane amyloid precursor 
protein by the consecutive action of β- and γ-secretase (Borchardt et al., 1999; 
Castellani et al., 2010; Ballard et al., 2011; Budimir, 2011; Tougu et al., 2011). 
Aβ peptides have been shown to bind copper with high affinity (Atwood et al., 
2000) and senile plaques are strongly enriched in copper (Lovell et al., 1998). 
Furthermore, copper has been shown to precipitate Aβ peptides in vitro and it 
has been suggested that copper triggers the formation of senile plaques 
(Atwood et al., 2000; Kenche and Barnham, 2011; Tougu et al., 2011; Roberts et 
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al., 2012). In support of this view, Aβ deposition begins within the 
glutamatergic synapse (Cater et al., 2008), where both copper (Kardos et al., 
1989; Hopt et al., 2003) and Aβ (Lesne et al., 2005; Tougu et al., 2011) are 
released during synaptic transmission. However, although accumulation of Aβ 
peptides in the form of senile plaques are the most prominent feature of AD, it 
is now widely accepted that soluble oligomeric Aβ species are the most toxic 
form of Aβ peptides (Karran et al., 2011; Roberts et al., 2012). Since Aβ can 
mediate the reduction of Cu2+ to Cu+, copper may promote the toxicity of such 
Aβ oligomers through the formation of ROS (Robertson et al., 1991; Huang et 
al., 1999; Multhaup et al., 2002; Kenche and Barnham, 2011). In addition, copper 
has been reported to increase the inhibition of cytochrome c oxidase by Aβ 
(Crouch et al., 2005). 
While the enhancement of Aβ-toxicity by copper in vitro suggest a detrimental 
role of copper in AD, the observed lower copper contents in the brain of AD 
patients (Deibel et al., 1996; Loeffler et al., 1996) and mouse models for AD 
(Maynard et al., 2002; Bayer et al., 2003) as compared to controls rather argue 
for a copper deficit contributing to the neurodegeneration in AD. In this line, 
copper supplementation of a mouse AD model improved the survival of these 
animals (Bayer et al., 2003). Improved cognitive functions were also observed in 
another mouse model of AD following administration of Cu(gtsm) as copper 
source (Crouch et al., 2009). However, intake of copper had no effect on 
cognition in patients with mild AD in a phase 2 clinical trial, even though a 
positive effect on a relevant AD biomarker was observed (Kessler et al., 2008a; 
Kessler et al., 2008b). Mechanistically, copper deficiency may exacerbate disease 
progression by influencing amyloid precursor protein-processing and Aβ-
metabolism (Cater et al., 2008). Indeed, copper treatment has been shown to 
inhibit the amyloidogenic pathway in chinese hamster ovary cells, thereby 
reducing Aβ synthesis (Borchardt et al., 1999) and treatment of amyloid 
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precursor protein overexpressing cell lines with a clioquinol-copper complex 
has been associated with both an increase in copper levels and an up-regulation 
of  Aβ degrading metalloproteinases (White et al., 2006). In addition, copper 
deficiency may also influence the activity of copper-dependent enzymes. In this 
regard low activities of cytochrome c oxidase (Mutisya et al., 1994; Parker et al., 
1994; Maurer et al., 2000) and SOD1 (Chen et al., 1994; Marcus et al., 1998) have 
been reported for the AD brain.  
In view of the high copper contents in senile plaques (Lovell et al., 1998) and the 
overall low copper content in AD brain, it is now widely acknowledged that in 
AD copper is abnormally redistributed to senile plaques, leaving the tissue and 
cells deficient in copper (Macreadie, 2008; Kaden et al., 2011; Roberts et al., 
2012). Therapeutic strategies aiming to restore the normal copper distribution in 
AD brain are currently under investigation (Zatta et al., 2009; Kenche and 
Barnham, 2011). Thus, the copper chelator PBT-2, which has been shown to 
reduce senile plaques and to enhance brain copper levels by its copper 
ionophore function (Adlard et al., 2008), has recently been shown to improve 
AD biomarkers as well as cognition in AD patients in a phase 2 clinical trial 
(Lannfelt et al., 2008). 
1.3.4.3 Parkinson’s disease 
With an overall prevalence ranging between 0.1% and 0.3%, Parkinson’s disease 
(PD) is the second most common neurodegenerative disease in humans 
(Wirdefeldt et al., 2011). PD is characterized by a complex motor disorder 
known as Parkinsonism that manifests with resting tremor, bradykinesia, 
rigidity and postural instability, but clinical symptoms also include cognitive 
and psychiatric problems (Thomas and Beal, 2007; Breen and Barker, 2010; 
Ferrer et al., 2011). The pathological hallmarks of PD are the loss of 
neuromelanin containing dopaminergic neurons in the substantia nigra pars 
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compacta and the presence of intracellular inclusions, called Lewy bodies, in 
the remaining neurons (Thomas and Beal, 2007; Jomova et al., 2010; Ferrer et al., 
2011; Sian-Hulsmann et al., 2011). The majority of cases are idiopathic with less 
than 10% of PD having a strict familial etiology (Thomas and Beal, 2007; Jomova 
et al., 2010; Sian-Hulsmann et al., 2011; Wirdefeldt et al., 2011). The underlying 
mechanisms of idiopathic PD are not fully understood. Among others 
mitochondrial dysfunction, oxidative stress and inflammation have been 
suggested in the pathogenesis of PD (Thomas and Beal, 2007; Jomova et al., 
2010).  
Parkinsonism is frequently present in patients with neurological Wilson’s 
disease (Lorincz, 2010) and copper has been demonstrated to accelerate 
aggregation of α-synuclein into fibrillar plaques, the precursors to Lewy bodies 
(Uversky et al., 2001). However, while the total copper content in brains of PD 
patients does not differ strongly from healthy controls, copper levels are 
substantial lower in substantia nigra of PD patients (Dexter et al., 1989; Dexter 
et al., 1991; Loeffler et al., 1996; Popescu et al., 2009). This reduction in the 
copper content of the substantia nigra in PD has been discussed to result in an 
impairment of copper-dependent pathways, thereby contributing to the 
pathogenesis of PD (Double, 2012). In support of this view, copper 
supplementation has been shown to prevent the increase in lipid peroxidation, 
striatal dopamine depletion and the reduction in the activity of tyrosine 
hydroxylase in an animal model for PD (Alcaraz-Zubeldia et al., 2001; Alcaraz-
Zubeldia et al., 2009) while copper chelation was reported not to be protective 
in PD animal models (Youdim et al., 2007).  
1.3.4.4 Huntington’s disease 
Huntington’s disease (HD) is a rare autosomal-dominant, progressive 
neurodegenerative disease that results in motor, cognitive and psychiatric 
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abnormalities (Anderson, 2011; Shannon, 2011). The genetic defect underlying 
HD is an expansion of the cytosine-adenine-guanine (CAG) repeat in exon 1 of 
the huntingtin gene that is translated into an expanded polyglutamine domain 
at the N-terminus of the huntingtin protein (McFarland and Cha, 2011). The 
length of this extension determines the onset as well as the velocity of the 
clinical progression of HD (Anderson, 2011; McFarland and Cha, 2011; 
Shannon, 2011). However, the exact pathogenic mechanism in HD remains to be 
elucidated. Among others, aggregation of the mutant huntingtin protein, 
oxidative stress, impaired energy metabolism, loss of neurotrophic support and 
transcriptional dysregulation have been discussed to contribute to the 
development and progression of HD (Gauthier et al., 2004; Chen, 2011; 
McFarland and Cha, 2011). 
Accumulation of copper in the HD brain has been hypothesized to promote 
disease progression (Fox et al., 2007). The brain copper levels of HD patients 
(Dexter et al., 1991) and of a mouse model for HD (Fox et al., 2007) have been 
found to be elevated compared to controls and copper has been shown to 
strongly interact with the huntingtin protein and to promote its aggregation 
(Fox et al., 2007). In addition treatment with the copper chelators 
tetrathiomolybdate (Tallaksen-Greene et al., 2009) or clioquinol (Nguyen et al., 
2005) delayed the decline in motor function in mouse models for HD, further 
supporting a potential role of copper in disease progression. Currently, the 
copper chelator PBT-2, an 8-hydroxyquinon derivate of clioquinol, is under 
clinical investigation for the treatment of HD (http://www.huntington-study-
group.org/HSGResearch/ClinicalTrialsObservationalStudiesinProgress/Reach2
HD/tabid/243/Default.aspx; date visited: 14/03/2012). 
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Astrocytes, which constitute the main class of neuroglia, are the most abundant 
cells in the brain (Markiewicz and Lukomska, 2006; Sofroniew and Vinters, 
2010). These cells are distributed throughout the entire brain and fulfill a range 
of important functions essential for brain physiology (Nedergaard et al., 2003; 
Sofroniew and Vinters, 2010; Parpura et al., 2012). Among other functions, 
astrocytes have been discussed to be involved in the control of brain energy 
metabolism, metabolic support of neurons, maintenance of the BBB as well as in 
the modulation of synaptic transmission, synaptic plasticity and extracellular 
ion homeostasis (Nedergaard et al., 2003; Pellerin et al., 2007; Barker and Ullian, 
2010; Barros and Deitmer, 2010; Deitmer and Rose, 2010; Hirrlinger and 
Dringen, 2010; Perea and Araque, 2010; Dienel, 2011). Moreover astrocytes have 
been considered to play a key role in the metal metabolism of the brain 
(Tiffany-Castiglion and Qian, 2001; Dringen et al., 2007; Tiffany-Castiglioni et 
al., 2011).  
Astrocytes possess several features that allow them to function as regulators for 
the uptake and distribution of essential metals to other types of brain cells and 
to serve as metal depots (Tiffany-Castiglioni et al., 2001; Dringen et al., 2007; 
Tiffany-Castiglioni et al., 2011). These cells have a strategically important 
location in the brain, being in close contact to neuronal cell bodies and to 
capillary endothelial cells via their cytoplasmic processes that terminate in so 
called end-feet (Demeuse et al., 2002; Nedergaard et al., 2003). Astrocytic end-
feet cover most of the brain capillaries (Demeuse et al., 2002; Nedergaard et al., 
2003; Mathiisen et al., 2010) and have been shown to express metal transport 
proteins such as DMT1 (Burdo et al., 2001) or ferroportin (Wu et al., 2004). Thus, 
astrocytes are the first brain parenchyma cells to encounter metals that cross the 
BBB. In addition, astrocytes can express ferritin in an iron-dependent manner 
(Hoepken et al., 2004) and contain high cellular contents of MTs (Aschner, 1997; 
Aschner et al., 1997; Dineley et al., 2000; Hidalgo et al., 2001) and GSH (Dringen 
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and Hamprecht, 1998; Hirrlinger and Dringen, 2010), endowing them with a 
high capacity to store and to prevent the toxicity of metals and of metal-induced 
oxidative stress.  
At the start of the work on this thesis little was known on the copper 
metabolism of astrocytes. However, multiple evidence suggest that these cells 
are likely to play an important role in the copper homeostasis of the brain. 
Within the brain copper has been shown histochemically to concentrate in 
astrocytes and it has been suggested that astrocytes may regulate the copper 
supply to neurons (Szerdahelyi and Kasa, 1986; Kodama et al., 1991; Kodama, 
1993). In the North Ronaldsay sheep elevated brain copper content was 
accompanied by copper accumulation in astrocytes and by a strong astrocytic 
immunoreactivity for MTs (Haywood et al., 2008). In cell culture, astrocytes 
have been reported to take up copper more efficiently than cultured neurons 
and to protect neurons from copper toxicity (Brown, 2004). This protection of 
neurons against copper toxicity could involve the removal of copper by uptake 
into astrocytes. In addition, astrocytes release compounds that prevent the 
copper-mediated inactivation/degradation of extracellular GSH (Pope et al., 
2008). Since trafficking of GSH from astrocytes to neurons is essential to 
maintain neuronal GSH levels (Dringen et al., 1999; Hirrlinger and Dringen, 
2010), this stabilization of extracellular GSH may also have neuroprotective 
functions (Pope et al., 2008).  
Astrocytes have been demonstrated to accumulate copper in vivo (Haywood et 
al., 2008) and in vitro (Kodama et al., 1991; Brown, 2004). Copper accumulation 
by cultured astrocytes has been reported to follow Michaelis-Menten kinetic 
with apparent KM and vmax-values of 2.9 nM and 12 pmol/(min x mg), 
respectively (Brown, 2004). Since Ctr1 mRNA has been shown to be expressed 
in cultured astrocytes (Qian and Tiffany-Castiglioni, 2003), this transporter is 
likely to participate in the copper uptake by astrocytes. DMT1, which has been 
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shown to be expressed in the astrocyte end-feet that contact capillary 
endothelial cells (Burdo et al., 2001) as well as in cultured astrocytes (Jeong and 
David, 2003; Erikson and Aschner, 2006; Tulpule et al., 2010), may also 
contribute to astrocytic copper uptake. Both Ctr1 and DMT1 have been reported 
to mediate the transport of Cu+ rather than of Cu2+ (Lee et al., 2002a; Lee et al., 
2002b; Arredondo et al., 2003; Bertinato et al., 2010), necessitating a reduction of 
Cu2+ by an ecto-cuprireductase prior to transport. The reductase Dcytb, which is 
known to reduce copper (Wyman et al., 2008) has been shown to be expressed 
in cultured astrocytes (Jeong and David, 2003; Tulpule et al., 2010) and could 
therefore provide Cu+ for cellular accumulation.  
Despite the efficient accumulation of copper, astrocytes have been observed to 
be remarkably resistant against copper-induced toxicity (Chen et al., 2008b; 
Reddy et al., 2008). However, incubation of cultured astrocytes for hours or 
days with micromolar concentrations of copper has also been reported to 
severely compromise the integrity and function of these cells (Ferretti et al., 
2003; Merker et al., 2005; Reddy et al., 2008). While elevated levels of peroxides 
and increased protein oxidation that have been observed for copper-treated 
human astrocytoma cells suggest an involvement of oxidative stress in copper-
induced toxicity (Ferretti et al., 2003; Merker et al., 2005; Qian et al., 2005), 
cultured astrocytes did not show a significant increase in the levels of ROS after 
exposure to 100 µM copper sulfate (Gyulkhandanyan et al., 2003) 
Neurons depend on sufficient amounts of copper which has been suggested to 
be supplied by neighboring astrocytes (Kodama et al., 1991; Kodama, 1993). For 
such a copper supply function astrocytes have to be able to release copper. C6 
glioma cells, a commonly used model for astrocytes, have been shown to 
express ATP7A (Qian et al., 1997, 1998a) and to export copper with apparent 
KM- and vmax-values of 0.15 µM and 65 pmol/(mg x h), respectively (Qian et al., 
1995). Considering that astrocytes also express ATP7A (Barnes et al., 2005; 
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Niciu et al., 2006; Niciu et al., 2007) and that astrocytes in the brindled mouse 
model of Menkes disease excessively accumulate copper (Kodama et al., 1991), 
it is highly likely that these cells play an important regulatory role in the brain 
copper metabolism by providing the essential trace element copper to neurons 
and to other brain cells, as already postulated two decades ago (Kodama et al., 
1991; Kodama, 1993). 
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Copper is an essential element. Its cellular and tissue concentrations are strictly 
regulated by various complex mechanisms and disturbances of copper 
homeostasis have been linked to several neurodegenerative diseases. In brain, 
astrocytes are thought to be key players in the regulation of metal homeostasis. 
Since only little was known about the copper metabolism in astrocytes and on 
potential effects of copper on the metabolism of astrocytes, this thesis aims to 
experimentally address such questions by using astrocyte-rich primary cultures 
as model system for brain astrocytes.  
This thesis will investigate: 
 mechanism(s) that are involved in copper accumulation 
 the presence of potential transporters involved in the copper transport 
by astrocytes 
 the copper export after loading the cells with copper  
 the trafficking of the copper-transporting ATPase ATP7A in response to 
extracellular copper 
 the effects of copper accumulation on cellular integrity and functions  
 copper-induced alterations of the glucose and GSH metabolism of 
astrocytes.
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Copper is an essential trace metal that is required for a variety of functions. 
Amongst the different type of brain cells, astrocytes are discussed to play a key 
role in metal homeostasis (Tiffany-Castiglion and Qian, 2001; Dringen et al., 
2007; Tiffany-Castiglioni et al., 2011). In addition, astrocytes are metabolically 
coupled to neurons and provide them with GSH precursor amino acids 
(Hirrlinger and Dringen, 2010; Schmidt and Dringen, 2012) as well as substrates 
for energy production such as lactate (Pellerin et al., 2007; Barros and Deitmer, 
2010; Dienel, 2011). Consequently, alterations of the astrocytic metabolism are 
likely to indirectly affect the functions of neurons.  
The aim of this thesis was to study the copper homeostatic mechanisms of 
astrocytes and the effects of copper on the metabolism of these cells, using 
astrocyte-rich primary cultures as model system. Immunocytochemical 
characterization of the cultures used in this thesis had previously revealed that 
more than 90% of the cells were stained positive for the astrocytic marker glial 
fibrillary acidic protein (GFAP; (Reinhart et al., 1990; Gutterer et al., 1999; 
Schmidt, 2010). Basal biochemical parameters such as the specific GSH content, 
glucose metabolism as well as the activities of enzymes involved in GSH or 
glucose metabolism are very well known for these cultures (Schmidt, 2010). 
Thus, astrocyte-rich primary cultures were considered as suitable model system 
to investigate the transport and storage of copper in astrocytes as well as 
metabolic consequences of a copper exposure. 
Copper metabolism as well as the effects of copper on the metabolism of 
cultured astrocytes was investigated for copper concentrations in the range 
from 0 to 30 µM which is likely to represent the physiological range of copper 
concentrations in the extracellular fluids in brain. Although the copper 
concentration in the CSF was estimated to be in the range of 0.3 µM – 0.5 µM 
(Stuerenburg, 2000; Forte et al., 2004; Nischwitz et al., 2008; Strozyk et al., 2009), 
the extracellular copper concentrations in brain tissue are likely to be much 
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higher, since at least for the synaptic cleft copper concentrations have been 
reported to range from 4 µM to up to 250 µM (Kardos et al., 1989; Hopt et al., 
2003). 
3.1 Copper metabolism in astrocytes 
Astrocytes have long been considered to play a role in brain copper metabolism 
(Kodama et al., 1991; Tiffany-Castiglion and Qian, 2001; Tiffany-Castiglioni et 
al., 2011). However, the cellular copper metabolism in astrocytes or other brain 
cells has not been studied as extensively as that of peripheral cell types such as 
hepatocytes or intestinal cells. To gain more knowledge about the copper 
metabolism in astrocytes, this thesis investigated the copper metabolism of 
cultured astrocytes in detail. The results obtained and presented in chapters 2.1, 
2.2 and 2.3 of this thesis extended the knowledge on functions of astrocytes in 
copper homeostasis. The updated current model of copper metabolism in 
astrocytes is depicted in Figure 1. 
Untreated astrocyte-rich primary cultures contain a low basal copper content of 
about 1.5 nmol per mg protein. This copper level is most likely sufficient to 
meet the physiological requirement of astrocytes for copper. These cells 
accumulate copper efficiently in vitro (Brown, 2004; Qian et al., 2012) and in vivo 
(Haywood et al., 2008). Cultured astrocytes can take up copper by both Ctr1 
and Ctr1-independent mechanisms (Chapter 2.1). These cells express Ctr1 
protein, extending the previous observation that astrocytes contain mRNA for 
this high-affinity copper transporter (Qian and Tiffany-Castiglioni, 2003). The 
kinetic parameters observed for copper accumulation in astrocytes were also 
consistent with that reported for Ctr1-mediated copper transport in other cells 
(Eisses and Kaplan, 2002; Lee et al., 2002a; Eisses et al., 2005). However, results 
from zinc inhibition experiments suggest that astrocytes can take up copper by 
additional mechanisms. Such a Ctr1-independent transport has previously been 
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described for other cell types (Lee et al., 2002b; Arredondo et al., 2003; Eisses et 
al., 2005; Kidane et al., 2012), but the identity of the transporters involved in this 
process remains unknown. One likely candidate is DMT1, which has been 
demonstrated to account for at least 50% of copper uptake in the human
Figure 1: Copper metabolism in cultured astrocytes. Copper can be taken up 
into cultured astrocytes by the copper transporter receptor 1 (Ctr1) and 
probably by additional transporters such as the divalent metal transporter 1 
(DMT1) or members of the ZIP family of metal transporters. Since Ctr1 
transports Cu+ rather than Cu2+, astrocytes are likely to possess an ecto-
cuprireductase. Accumulated copper is sequestered by GSH, stored in MTs or 
shuttled to its specific cellular targets by copper chaperones. The copper 
chaperone for superoxide dismutase (CCS) delivers copper to superoxide 
dismutase 1 (SOD1). Cox17 delivers copper to Sco1, Sco2 and Cox11 for 
subsequent incorporation into cytochrome c oxidase. Antioxidant protein 1 
(Atox1) delivers copper to ATP7A and ATP7B for translocation into the trans-
Golgi network and subsequent incorporation into copper-dependent enzymes 
such as glycosyl phosphatidylinositol-anchored ceruloplasmin (GPI-Cp). 
When the cellular copper level rises above a certain threshold, ATP7A 
translocates via vesicles to the plasma membrane. ATP7A imports copper into 
these vesicles for release after fusion with the plasma membrane and/or 
exports copper directly from the astrocyte. Redistribution of ATP7A back to 
the trans-Golgi network occurs when cellular copper levels return to normal. 
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intestinal cell line CaCo2 (Arredondo et al., 2003). DMT1 has been shown to be 
expressed in cultured astrocytes (Jeong and David, 2003; Erikson and Aschner, 
2006; Tulpule et al., 2010) and the increased copper accumulation at lower pH, 
the stimulation by ascorbate and the reduction of cellular copper accumulation 
by cadmium and manganese is consistent with a contribution of this transporter 
to the copper accumulation by astrocytes. The strong inhibition of copper 
accumulation by zinc hints to a possible involvement of members of the ZIP-
family of metal transporters. ZIP transporters have broad substrate specificity 
and have been demonstrated to transport zinc, manganese, cadmium and iron 
(Kambe et al., 2004; Eide, 2006). Direct evidence of a contribution of ZIP 
transporters in copper uptake has not been reported so far, but the strong 
competition by copper of the uptake of zinc and cadmium by Zip1, Zip2 and 
Zip14 (Gaither and Eide, 2000, 2001; Girijashanker et al., 2008) suggests that 
these transporters may be capable of transporting copper. However, in addition 
to the functional characterization of the various members of the ZIP family 
proteins with respect to copper transport, the expression of these transporters in 
astrocytes needs further studies, since so far only mRNA for Zip1 (Belloni-Olivi 
et al., 2009) and  Zip14 (Bishop et al., 2010) have been shown to be present in 
astrocytes.  
Ctr1 and DMT1 have been reported to transport Cu+ rather than Cu2+ (Lee et al., 
2002a; Arredondo et al., 2003), yet cultured astrocytes rapidly accumulated 
copper from Cu2+ when added to the culture medium. The copper accumulation 
was strongly stimulated by ascorbate, suggesting that reduction of Cu2+ to Cu+ 
is the rate-limiting step in copper uptake by astrocytes. This observation 
indicates the involvement of an ecto-cuprireductase in copper uptake that is 
located on the astrocyte plasma membrane in close proximity to Ctr1 and 
DMT1. All metal reductases known to reduce Cu2+ do also reduce Fe3+ and 
belong either to the cytochrome b (Knopfel and Solioz, 2002; Wyman et al., 
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2008) or to the Steap family of proteins (Ohgami et al., 2006; Knutson, 2007). 
While the expression of members of the latter family of metal reductases has 
not been investigated for astrocytes, Dcytb, the homologue of the cytochrome b 
family has been shown to be expressed in cultured astrocytes (Jeong and David, 
2003; Tulpule et al., 2010). However, if a cupri-/ferri-reductase supports copper 
uptake into astrocytes, it would be expected that ferric iron would inhibit 
copper uptake from Cu2+-salts, which was at least not the case for the copper 
accumulation investigated here (Chapter 2.1). Thus, astrocytes appear to 
possess mechanisms to transport both Cu+ and Cu2+, and Cu2+-transport in the 
absence of ascorbate appears to outweigh Cu+ transport. 
Cultured astrocytes accumulated copper much more rapidly from amino acid-
free buffers than from Dulbecco’s modified Eagle’s medium (DMEM; Chapter 
2) or histidine-buffer (Brown, 2004). The reason for this difference is most likely 
the chelation of copper by components of the latter two media. The observed 
difference in the rates of copper accumulation from different media supports 
the view of the existence of multiple copper uptake processes in astrocytes: (1) a 
high-affinity and low uptake capacity process, which probably involves Ctr1-
mediated transport, and (2) an additional process of high uptake capacity but 
low-affinity. The relative importance of these processes in vivo is difficult to 
assign, although Ctr1-mediated transport appears to prevail only when copper 
is bound to ligands such as histidine (Lee et al., 2002a). This observation, 
together with the almost complete inhibition of copper uptake by zinc, suggests 
that cultured astrocytes predominantly accumulate copper from amino acid-
free buffers by a Ctr1-independent transport process. Thus, studying copper 
transport by cultured astrocytes under this condition may represent a suitable 
tool to further investigate Ctr1-independent transport. 
In cells, copper is sequestered by GSH, stored in MTs or shuttled by copper 
chaperones to its specific targets, keeping the levels of potential toxic free 
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copper low (Freedman and Peisach, 1989; Tapia et al., 2004; Robinson and 
Winge, 2010). Astrocytes contain high cellular contents of GSH (Dringen and 
Hamprecht, 1998) and MTs (Aschner et al., 1997; Dineley et al., 2000), providing 
these cells with a high storage capacity for copper. When exposed to copper in 
DMEM for prolonged time cultured astrocytes elevate their contents of GSH 
(Chapter 2.5) and MTs (data not shown). These compensatory responses further 
increase their storage capacity for copper and are likely to explain the 
remarkably resistance of these cells against copper-induced toxicity (Brown et 
al., 1998; Chen et al., 2008b; Reddy et al., 2008). In contrast, when copper uptake 
is very rapid the protective mechanisms of astrocytes against copper-induced 
toxicity are overwhelmed. For example, exposure to 30 µM copper in amino 
acid-free buffer results in an 8-fold increase in cellular copper content within 1 h 
and led to severe toxicity within 2 h (Chapter 2.3). These observations indicate 
that the rate of copper accumulation determines the velocity and extent of 
copper-mediated cell damage in cultured astrocytes. 
The expression and function of copper chaperones in astrocytes has not been 
addressed in this thesis. However, CCS which delivers copper to SOD1 has 
been demonstrated in astrocytes (Rothstein et al., 1999). In addition, the finding 
that cultured astrocytes express ATP7A (Chapter 2.2) provides indirect 
evidence for the presence of Atox1 in these cells, since the cellular functions of 
this copper-transporting ATPase relies on the presence of the copper chaperone 
Atox1 (Klomp et al., 1997; Hung et al., 1998). 
Viable astrocytes have been shown for the first time in this thesis to export 
copper. This copper export involves most likely ATP7A, since this protein is 
expressed in astrocyte cultures (Chapter 2.2), confirming literature data (Barnes 
et al., 2005; Niciu et al., 2006; Niciu et al., 2007). However, a contribution of 
ATP7B in copper export from astrocytes can also not be excluded, since mRNA 
for ATP7B was found to be expressed in cultured astrocytes (data not shown). 
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As demonstrated for other cell types, ATP7A in astrocytes traffics to sites close 
to the plasma membrane when cellular copper levels exceed certain thresholds 
and returns back to its initial TGN localization after removal of copper (Chapter 
2.2), further supporting a contribution of ATP7A  in the observed copper export 
from astrocytes. 
In conclusion, this thesis provides further evidence for a pivotal role of 
astrocytes in the copper metabolism of the brain. Astrocytes have been shown 
to efficiently accumulate copper by both Ctr1 and Ctr1-independent 
mechanisms. An increase in cellular copper levels was observed to cause an 
increase in cellular contents of GSH and MTs, providing astrocytes with a high 
storage capacity for copper and making them remarkably resistant against 
copper induced-toxicity. The ability to efficiently take up and store copper may 
be important to protect neurons from copper-induced toxicity and may 
contribute to the neuroprotective function of astrocytes against copper-
mediated toxicity (Brown, 2004; Pope et al., 2008). Furthermore, astrocytes have 
been demonstrated in this thesis for the first time to be capable of exporting 
copper. With their strategically important localization between capillary 
endothelial cells and neuronal cell bodies (Nedergaard et al., 2003; Parpura et 
al., 2012) and with their potential to both taking up and exporting copper, 
astrocytes are ideal to provide copper to neurons. Disturbances of brain copper 
homeostasis have been connected with the development and progression of 
neurodegenerative diseases (Waggoner et al., 1999; Gaeta and Hider, 2005; 
Klevay, 2008; Macreadie, 2008; Hung et al., 2010; Rivera-Mancia et al., 2010). 
Assuming a pivotal role of astrocytes in brain copper homeostasis, astrocytic 
copper metabolism should be considered as a new therapeutic target in the 
treatment of such diseases. 
3. Summarizing Discussion 
3.2 Effects of copper on the metabolism of astrocytes 
212 
3.2 Effects of copper on the metabolism of astrocytes 
As discussed in the previous section, astrocytes may have a pivotal role in the 
regulation of brain copper homeostasis and are likely to encounter high copper 
concentrations when homeostatic mechanisms are impaired. Indeed, astrocytes 
have been shown to excessively accumulate copper in North Ronaldsay sheep, 
an animal model for copper toxicosis (Haywood et al., 2008). The consequences 
of pathological copper accumulation have been largely linked to copper-
induced oxidative stress. However, the absence of any detectable ROS 
formation in astrocytes exposed to toxic concentrations of copper in DMEM 
(data not shown) argues against ROS-mediated damage as the major cause of 
copper-induced toxicity in these cells. This view is supported by the finding 
that at the early stage of copper accumulation in the liver of ATP7B deficient 
mice, strongly elevated copper concentrations did not correlate with liver 
damage (Huster and Lutsenko, 2007; Huster et al., 2007). In fact, in these 
animals elevated copper levels have been shown to affect specific cellular 
targets at the transcriptional and/or translational levels and to have distinct 
effects on metabolic functions of the liver (Huster et al., 2007; Sauer et al., 2011). 
Alterations of astrocytic metabolism by copper have been reported for the first 
time by articles that are part of this thesis (Chapters 2.4 and 2.5) 
Astrocytes play a key role in brain glucose metabolism (Figure 2). They are in 
direct contact with brain capillary epithelial cells (Demeuse et al., 2002; 
Nedergaard et al., 2003; Parpura et al., 2012) and thus are likely to be the first 
cells to receive glucose from the blood. According to the astrocyte-neuron 
lactate shuttle hypothesis lactate released from astrocytes serves as an essential 
metabolic fuel for neighboring neurons (Pellerin et al., 2007; Barros and 
Deitmer, 2010; Dienel, 2011). Consequently, altered glucose metabolism of 
astrocytes by copper would also affect neurons. Treatment of cultured 
astrocytes with copper led to an increase in their glucose consumption and 
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lactate release in a time- and concentration-dependent manner (Chapter 2.4). 
The observed induction of glycolytic flux was not due to mitochondrial 
impairment, although opening of the mitochondrial transition pore was shown 
for copper-treated astrocytes (Reddy et al., 2008) and  cerebella of ATP7B-
deficient mice displayed lower activities of respiratory chain complexes (Sauer 
et al., 2011). The effect of copper on glucose metabolism of astrocytes depended
 
Figure 2: Potential consequences of copper-induced alterations in astrocyte 
metabolism and on the metabolic coupling between astrocytes and neurons. 
Astrocytes take up glucose entering the brain and metabolize it to pyruvate via 
glycolysis. Pyruvate is used for ATP production via mitochondrial respiration, 
but can also be reduced to lactate which is exported for uptake by neurons to 
serve as a substrate for oxidative phosphorylation. Exposure of cultured 
astrocytes to copper increased both glucose consumption and lactate release. 
Glutathione (GSH) is synthesized from the amino acid substrates glutamate 
(Glu), cysteine (Cys) and glycine (Gly) by the sequential action of glutamate 
cysteine ligase (GCL) and glutathione synthetase (GS). GSH can be exported by 
multidrug resistance protein 1 (Mrp1) from astrocytes. Extracellular GSH 
serves as substrate for astrocytic γ-glutamyl transpeptidase (γGT) to produce 
cysteinylglycine (CysGly). CysGly is hydrolyzed by neuronal aminopeptidase 
N (ApN) and the generated amino acids cysteine and glycine are taken up by 
neurons, where they can serve as precursors for GSH synthesis. Copper 
treatment increases the cellular GSH content and accelerates GSH export from 
cultured astrocytes. 
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on protein synthesis. Copper-induced changes in the transciptome have for 
example been observed in HepG2 cells exposed to copper (Song et al., 2009; 
Song and Freedman, 2011), in mice fed a copper-rich diet (Muller et al., 2007) 
and in mice deficient in ATP7B (Huster et al., 2007). Although the transcription 
factor Hif-1α is known to increase the glycolytic rate in cultured astrocytes 
(Schubert et al., 2009) and to be stabilized by copper (Martin et al., 2005), Hif-1α 
does not appear to be involved in the observed stimulation of glycolytic flux 
(Chapter 2.4). A possible role of other transcription factors in the copper-
induced stimulation of glycolytic flux in astrocytes that are known to be 
activated by copper, such as the nuclear factor kappa B (NF-κB; McElwee et al., 
2009) or the metal transcription factor 1 (MTF1; Mattie and Freedman, 2004), 
remains to be investigated. At least NF-κB has been shown to enhance 
glycolytic flux in mouse embryonic fibroblasts (Kawauchi et al., 2008). 
Interestingly, activation of NF-κB by copper was only observed for cells 
connected with the maintenance of copper homeostasis at the systemic level, 
whereas in other cell types copper had either no effect or an inhibitory effect on 
NF-κB-activation (McElwee et al., 2009).  
Astrocytes play an important role in the brain GSH metabolism (Figure 2). 
These cells provide neighboring neurons with GSH precursors in a process that 
involves the release of GSH from astrocytes by multidrug resistance protein 1 
(Mrp1) and subsequent processing of extracellular GSH to the amino acids 
required for neuronal GSH synthesis (Hirrlinger and Dringen, 2010; Schmidt 
and Dringen, 2012). GSH is synthesized in a two-step reaction by the 
consecutive action of glutamate cysteine ligase (GCL) and glutathione 
synthetase (Franklin et al., 2009; Lu, 2009; Schmidt and Dringen, 2012). The 
GCL-catalyzed reaction of glutamate and cysteine to γ-glutamylcysteine is the 
rate-limiting step of GSH synthesis (Franklin et al., 2009; Lu, 2009; Schmidt and 
Dringen, 2012). GCL is a heterodimeric protein that consists of a catalytic and a 
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modulator subunit (Franklin et al., 2009; Lu, 2009; Schmidt and Dringen, 2012). 
Both subunits, and thus GCL activity, are regulated on the transcriptional, post-
transcriptional and post-translational level (Franklin et al., 2009; Lu, 2009). 
Formation of the GCL holoenzyme is required for efficient GCL activity and is 
thought to regulate GCL activity in a redox-dependent manner (Franklin et al., 
2009; Lu, 2009).  
Treatment of cultured astrocytes with copper strongly increased the cellular 
GSH content and led, most likely as a direct consequence of the elevated GSH 
content, to an accelerated Mrp1-dependent GSH release from these cells 
(Chapter 2.5). This strong increase of cellular GSH contrasts reports for other 
cell types that describe cellular depletion of GSH after exposure to copper 
(Hansen et al., 2006; Singleton et al., 2010; Vidyashankar and Patki, 2010). The 
mechanism responsible for the observed elevated GSH content in copper-
treated astrocytes remains to be elucidated. However, it appears to be 
independent of protein synthesis, since an accelerated GSH release was also 
observed when protein synthesis was inhibited (data not shown). Consistently, 
nitric oxide, which has been reported to elevate GCL activity in astrocytes by 
inducing synthesis of GCL mRNA (Gegg et al., 2003), is unlikely to be involved 
in the elevation of the cellular GSH content of copper-treated astrocytes. More 
likely, elevated copper levels may enhance GCL activity by a post-translational 
mechanism. One possibility is that copper may facilitate the formation of the 
disulfide bond linking the catalytic with the regulatory subunit, thereby 
enhancing the levels of GCL holoenzyme (Franklin et al., 2009). Although an 
enhanced ROS production was not detected in copper-treated astrocytes, slight 
transient increases in ROS production induced by copper could also have 
caused an increase in GCL activity. Alternatively, an increased uptake of the 
GSH precursors cysteine or cysteine into astrocytes (Kranich et al., 1998) may 
contribute to the increased specific GSH content as reported for astrocytes 
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exposed to ammonia, cadmium or arsenite (Sagara et al., 1996; Wegrzynowicz 
et al., 2007). 
In conclusion, this thesis described for the first time effects of copper on the 
metabolism of cultured astrocytes. Copper was shown to alter both glucose 
metabolism and GSH metabolism of cultured astrocytes. The increase in 
glycolytic flux appeared not to be required for the survival of astrocytes in the 
presence of high copper concentrations. In vivo an increased export of lactate 
from copper-loaded astrocytes could be deleterious, since it could result in a 
lactic acidosis (Rehncrona, 1985; Paschen et al., 1987). Alternatively, moderately 
increased lactate availability could be neuroprotective, since lactate is 
considered as substrate for the energy metabolism of neurons (Pellerin et al., 
2007; Barros and Deitmer, 2010; Dienel, 2011). Whether such copper-induced 
alterations in astrocytic glucose metabolism occur in vivo is unclear. While one 
study found no evidence for an increased lactate concentration in the brain of 
Wilson’s disease patients, indicating that brain energy metabolism was normal 
(Kraft et al., 1999), another study showed strong lactate accumulation in the 
basal ganglia (Juan et al., 2005). The elevation of the cellular GSH content is 
likely to confer copper-treated astrocytes with increased resistance against 
copper-mediated toxicity. In addition, the accelerated release of GSH may also 
provide protection to neurons against the toxic effects of copper, since 
extracellular GSH may sequester extracellular copper and could supply 
neurons with GSH precursors. However, whether such metabolic changes occur 
in copper overload condition in vivo is questionable. At least in the brain of 
ATP7B deficient mice, increased copper levels were not associated with a 
significant change of GSH levels (Sauer et al., 2011) and the GSH content in 
brains of copper intoxicated rats was decreased (Alexandrova et al., 2008; 
Ozcelik and Uzun, 2009). 
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 3.3 Future perspectives 
Astrocytes have been shown to efficiently accumulate copper. The mechanism 
contributing to copper uptake by astrocytes has been shown to strongly depend 
on the medium in which copper is provided. While in amino acid-free media 
Ctr1-independent copper uptake appears to dominate, copper uptake is more 
likely to involve Ctr1 in DMEM. To proof this hypothesis and to study the 
relative contribution of the individual transporters to copper uptake by 
astrocytes under the different incubation conditions, knock-down approaches 
by RNA interference (McManus and Sharp, 2002) for the different candidate 
transporters could be used. Alternatively, astrocyte cultures derived from 
animals deficient in these transporters (e.g. Belgrade rat for studying possible 
contribution of DMT1; Fleming et al., 1998)) could be generated and 
investigated regarding their copper accumulation. If the hypothesis that copper 
accumulation from amino acid-free buffers by astrocytes primarily represents 
Ctr1-independent transport is validated, this system would provide a valuable 
tool to study the molecular mechanisms of Ctr1-independent transport in detail.  
Ctr1-independent transport has not been studied extensively. For CaCo2 cells 
DMT1 has been shown to contribute to copper accumulation (Arredondo et al., 
2003) and could be a likely candidate for Ctr1-independent copper uptake in 
astrocytes. Preliminary experiments have shown that extracellular copper 
specifically induces the translocation of DMT1 from the plasma membrane to 
cytosolic compartments (data not shown). Members of the ZIP family of metal 
transporters are additional candidates for Ctr1-independent copper uptake by 
astrocytes and other cell types. Currently 14 different ZIP transporters are 
known in mammals, but copper transport has not been studied for any of them. 
Thus, before investigating the contribution of ZIP transporters to copper 
transport by astrocytes, ZIP transporters should first be characterized with 
respect to their copper transport properties. 
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Astrocytes have been shown to be capable of exporting copper. This process is 
likely to be mediated by ATP7A. However, also mRNA of ATP7B has been 
found in astrocyte cultures (data not shown). Presence of ATP7B in these 
cultures should be investigated on protein level. If expression of ATP7B protein 
could be confirmed, altered copper export rates in cultured astrocytes derived 
from animals either deficient in ATP7A (e.g. mottled mice; Hunt, 1974) or 
ATP7B (e.g. LEC rats; Yamaguchi et al., 1994) could reveal the relative 
contribution of both ATPases in astrocytic copper export. In addition, such 
cultures could be used to study whether ATP7A and ATP7B can functionally 
substitute for each other in astrocytes. This could be tested by studying the 
activity of tyrosinase, LOX and/or PAM in ATP7A deficient astrocyte cultures 
and the Cp activity in ATP7B deficient cells. Of special interest would also be 
the investigation of the iron metabolism in astrocytes deficient in ATP7B, since 
those astrocytes may be unable to release iron as reported for astrocytes derived 
from Cp-deficient animals (Jeong and David, 2003)  
Astrocytes are remarkably resistant against copper-toxicity, most likely due to 
the strong elevation of cellular GSH contents in response to copper treatment. 
Although MT expression was found up-regulated in astrocytes when exposed 
to copper, it appears not to be essential for the protection of astrocytes to copper 
toxicity (data not shown). MTs have been reported to be secreted by astrocytes 
in response to brain injury. These secreted MTs are protective to neurons, which 
can take up extracellular MTs in a process that involves interaction with the 
megalin receptor (Chung et al., 2008). Given that copper induces MT expression 
and that copper is involved in non-classical secretion (Prudovsky et al., 2008), a 
release of MTs by astrocytes may also take place in response to copper. To test 
for the contribution of MT-release in the neuroprotective function of astrocytes 
against copper-mediated toxicity, the survival of neurons in co-cultures with 
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either wild type astrocytes or MT-deficient astrocytes (Yao et al., 2000) could be 
compared.  
While some information is now available on the uptake, storage and export of 
copper in astrocytes, almost nothing is known about the intracellular copper 
transport in these cells. To complete the model of copper metabolism in 
astrocytes, the expression and cellular localization of the known copper 
chaperones should be investigated. 
The hypothesis that astrocytes serve as a copper depots for the brain, distribute 
copper to brain parenchyma and protect other types of brain cells against 
copper toxicity is well-supported by literature data (Tiffany-Castiglioni et al., 
2011). However, this hypothesis has not been studied directly so far. Generation 
of mice with astrocyte specific knock-out of copper transporters (ATP7A, Ctr1) 
or chaperons/storage proteins (Atox1, MTs) by an inducible Cre/lox system 
(Sauer, 1998; Metzger and Chambon, 2001; Sun et al., 2007) should be 
considered to confirm the important role of astrocytes in brain copper 
metabolism in vivo.  
Copper has been shown to alter the glucose and GSH metabolism of cultured 
astrocytes. Mechanistically, these alterations have not been elucidated so far 
and should be further studied. A possible function of NF-κB in the stimulation 
of glycolytic flux by copper would be worth to investigate. In addition, the 
alteration of other metabolic pathways (e.g. lipid metabolism) in astrocytes by 
copper should be tested. Also, the consequence of a copper deficit on specific 
metabolic pathways in astrocytes has not been addressed so far. Such 
investigations may aid in the understanding of the role of astrocytes in 
neurodegenerative diseases associated with impaired copper homeostasis such 
as neurological Wilson’s disease, Alzheimer’s disease or Parkinson’s disease 
(Gaggelli et al., 2006; Lorincz, 2010; Rivera-Mancia et al., 2010). 
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Finally, since copper is essential for every type of brain cell the experiments and 
methods described here for investigating the metabolism of copper in and its 
metabolic effects on cultured astrocytes should be applied to study copper 
metabolism of other types of brain cells such as neurons, oligodendrocytes and 
microglial cells.  
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